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As the global obesity epidemic spreads, scientists struggle to understand the 
biological, cultural, and evolutionary bases for modern fatness. Understanding the 
contributions of the interaction between physical activity and the endocrine system to 
regulating metabolism could potentially help people who are overweight or obese in 
losing weight and illustrate one of the evolutionary pathways that encourage modern 
obesity. This study used an innovative approach that integrated a lifestyle physical 
activity and diet questionnaire coupled with endocrine analysis (leptin, osteocalcin) and 
anthropometric measures in order to create baseline measurements of fit individuals. The 
mean osteocalcin level was 4201.46 pg/mL and the mean leptin level was 1791.87 pg/mL 
for participants in this study. For leptin, the levels were significantly lower than that of 
the general population, especially obese groups. The conclusions from this study 
contribute to the understanding of what physical fitness looks like from an endocrine 
perspective, which reinforce the current recommendation to treat obesity with diet and 
exercise.  
The thrifty genotype hypothesis posits that although the modern environment is 
different from the evolutionary environment, the body is still adapted to a past where it 
was advantageous to store fat against future food insecurity. Regular physical activity 
with good nutrition causes a cascade effect for leptin, osteocalcin, and insulin that 
 improves the body’s sensitivity to glucose management and efficacy in metabolic 
regulation. This study found several statistically significant relationships that corroborate 
existing paradigms and data. Amongst the most important were a positive relationship 
between osteocalcin and speed of sound (P = 0.038); a negative relationship between 
leptin and time spent strength training per year (P < 0.05, R = -0.204) and time spent 
swimming (P = 0.012, R = -0.263); and a positive relationship between time spent 
strength training and stiffness index (P = 0.039, R = 0.195) and t-score (P = 0.034, R = 
0.202). Some relationships that were expected to be significant were not, possibly due to 
problems with the hormone assays or with statistical power. Future work remains to be 
done both on the biochemical front as well as for lifestyle data collection.  
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Chapter I: Introduction 
As the global obesity epidemic spreads, scientists struggle to understand the 
biological, cultural, and evolutionary bases for modern fatness. Overwhelming amounts 
of data demonstrate that people in industrialized countries are moving less and 
consuming more (Caspersen et al., 2000; Dugas et al., 2011; Hayes et al., 2005). Many 
believe that intervention methods combining diet and exercise are the most effective 
means of controlling weight from fat mass (Cao, 2011; Miller et al., 1997; Saleem et al., 
2010; Wolf, 2008). Interestingly, a recent study by Pontzer et al. (2012) posits that the 
decline in physical activity has little to do with modern obesity. Several recent studies 
show that total energy expenditure (TEE) does not vary according to mode of subsistence 
(e.g. subsistence farming groups spend on average the same amount of energy as groups 
from the industrialized West) (Dugas et al., 2011; Kanade et al., 2001; Speakman et al., 
2010; Goran et al., 1997; Westerterp, 2010). Pontzer et al.’s research supports this and 
hypothesizes that TEE is an evolved trait that is the result of the evolutionary 
environment rather than an individual’s current environment and energy usage. This view 
is contrary to the idea that the lack of physical activity in the Western world is a major 
cause of modern obesity. Rather, the increase in caloric availability is the major driver. 
As a result, Pontzer et al. (2012) and others like them recommend that physicians focus 
on dietary weight loss plans that emphasize caloric restriction to create an energy deficit. 
Pontzer et al. (2012) do acknowledge that the World Health Organization believes that 
exercise has “important, positive effects on health,” but any further contributions that 
physical activity might make in weight management are ignored. 
 2 
Many other researchers investigate the effects of physical activity on metabolism 
and mass. Studies demonstrate that exercise overall improves metabolic sensitivity and 
helps sustain a healthy weight over the long-term (Cao, 2011; Miller et al., 1997; Saleem 
et al., 2010; Wolf, 2008). Previous research unequivocally links physical activity and 
hormones, which Pontzer et al. (2012) disregard. Understanding how the interaction 
between physical activity and the endocrine system help regulate metabolism could 
illustrate one of the evolutionary pathways that encourages modern obesity. Additionally, 
understanding this relationship can better inform interventions to help people who are 
overweight or obese lose weight. 
Leptin, insulin, and osteocalcin are hormones of particular interest to researchers 
studying the connection between physical activity, bone metabolism, endocrinology, and 
obesity. This study’s primary purpose is to explore the interaction amongst all these 
factors in order to evaluate current research and to propose a potential link between the 
evolutionary environment and the modern obesity crisis. Insulin, the most well known 
hormone of the trio, is primarily responsible for controlling blood glucose levels by 
signaling muscle and fat to absorb free blood sugar (Hadley & Levine, 2009). Leptin is a 
satiety hormone. Its presence in the brain signals to the central nervous system that an 
individual is full and should stop eating, thus affecting other metabolic hormones like 
osteocalcin and insulin, as well as playing a role in diverse functions such as 
angiogenesis, immune response, and bone metabolism (Zhang et al., 2005). Osteocalcin, 
in contrast, is perhaps the least recognized hormone of the three. Bones produce 
osteocalcin during modeling and remodeling (Hauschka, 1986). Osteocalcin has multiple 
functions. There is a tight correlation between osteocalcin and bone turnover, which 
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indicates that it must play a role in bone remodeling (Lee et al., 2000). It appears that 
osteocalcin boosts native insulin production as well as insulin sensitivity (Hwang, 2012). 
Relatively new research shows that osteocalcin and insulin work together in a feed-
forward loop (i.e. the production and release of one hormone stimulates the production 
and release of a second hormone, triggering further secretion of the first hormone; this 
creates a self-perpetuating cycle that amplifies over time), which is the first hint that 
exercise may be an important component to individuals fighting obesity-related type II 
diabetes (Gordeladze & Reeseland, 2003; Creighton et al., 2001; Foresta et al., 2011; 
Levinger et al., 2011; Reinhr et al., 2010; Saleem et al., 2010; Hadley & Levine, 2006).  
Previous research has focused on this relationship in overweight, unfit samples. 
To date, no one has looked at insulin, leptin, and osteocalcin simultaneously in a healthy, 
fit sample. The latter would more closely approximate humans’ evolutionary 
environment, which is crucial to understanding function and dysfunction of these 
hormones in contemporary populations.  
To address the gap in knowledge regarding endocrine function in fit populations, 
baseline measurements of leptin, insulin, and osteocalcin in fit individuals who meet or 
exceed the CDC’s minimum weekly exercise requirements and have access to good 
nutrition (CDC, 2008). This study focuses on fit individuals in order to create baseline 
data for leptin and osteocalcin as well as to test hypotheses regarding the relationships 
amongst physical activity, bone density, and hormone levels in order to evaluate the 
utility of exercise in combating excess weight. Previous studies have focused on either 
obese individuals, typically undergoing some sort of diet and/or exercise intervention or 
individuals in the normal BMI range, but with no physical fitness requirements 
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(Fernández-Real et al., 2009; Kwon et al., 2012; Miller et al., 1997; Pritchard et al., 1996; 
Reinehr and Roth, 2010).  
This study also sought to assess whether or not exercise, bone turnover, and 
hormones work in concert to help regulate metabolism and body mass beyond the effects 
of caloric deficit created by exercise. More specifically, the study sought to test the 
following findings from current research. Healthy, highly active individuals will have:  
• Lower leptin than the general population 
• Higher osteocalcin than the general population 
• Normal insulin levels 
• A positive correlation between bone health measures, osteocalcin, and exercise, 
coupled with a negative correlation with leptin 
Additionally, this study attempted to apply the principles of the thrifty genotype 
hypothesis and thrifty phenotype hypothesis to contextualize study results in terms of 
evolutionary theory. In order to understand the larger picture of the interaction amongst 
physical activity, endocrinology, and metabolic regulation, current hypotheses on the 
evolutionary origins of obesity are also evaluated as a part of the literature review. 
The end goal of this study is to combine the baseline data that was found, the data 
from the four hypotheses listed above, and the thrifty genotype/phenotype interpretations 
to better understand obesity in order to recommend a better intervention plan for obese 
individuals. This type of research is important because obesity has become a global 
epidemic with serious health and economic consequences. This study can help illuminate 
how the evolutionary environment shaped human ancestors in such a way that the 
descendants have become predisposed to obesity.  
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Chapter II: Biology Literature 
Bone Biology 
 The skeletal system is a vital and dynamic component of the human body. It 
protects and supports vital organs, provides leverage for muscles to move, is the main site 
for hematopoiesis, and acts as a depository for important minerals. The skeletal system’s 
regulation of calcium is essential to homeostasis because humans use calcium for 
important tasks, including muscle contraction, inter-cellular communication, mitosis, 
nerve transmission, and exocytosis. Homeostasis is a global process and the endocrine 
system is the communication system that allows for distant organs to exchange 
information (Widmaier et al., 2010). Like all other tissues, the skeletal system is a 
sensitive and sophisticated endocrine organ. Bones must interact with systemic 
hormones, like calcitonin or parathyroid hormone, as well as produce its own hormones. 
Bones help maintain homeostatic balance through management of mineral deposits, but 
they can also affect the function of systems as diverse as the immune and metabolic 
systems through endocrine interactions (Hadley & Levine, 2006; Martini et al., 2008).  
Overall bone anatomy consists of the periosteal envelope, compact bone, 
trabecular (or spongy) bone, endosteal envelope, and bone marrow (Burr & Allen, 2013). 
The periosteal envelope is the outer layer of bone. The tough, dense compact bone lies 
beneath the periosteal envelope. It surrounds and protects the trabecular bone, which is 
characterized by an open structure. The medullary cavity resides inside the endosteal 
envelope within the spongy bone and it contains bone marrow. Red bone marrow is 
responsible for hematopoiesis and thus is composed of a combination of immature and 
mature erythrocytes (red blood cells) and leukocytes (white blood cells) as well as the 
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stem cells responsible for producing them. Yellow bone marrow is made up mostly of fat 
cells known as adipocytes. During times of starvation or extreme illness, the body can 
convert yellow bone marrow to red bone marrow in order to bolster production of blood 
cells (Burr & Allen, 2013; Widmaier et al., 2010). 
 Bone is a dense connective tissue composed of an intricate combination of 
specialized cells, extracellular matrix of protein fibers, and a ground substance (Martini et 
al., 2008). Bones are composed of calcium phosphate and calcium hydroxide, which react 
to form hydroxyapatite. The hydroxyapatite crystals consolidate other calcium salts and 
ions like sodium, magnesium, and fluoride. This ground substance is hard and stiff; it 
gives bone the ability to resist compressive force. It also makes up approximately two-
thirds of the bone’s weight. The collagen fibers give bone the necessary flexibility to 
withstand tensile forces. Collagen makes up roughly one-third of a bone’s weight. Other 
cell types constitute the remaining 2% of mass (Martini et al., 2008). Interestingly, the 
material properties of bone vary little across vertebrate species, so size and shape of a 
bone are the major determinant factors of bending strength (Currey, 2002). 
   There are four major categories of bone cells: osteocytes, osteoblasts, osteomacs, 
and osteoclasts (Burr & Allen, 2013). Osteoblasts are responsible for osteogenesis, which 
means that they secrete the organic component of the bony matrix. They can reside on 
either the outer or inner surface of bone. The organic compound secreted by the 
osteoblast becomes mineralized over time. Eventually, the osteoblast either undergoes 
apoptosis or becomes completely encased in the mineral matrix, transforming into an 
osteocyte (Burr & Allen, 2013). An osteocyte is a mature bone cell complete with 
specific structures that allow for vascularization and exchange/transport of substances 
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throughout the bone (Martini et al., 2008). Osteoclasts’ primary function is to break down 
bone by lowering the pH level using acid proteases. This breaks up the bone’s mineral 
structure and frees the minerals and elements formerly trapped within the bony matrix to 
be used in other areas of the body by other tissues (Burr & Allen, 2013). Osteocalcin is 
produced by the osteoclasts as a byproduct of the re/modeling processes (Hauschka, 
1986). Osteomacs derive from the same cell lineage as osteoclasts. Like osteoclasts, 
osteomacs act as macrophages that help regulate osteoblast mineralization (Chang et al., 
2008; Raggatt & Partridge, 2010). Recent research suggests that osteomacs also help 
maintain mature osteoblasts and may play a role in regulating the remodeling process 
(Raggatt & Partridge, 2010). 
Bones are popularly perceived as a static body part when in fact they are 
incredibly dynamic. The skeletal system is highly adaptive to the demands placed upon it 
mechanically as well as an erythrocyte/cytokine production center and calcium 
depository. The skeleton has two main modification processes known as modeling and 
re-modeling that allow it to deal with body’s requirements. They are an essential part of 
growth and development because they allow the bones to change shape and grow while 
maintaining proportions that allow for movement (Burr & Allen, 2013). As per Wolff’s 
Law, the shape, size, and section modulus (i.e. bending strength) of bones are determined 
by the loads placed upon them.  Modeling and remodeling are also the core processes that 
allow bones to adapt to physical stress (Frost, 2003).  
Modeling is either the formation or resorption of bone on an existing surface 
(Clarke, 2008). It occurs on the periosteal, endosteal, and trabecular surfaces. Modeling 
primarily happens during the growth and development period, but can also be initiated in 
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adulthood by local bone tissue stress. There are two types of modeling – formation (new 
bone is laid down) and resorption (existing bone is broken down) – that can work 
independently from each other at different times and locations (Burr & Allen, 2013). If 
there is a high degree of strain, then formation modeling and resorption modeling act in 
concert in order to add bone mass and/or re-shape the bone in order to better withstand 
future stresses. If there is a low degree of strain, typically only resorption modeling is 
activated to reduce bone mass and thereby free the stored minerals (Frost, 2003).  
Remodeling is the process of osteoclast-mediated bone resorption followed by 
osteoblast-mediated bone formation in the same location (Clarke, 2008). This differs 
from modeling, which does not require the processes of resorption modeling and 
formation modeling to occur sequentially or in the same location. Bone remodeling 
occurs on the periosteal, endosteal, trabecular, and intracortical surfaces (Burr & Allen, 
2013). There are two types of remodeling: targeted and stochastic. Targeted remodeling 
is thought to help maintain bones’ mechanical integrity and thus it is postulated that it is 
activated by microdamage to the bone or osteocyte apoptosis. Stochastic remodeling, as 
the name implies, is random. Current hypotheses propose that stochastic remodeling is an 
important process for maintaining calcium homeostasis by alternately releasing or 
trapping the element in bones (Burr & Allen, 2013).  
This study focuses on the interaction between hormones that regulate metabolism 
and bones that are adapted to regular, vigorous physical activity in healthy young adults. 
Most modeling and re-modeling takes place at the periosteal and endosteal envelopes 
(Burr & Allen, 2013). The periosteal envelope is typically associated with a rate of 
apposition that exceeds the rate of resorption, while the opposite is true of the endosteal 
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envelope. The periosteal surface is normally remodeled during activity or after a fracture 
(Clarke, 2008). During childhood growth, bone is deposited on the periosteal envelope, 
while the amount of resorption on the endosteal envelope is decreased. Later in adulthood 
and through senescence, the process reverses and bone density decreases at the endosteal 
envelope (Burr & Allen, 2013; Seeman, 2007; Szulc et al., 2006; Jepsen & Andarawis-
Puri 2012). Researchers hypothesize that resorption is higher in the endosteal envelope 
because of its direct contact with cytokines from the marrow or perhaps because of 
greater mechanical stress (Clarke, 2008). Although age-related bone loss due to the 
increased rate of resorption at the endosteum coupled with the decreased rate of 
apposition at the periosteum is common, it is important to note that periosteal apposition 
never entirely ceases during adulthood (Jepsen & Andarawis-Puri 2012; Seeman, 2007). 
In fact, regular weight-bearing exercise is often prescribed prophylactically for elderly 
women in order to halt or reverse bone loss caused by post-menopausal estrogen 
deficiency (Dalsky et al., 1988). The mechanosensitive nature of the periosteal envelope 
is a key aspect of this study because it is the mechanism through which osteocalcin is 
produced.  
 Skeletal biology plays key roles in maintaining homeostasis and in conditioning 
the body to better respond to future physical tasks. The complex mechanisms regulated 
by bone cells allow an organism to adapt to mechanical stressors in order to better 
withstand them in the future (Frost, 2003). For this study, it is important to understand 
that the process of mechanical adaptation helps trigger a global endocrine response that 
improves metabolic function, which in turn supports more efficient osteoblast and 
osteoclast activity.   
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Mechanostat 
It has been well established that regular physical activity increases bone strength, 
often with a commensurate increase in bone mineral density (BMD) and/or bone mineral 
content (BMC). Increases in bone strength can be attributed to a change in section 
modulus and/or the deposition of new bone. As discussed above, bone apposition or 
resorption can happen at any one of the many different levels of bone (e.g. periosteal 
envelope, endosteal envelope, trabecular regions, etc.) beyond just the surface. This 
allows for an increase in strength or bending rigidity even though bone mass or external 
bone size may not change (Burr & Allen, 2013). Conversely, a lack of mechanical stress 
causes a decrease in bone mass and strength (Creighton et al., 2001; Frost, 2003; Huang 
et al., 2003; Yung et al., 2005). In 1960, Harold Frost first proposed the mechanostat 
model for the dynamic relationship between physical exercise (or the lack thereof) and 
bone behavior (Frost, 2003). According to Frost (2003), there are four strain zones that 
have an effect on bone: disuse, adapted state, overload, and fracture. Elastic bone 
deformation stimulates osteoblasts to lay down more bone.  
The degree of deformation predicts the amount of osteoblastic activity and the 
general strength of the bone. The disuse state indicates that there is little to no physical 
activity, meaning that the elastic bone deformation stimulus that is necessary to build 
bone is absent. As a result, osteoclast activity will surpass osteoblast activity and cause 
bone loss. This state is common among sedentary populations. The adapted state is the 
balance between bone deformation and growth in which bone strength and mass remains 
constant. Bone resorption is equal to bone formation, meaning that there is sufficient 
deformation to cause an osteoblastic response that can keep pace with osteoclast activity. 
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In the overload state, the elastic bone deformation is sufficient to cause the osteoblasts to 
lay down bone even faster than osteoclasts break it down, which increases bone strength. 
Although the increase in strength and ability to withstand bending rigidity is often 
associated with increased bone size, it is important to note that the external dimensions of 
the bone may not change since the apposition could be occurring internally on the 
endosteal envelope or within the trabecular bone. In the fracture state, the bone reaches 
the peak deformation level and fails, resulting in fracture (Frost, 2003).  
The mechanostat is an important concept for this study because it is the actual 
mechanism whereby physical activity affects bone and, in turn, the hormones produced 
by the skeletal system. As bone models or remodels consequent to physical activity, 
osteocalcin is produced. Osteocalcin increases insulin synthesis as well as overall insulin 
sensitivity. Interestingly, leptin affects the body’s ability to produce osteocalcin. On a 
neurologically-controlled systemic level, leptin increases OC production. However, on a 
local osteological level, leptin inhibits osteocalcin production. The interactions amongst 
leptin, osteocalcin, and insulin demonstrate a connection between physical activity and 
metabolic regulation, but the nature and evolutionary trajectory of the link is not well 
understood.  
Physical Activity 
 Physical activity can be defined as “any bodily movement produced by skeletal 
muscles that results in energy expenditure” (Caspersen et al., 2000). Clearly not all 
activities induce the same physiological effect, so quantification of physical activity often 
involves categorization based on effort and duration. Exercise is a subset of physical 
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activity and is differentiated by its “planned, structured, and repetitive” nature. Over time, 
both physical activity and exercise have been decreasing in modern humans.  
 Physical activity is an important component to healthy weight management. 
Understanding energy balance and its relationship with life history theory allows 
individuals to successfully control body composition. Energy in the body is the same as 
energy in the universe; the laws of thermodynamics are preserved. Energy is neither 
created nor destroyed. Rather, humans ingest food and extract energy from their 
sustenance. A certain amount of energy is necessary to sustain life. Beyond that, energy 
is necessary to accomplish any other physical activity. Two relatively simple terms are 
useful in understanding the relationship between food and physical activity: energy 
balance and energy flux. Energy balance, in its most distilled form, refers to the ratio of 
energy intake to energy expenditure. When energy intake is higher than energy 
expenditure, the balance is positive and results in a person gaining weight and building 
fat stores. When energy intake is less than energy expenditure, the balance is negative 
and results in a person losing weight. Energy flux is related to energy balance. Energy 
flux is, in the words of Peter Ellison (2001), “the rate at which energy is flowing through” 
a body. High flux is characterized by a high caloric intake paired with heavy energy 
expenditure, while low flux is defined by low energy consumption and use.  
 With very few exceptions, everyone performs some sort of physical activity in 
order to survive; however, there is a wide range in the amount and types of physical 
activity among individuals. Low physical activity levels when coupled with high caloric 
intake create a positive energy balance that, over sustained periods, results in obesity. 
Over the last 50 years, physical activity levels have declined. Although there are slight 
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increases in the percentage of the population in the United States engaged in recreational 
physical activity, there is overall far less energy expended in transportation, work, and 
household tasks (Brownson et al. 2005). Obesity rates in the United States parallel 
Americans’ increasing sedentism.  
Accompanying the rise in obesity are the skyrocketing costs associated with 
treating it. In 2005, the United States spent an estimated $190 billion on obesity-related 
health problems. Per capita, obese individuals can expect to pay $2741/year more than 
their normal-BMI peers in health-related spending (Cawley & Meyerhoefer, 2012). Using 
2006 data, Finkelstein et al. (2009) estimated that the direct costs of obesity created by 
medical treatments were 10% of total medical costs in the nation, which is the equivalent 
of almost $86 billion a year. Obesity-related diseases accounted for 8.5% of Medicare 
spending, 11.8% of Medicaid spending, and 12.9% of private-payer spending. This does 
not take into account the indirect costs of obesity such as missed work and higher life and 
insurance premiums paid by employers for obese employees (Colditz, 1992; Trogdon et 
al., 2008). The costs of moving less and the associated obesity are key considerations for 
public and individual health.   
In terms of this study, physical activity is an important factor in understanding 
bone physiology (the mechanostat principle) and hormone levels. Physical activity is the 
independent variable that theoretically influences bone strength as well as leptin and 
osteocalcin levels. Hypothetically, increased physical activity and exercise causes an 
increase in bone strength and osteocalcin, with an associated diminution of leptin. 
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Leptin 
Leptin is a 167 amino acid peptide hormone produced mostly in white adipose 
tissue (adipocytes) (Hadley & Levine, 2006). At least 65% of leptin’s sequence is 
conserved across mammals as diverse as dogs, rats, mice, cows, pigs, humans, 
chimpanzees, gorillas, orangutans, chimpanzees, and rhesus monkeys. Chimpanzees’ 
leptin sequence most closely matches that of humans, with a single amino acid 
substitution at position 73 (Gaucher et al., 2003). Researchers discovered leptin in 1996 
(Hadley & Levine, 2006). In mouse models, leptin has a direct effect on metabolism and 
weight regulation (Friedman & Halaas, 1998). When scientists injected mice with leptin, 
the animals’ hunger drive and weight decreased (Friedman & Halaas, 1998). Because of 
this, leptin was initially lauded as a miracle weight-loss cure. It quickly became clear, 
however, that leptin’s mechanism in humans is much more complex; thus, administering 
exogenous leptin in humans would not produce the same weight loss results seen in mice 
models. For all animals, as the amount of adipose tissue increases, so, too, does the 
amount of leptin secreted from the fat cells. It is a pleiotropic hormone whose primary 
function is to act as a hunger regulator, namely by reducing the desire to eat while 
simultaneously encouraging greater energy expenditure (Zhang et al., 2005). However, 
leptin has multiple secondary functions that are equally important. Leptin is involved in 
angiogenesis, hematopoiesis, immune regulation, and reproductive function (Zhang et al., 
2005; Fantuzzi & Faggioni, 2000; Lago et al., 2008; Moschos et al., 2002). 
Leptin receptors (ObR) can be found throughout the body in varied locations like 
the brain, liver, placenta, fetal lung, and vasculature (Hadley & Levine, 2006). The 
diversity of location mirrors the importance and variety of leptin’s role throughout the 
 15 
body. Interestingly leptin encourages the production of highly permeable vasculature, 
which increases leptin’s ability to spread quickly throughout the body and act globally 
(Carmeliet & Jain, 2000; Cao et al., 2001). Free and protein-bound leptin can both be 
found circulating in serum. ObR use the Janus kinases (JAK) and signal transducers and 
activators of transcription (STAT) signaling. The JAK-STAT signaling pathway 
transmits a signal from outside the cell into the cell. When a hormone docks with its 
cytokine receptor, it triggers a chain reaction within the cell whereby the JAKs are 
activated, which then causes the STATs to be phosphorylated and become active. The 
STATs then transmit the information to the cell’s nucleus, where the required gene is 
activated to carry out the hormone’s instructions. There are six isoforms of the ObR. The 
short form (ObRa) is found in the brain’s microvasculature as a means of bringing leptin 
across the blood-brain barrier using receptor-mediated transport. The long form of ObR 
resides in the basal hypothalamus’ nucleus groups, including the arcuate nucleus, 
ventromedial nucleus, and dorsomedial nucleus, which are all areas associated with 
hunger control (Hadley & Levine, 2006).  
It is proposed that the brain receives information about the body’s energy reserves 
from leptin that has penetrated the blood brain barrier (Zhang et al., 2005). Life history 
theory posits that the body can allocate energy towards three activities: 
survival/maintenance, growth and development, and sexual reproduction. Energy will be 
differentially allocated to the three activity categories depending on an individual’s 
environment and access to food (Kaplan et al., 2000). In an energy rich environment, the 
body does not have to ‘choose;’ it can successfully fund all three activities at once. In 
energy poor environments, the body must ‘decide’ which activity or activities are most 
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important (Kaplan et al., 2000). For example, it would be useless for a female to 
contribute energy towards sexual reproduction rather than survival in circumstances of 
extreme nutritional deprivation. It is likely that the woman would miscarry since there 
would not be sufficient energy to carry the child to term. Instead, it is better to put energy 
towards survival and maintenance so that she might survive until a time when there is 
sufficient excess energy to successfully reproduce (Ellison, 2001).  
Clearly the body and brain have a means of monitoring current energy status so 
that it may effectively manage these energy tradeoffs. It is proposed that the brain 
receives information about the body’s energy reserves from leptin that has penetrated the 
blood brain barrier. Since fat is a major energy source for the body, it makes sense that 
the hormone produced by adipocytes is the best indicator of how much energy is 
available (Zhang et al., 2005, Havel, 2000; Jéquier, 2002).  
Typical accommodation to energy deficiency amongst adults includes losing 
weight (mostly water and fat), lowering basal metabolic rate (BMR) and physical activity 
levels (PAL), decreasing the threshold for thermogenesis to occur, and, if the energy 
deficit persists, the body may begin using its lean energy stores (Ellison, 2001; Widmaier 
et al., 2010). People may experience behavioral changes, such as becoming withdrawn or 
irritable, demonstrate diminished cognitive skills, and become less inclined to do physical 
activity, which helps lower their BMR. Immune function and ability to reproduce may be 
impaired until the caloric imbalance is corrected (Ellison, 2001; Widmaier et al., 2010). 
As the body’s fat stores are depleted, leptin production, which is based in adipose cells, 
also drops. Low leptin levels communicate to the central nervous system and peripheral 
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tissues that there is little energy available, thereby inducing accommodation to starvation 
(Zhang et al., 2005; Lago et al., 2008). 
Interestingly, the body’s response to low levels of leptin caused by starvation or 
malnutrition is similar to its response to leptin insensitivity caused by obesity (Elmquist 
et al., 1999; Friedman & Halaas, 1998). Obesity can create a state of perceived starvation 
due to leptin insensitivity (Münzberg & Myers, 2005). Some studies imply that leptin 
insensitivity in obese individuals is caused by the hormone’s inability to penetrate the 
blood-brain barrier (Banks et al., 2004; Caro et al., 1996). Others simply advocate for 
insensitivity through receptor exhaustion or overexpression of suppressors of cytokine 
signaling 3 (SOCS3) (Hadley & Levine, 2006; Mori et al., 2004; Bjørbæk et al., 1998). If 
the brain or peripheral tissues cannot register leptin’s signal, then it operates under the 
assumption that there is less energy available and it begins making energy tradeoffs. 
Centrally regulated factors such as BMR and PAL will be reduced, however no weight 
will be lost because there is still a positive energy balance. In fact, the individual might 
gain more weight than they normally would since their BMR is decreased. Additionally, 
leptin insensitivity may induce the body to differentially allocate energy (Münzberg & 
Myers, 2005; Kaplan et al., 2000). Since the body thinks it is starving, it will shunt 
energy away from the reproductive and immune systems, and instead focus on 
maintaining and building energy stores. Indeed, obese women often have decreased 
fertility in comparison to their more fit peers. Additionally, the obese often have impaired 
immune function when compared against normal weight individuals (Zhang et al., 2005; 
Moschos et al., 2002). 
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Genetically manipulated mice born without the ability to produce leptin (ob/ob) 
are hyperphagic, obese, and infertile. Administration of exogenous leptin quickly corrects 
these problems (Friedman & Halaas, 1998). Although exogenous leptin helps return 
humans with a congenital inability to produce leptin back to a normal state, it does not 
seem to have the ability to curb hunger in people without the mutation (Elmquist et al., 
1995). In mice however, exogenous leptin administration limits the animal’s hunger, 
regardless of their genetic status. This indicates that the human model has added 
complexity that has yet to be clarified (Friedman & Halaas, 1998).   
Several hormones affect leptin secretion. Insulin, steroid hormones, and 
noradrenaline stimulate secretion (Hadley & Levine, 2006). Glucocorticoids elicit the 
strongest response by acting directly on the adipocytes (Ahima & Flier, 2000; Lago et al., 
2008). Leptin levels increase in response to inflammatory stimuli (Fantuzzi & Faggioni, 
2000). Exposure to endotoxins (lipopolysaccharide), tumor necrosis factor α (TNF- α), 
and interleukin 1 (IL-1) all provoke increased leptin production. The response is 
transient, but consistent. Chronic inflammatory stimulation, however, will gradually 
provoke a suppression of leptin secretion over time. Exercise inhibits TNF-α and some 
interleukin production, which helps reduce overproduction of leptin and prevents leptin 
insensitivity (Lago et al., 2008).   
Leptin shares inhibitors with hormones that use tyrosine kinase receptor (TKR) 
signaling, such as insulin (Hadley & Levine, 2006). The SOCs (suppressors of cytokine 
signaling) are the primary inhibitors. They work by attaching themselves directly to the 
receptor to prevent the phosphorylation of the signal transducing protein or by binding 
directly to the signal transducer to block the protein from activating transcription in the 
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nucleus. Additionally, the cellular activity of hormones that signal through TKR can be 
down-regulated by protein tyrosine phosphatases by de-phosphorylating the TKR directly 
or by de-phosphorylating the intra-cellular signal transducing protein. Leptin and insulin 
resistance have been linked to overproduction of both these hormones, which, in turn, 
causes a concomitant rise in SOCs (Hadley & Levine, 2006).  
 Leptin follows general secretion patterns in regards to time and sex. The 
hormone’s expression is sexually dimorphic, with higher levels in females than males 
even after adjusting for women’s naturally greater tendency towards higher body fat 
percentage (Saad et al., 1997). Some studies show that testosterone down-regulates 
leptin, which may help explain this dimorphism (Blum et al., 1997; Luukkaa et al., 1998). 
This fits with the model of testosterone acting as an immunosuppressant. Leptin increases 
immune function by signaling the brain that there is sufficient energy to mount an 
effective defense against foreign pathogens (Folstad & Karter, 1992; Roberts et al., 
2004). Potentially, women have more leptin because they need to more carefully regulate 
energy due to increased demands on energy reserves for pregnancy and lactation (Ellison, 
2001). Additionally, both sexes experience a circadian nocturnal surge between midnight 
and early morning with a significant drop between noon and the early afternoon, 
independent of body weight. Diurnal leptin release is dependent on habitual mealtimes 
(Sinha et al., 1996).  
 Interestingly, mean concentration of leptin varies according to population. For 
example, a study conducted amongst the Aché of Paraguay found that Aché women had 
higher body fat when compared against an American control group, yet had low leptin 
levels that were comparable to a sample made up of American women anorexics. This is 
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unusual, as one would expect the Aché women to have higher leptin as a result of greater 
adipose tissue (Bribiesecas, 2001). This disparity is potentially caused by the high 
amount of physical activity undertaken by Aché women in comparison to the American 
control groups. These findings imply that environmental conditions contribute to 
variations in mean leptin concentration across populations. Further study is needed, but it 
seems that hormonal adaptations are highly sensitive to the environment, likely as a result 
of the variation in food availability (feast/famine cycles) that affects the body’s energy 
stores (Bribiesecas & Hickey, 2006). Interestingly, humans seem to have trouble 
hormonally coping with the modern, constantly energy-rich and available diet, which 
would mean that the evolutionary environment was extremely dissimilar. 
 In theory, leptin provides the basis for the body’s portioning of energy. It is thus 
important to include it in an endocrine investigation into potential evolutionary origins of 
obesity as well as the relationship amongst physical activity, hormones, and metabolism. 
Leptin measurements were taken for this study in order to help establish each individual’s 
baseline leptin levels, which give a rough estimate of how much energy is available to the 
body. Comparing the amount of leptin against the amounts of other hormones might 
illustrate the relationship between leptin, an important hormone for the regulation of 
metabolism, and other hormones related to obesity.  
Osteocalcin 
Osteocalcin (OC) is a small non-collagenous protein produced by osteoblasts. It is 
also known as bone gamma-carboxyglutamic acid-containing protein (BGLAP) and bone 
Gla protein (Hadley & Levine, 2006). In literature, it is often shortened to OC, BGLAP, 
or BGP. The genes responsible for regulating OC can be found on chromosome 1 
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(Puchacz et al., 1989; UCSC Genome Browser, 2009). Human osteocalcin is composed 
of 49 amino acids (Hauschka & Carr, 1982). The structure of osteocalcin is similar across 
species, indicating a high degree of evolutionary conservation. Kelly et al. (1991) found 
that genetics explained up to 80% of the variation in osteocalcin production.  
OC contains three gamma-caboxyglutamic (Gla) residues. It appears that 
osteoblasts begin to produce osteocalcin as soon as bone mineralization begins. There are 
two primary components to OC’s structure: an alpha-helix and a COOH-terminal beta-
sheet. The alpha-helix contains the three Gla residues, which are strategically positioned 
on the same face to accumulate hydroxyapatite molecules (Hauschka, 1986). The alpha-
helical structure is dependent on CA2+; the more CA2+ bound, the greater the proportion 
of the protein that is maintained in the alpha helix structure (Hauschka & Carr, 1982). 
Greater calcium levels promote hydroxyapatite binding (MeSH, 2011). The beta-sheet 
appears to be chemo-attractant to monocytes, which are a type of white blood cell 
involved in the immune system and are a precursor to osteoclasts (Hauschka, 1986).  
 Osteocalcin synthesis is dependent on several other hormones and vitamins. It 
needs vitamin D because calcitriol triggers production by binding to vitamin D receptors 
as well as a vitamin D element on the osteocalcin gene (Hauschka, 1986). Researchers 
found that restriction fragment length polymorphisms (RFLPs) in the vitamin D receptor 
gene predict osteocalcin levels. Different vitamin D alleles result in differential 
production of osteocalcin (Morrison et al., 1992). Administration of exogenous 
1,25(OH)2-vitamin D3 results in greater osteocalcin production (Hauscka, 1986). OC also 
requires the presence of vitamin K for Gla production and vitamin C for the 
hydroxylation of Prog (proline) into hydroxyproline. Medical observers have recorded 
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that fetuses or infants with vitamin K deficiencies (typically from exposure to warfarin) 
have a specific pathology, including hypoplastic nasal bones and diffuse pinpoint 
calcifications in the epiphyses. This condition is known as warfarin embryopathy (Pauli, 
1988; Hall et al., 1980). Vitamin K aids in the carboxylation of OC. People with reduced 
levels of vitamin K tend to produce under carboxylated OC, which is less active. In a 
study of healthy post-menopausal women (with pre-menopausal women used as a 
control), administering exogenous vitamin K increased the post-menopausal subjects’ 
levels of osteocalcin and decreased the amount of calcium excreted, with no effect on the 
pre-menopausal volunteers (Knapen et al., 1989). This indicates that vitamin K may play 
a role in conservation of post-menopausal bone mass and cements the vitamin’s 
importance in the production and regulation of OC.  
Osteocalcin levels in a normal, adult human range from 5 to 7 ng/mL, although 
the vast majority of it is trapped within the skeleton (Gundberg et al., 1983). Although 
experiments to determine the metabolic processes associated with osteocalcin have not 
been conducted in humans, rodent and sheep models exist. Both show that excess OC is 
quickly taken up by the kidneys, liver, and bone. The liver and kidneys rapidly break 
down osteocalcin. It seems that osteocalcin is likely metabolized via destructive methods 
rather than through excretion (Farrugia & Melick, 1986).  
Osteocalcin appears to have a circadian rhythm. Six healthy 20- to 30-year-old 
men and four women were monitored over a period of 24 hours. Osteocalcin 
measurements were taken every 30 to 60 minutes. Osteocalcin levels were low in the 
morning, but rose in the afternoon and early evening. OC’s maximum level was achieved 
at night (Gundberg et al., 1985). Interestingly, OC levels begin to rise and peak on a 
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schedule opposite to leptin. The rhythmicity of OC secretion was supported in a mouse 
study (Gafni et al., 2009). Additionally, Gafni et al. used transgenic mice with a human 
OC promoter and measured OC levels at different sites over the course of several 24-hour 
periods. Certain bones, such as the maxillomandibular complex, experience a greater 
amplitude in oscillations of the volume of osteocalcin released compared to others. 
Another study found that the administration of 1,25 dihydroxyvitamin D3 ameliorated the 
effects of the natural circadian morning drop in OC in humans (Markowitz et al., 1987).  
Osteocalcin has a plethora of functions, including metabolic regulation and bone 
formation/resorption. In a large 2010 study, researchers found that osteocalcin levels 
were inversely proportional to BMI, fat mass, and free glucose levels. Interestingly, it 
was not associated with height or fat-free mass, indicating that the connection between 
energy regulation and osteocalcin is primarily fat-based (Foresta et al., 2010; Kindblom 
et al., 2009). OC levels are inversely associated with presence of metabolic syndrome 
(Oosterwerff et al., 2013). Mice studies that use genetic manipulation to delete the 
osteocalcin gene have found that knockout mice are insulin resistant. Exogenous 
administration of osteocalcin leads to improved responsiveness from β-islet cells and 
increased insulin production (Hwang, 2012). Although removing osteoblasts in mice 
impaired glucose regulation, it improved gonadal fat weight and energy expenditure. 
Exogenous administration of OC restored blood sugar balance in mice, but not insulin 
sensitivity. Positive side effects such as increased energy expenditure and reduced 
gonadal fat remained (Yoshikawa et al., 2011).  
Although the primary function of osteocalcin in relation to bone remains 
unknown, it seems certain that it must be related to osteoblast function. A 1996 study 
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produced a strain of mice that have congenital osteocalcin deficiency, causing increased 
bone formation but normally functioning resorption (Ducy et al., 1996). A study in post-
menopausal women found that increased OC levels were associated with increased age 
and positive osteoporosis status (Lumachi et al., 2009; Garnero et al., 1996). Osteocalcin 
levels predicted differences in dizygotic twins’ bone densities. Because of its tight 
relationship with bone turnover, osteocalcin has been used as a proxy measure for bone 
activity for approximately the last twenty years (Lee et al. 2000).  
One of the major reasons osteocalcin was chosen for inclusion in this study its 
accuracy in measuring bone turnover. Measuring osteocalcin helps elucidate the 
connection between physical activity and bone re/modeling. Additionally, osteocalcin’s 
relationship with both leptin and insulin indicates that it is likely an important part of the 
exercise-bone-hormone axis. By measuring both osteocalcin and leptin, it becomes 
possible to begin to hypothesize on the intricacies of bone metabolism’s effects on body 
mass regulation. 
Insulin 
 Insulin is a 51 amino acid peptide metabolic hormone produced by the β-islet 
cells of the pancreas. Its primary function is to regulate carbohydrate and fat metabolism 
in the body by signaling various tissues to absorb glucose from the blood and store it as 
glycogen in the liver and skeletal muscles or as triglycerides in adipocytes. Insulin 
signaling works through a tyrosine kinase receptor that uses the intracellular signal 
protein known as insulin receptor substrate-1 (Hadley & Levine, 2006). Despite leptin 
using a different intracellular signaling protein, both insulin and leptin work through 
tyrosine kinase receptors, meaning that insulin can be down-regulated through similar 
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mechanisms (Hadley & Levine, 2006). Insulin works by activating the GLUT 
transporters, especially the GLUT2, which act to collect glucose from the bloodstream 
Insulin’s energy storing effects are enhanced by its inhibitory effect on glucagon, the 
hormone responsible for raising blood sugar by converting the stored glycogen back into 
glucose. Insulin and glucagon are part of a feedback loop essential for maintaining 
glucose homeostasis (Hadley & Levine, 2006).  
 Insulin is one of the most well-documented and researched hormones, mostly 
because of the widely known metabolic disease that accompanies insulin dysfunction. 
Type I diabetes is the result of the body’s inability to produce insulin (Daneman, 2006). It 
can be managed through constant blood glucose testing and the administration of 
exogenous insulin. Although the exact cause or vector for the disease is unknown, type I 
diabetes is ultimately caused by some sort of autoimmune destruction of the β-islet cells 
(Daneman, 2006). Type II diabetes is caused by insulin resistance, likely via obesity 
exacerbating a pre-existing genetic predisposition (Kahn & Flier, 2000).  
 Insulin’s structure is strongly conserved across species. In humans, the gene for 
insulin can be found on the eleventh chromosome (Harper et al., 1981). The inactive form 
of insulin is stored in a hexamer and the active form is a monomer (Hadley & Levine, 
2006). Insulin is initially produced as preproinsulin and then cleaved into proinsulin by 
the endoplasmic reticulum where it is also folded into its final shape attached by disulfide 
bonds. Prohormone convertases then cleave the proinsulin into insulin. Once the peptide 
is complete, it is packaged inside a vesicle to await exocytosis that will be triggered by 
external cellular messengers (Hadley & Levine, 2006).  
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 Insulin has several powerful secretogues and inhibitors. The most powerful of 
these are gastrointestinal hormones such as cholecystokinin and glucose-dependent 
insulinotropic peptide. Gastrointestinal hormones are released when food enters the 
digestive tract. This physical cue alerts the body that free glucose will soon be available 
(Hadley & Levine, 2006). Too much glucose in the bloodstream can be deadly, which is 
why it is essential to effectively regulate sugar levels. Revving up the insulin secretion 
process before the glucose enters the blood allows it to be ready if necessary for rapid and 
efficient metabolic management (Widmaier et al., 2010). Although osteocalcin does not 
actively encourage the release of insulin, it does increase the body’s sensitivity to insulin, 
which could help type II diabetics eventually manage their disease (Clemens & Karsenty, 
2011). Catecholamines’ overall effect on insulin is inhibitory. When the body enters 
fight-or-flight mode, it marshals all of its resources to survive, including glucose to fuel 
the muscles and brain during rapid stress response (Hadley & Levine, 2006). Insulin 
release is linked to the consumption of food. During and directly following mealtimes, 
insulin levels rise. In between eating sessions, insulin levels hover around 57-79 pmol/L 
(Hadley & Levine, 2006).  
 Insulin is an important part of this study because it is the main hormone 
responsible for blood glucose regulation, which is an important component of obesity. 
Type II diabetes, characterized by insulin insensitivity, is one of obesity’s major 
comorbidities. Uncontrolled blood sugar is typically caused by an overproduction of 
insulin, insulin insensitive cell receptors, or a combination of both. Measuring insulin 
would have allowed the researcher to ascertain that participants had a healthy mechanism 
for blood sugar management as well as providing insight into how insulin efficacy ties 
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into the greater picture of exercise, bone turnover, and mass regulation. Unfortunately, 
the test for measuring insulin failed so insulin’s relationship with the other factors in the 
study can only be considered from a theoretical perspective.  
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Chapter III: Hypotheses on the Evolutionary Origins of Modern Obesity 
 There are currently five major hypotheses about modern obesity: the thrifty gene 
hypothesis, the drifty gene hypothesis, the thrifty phenotype hypothesis, the genetically 
unknown food hypothesis, the aggression control hypothesis, and the climate adaptation 
hypothesis. Like all hypotheses, each has its merits and problems. Ultimately, the thrifty 
gene and thrifty phenotype hypotheses have the most merit.  
 The newest and least tested proposals for the evolutionary origin of human 
obesity include the genetically unknown food hypothesis, the climate adaptations 
hypothesis, and the aggression control hypothesis. A brief summary of each will be 
provided in the interest of presenting a complete review of the literature. However, as 
they have the least amount of data to support them, they will not be considered as a 
potential explanatory framework for this study.  
Current Literature Review 
Baschetti (1998) is the main proponent of the genetically unknown foods 
hypothesis. He observed that native populations (e.g. the Pima of Arizona) had low 
incidence of obesity and related diseases until coming in contact with Western diets. He 
believes that this is caused by the excessive amount of fat and sugar found in modern 
foods when compared to the types of food available to the vast majority of human 
ancestors over evolutionary time. The discrepancy between the evolutionary diet and the 
modern diet causes obesity. Baschetti fails to account for increased calorie consumption 
and decreased physical activity, relying solely upon the difference in food composition 
(Ravussin et al., 1994; Baschetti 1998). Although an increased amount of fat and sugar 
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almost certainly plays a role in modern obesity levels, Baschetti’s work lacks sufficient 
data and testing to be considered a primary theory. 
A 2010 article by Belsare et al. introduced the aggression control hypothesis. 
Building on work showing that violence and warfare have decreased over time, the 
authors posited that obesity became less of a hindrance for survival as intra-species 
aggression decreased. They argue that males who are fully satiated are more lethargic and 
docile. Additionally, being overweight or obese would make survival less likely during 
violent encounters. The authors assert that there was a cultural shift away from ‘soldier’ 
mode to ‘diplomat’ mode. In this environment, it became advantageous to curb one’s 
aggression. The endocrine shift associated with obesity (more serotonin, lower sex 
hormone and epidermal growth factor) helps keep individuals calm, submissive, and 
better able to survive in low aggression groups. Modern societies are so low in violence 
and personal injury compared to prehistoric ancestors that that the endocrine and 
metabolic shifts have spiraled out of control and result in obesity and its related 
comorbidities.  
The major failure of Belsare et al.’s work is the lack of an explanation for why 
becoming less aggressive would be advantageous to survival or what triggered the 
cultural shift away from warfare. Animal models and human studies clearly show that 
more aggressive individuals have higher rates of reproduction (Pasternak et al., 1997). 
Additionally, their hypothesis only works if it is the lack of aggression causing obesity, 
rather than non-violence being a side effect of obesity. One could perhaps make the 
argument that, once violence began to ebb in human groups, obesity became less of a 
disadvantage and thus was no longer actively selected against, which allowed a larger 
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proportion of the population to carry genes that encourage obesity. Indeed, John 
Speakman (2008) argues this very point, but his hypothesis has its own flaws as 
discussed below.  
Sellayah et al. introduce the most recent hypothesis in a 2014 article entitled “On 
the Evolutionary Origins of Obesity: A New Hypothesis.” They propose that, as humans 
migrated out of Africa and into varying climates, they adapted to best survive their new 
environments. In places that are extremely cold, people have higher resting metabolic 
rates coupled with a better ability to metabolize fat for superior thermoregulation. In 
contrast, populations living in warmer climates adapted to prevent heat exhaustion and 
heat stroke, both of which are known to shorten lifespans. (A similar argument is made 
for variations in skin pigmentations across populations in disparate geographic locations. 
(Jablonski & Chaplin, 2010; Loomis, 1967).) A lower metabolic rate is adaptive to hotter 
regions because it reduces the amount of thermogenesis, allowing for better internal 
temperature regulation. Slower metabolisms also mean a reduced ability to burn fat and a 
greater likelihood of obesity. According to the authors, the pressure to adapt to climate 
would supersede adaptive pressures like periodic famine or predation. As evidence for 
their hypothesis, the authors use differential population obesity rates. Europeans and East 
Asians have the lowest levels of obesity at 26% and 11% respectively. In contrast, 43% 
to 45% of Pacific Islanders are obese, with Native Americans at 39-41%, African 
Americans at 38-40%, and 31-34% of Hispanics. The two lowest levels of obesity are 
found in groups that spent the most time in colder climes, while the highest levels are 
found in groups who spent the most time in hotter areas. It is certainly possible that 
climate adaptations are a contributing factor to the modern obesity pandemic, but since 
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the hypothesis is so new there is relatively little data to support it. A major concern would 
be validating their assertion that their study took into account the known socioeconomic 
factors that may play a role in health and obesity. More research needs to be done on this 
interesting perspective. 
Theoretical Framework 
 JV Neel first introduced the thrifty gene hypothesis in 1962 with his 
groundbreaking article, “Diabetes mellitus: a ‘thrifty genotype’ rendered detrimental by 
‘progress’?”. Of the five hypotheses, it is the longest standing and most well researched. 
Neel advocates for positive selection. He argued that human ancestors lived in food 
insecure environments in which it would have been advantageous to lay down as much as 
fat as possible in times of plenty in order to insulate against future, almost certain 
starvation. Parasite stress might have also contributed to the thrifty genotype hypothesis. 
Parasites alter individuals’ energy balance (Dama, 2011). Those that were able to lay 
down more fat and remain healthy would have been better able to reproduce and survive. 
Being a healthy weight in a place where parasite load is high (which is most of Africa) 
would signal to prospective mates that the individual has good genes (Gangestead & 
Buss, 1993). These adaptive pressures selected for ‘thrifty’ genes over the course of 
millennia that maximized fat storage efficiency. The mismatch of modern and ancient 
milieus is responsible for the current obesity epidemic. Humans’ evolutionary history has 
predisposed them to fat accumulation, and the modern calorie dense and perpetually 
available diet has allowed large portions of the population to become bigger than ever 
before.   
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In 1989, Neel revised his theory to specify that the genotype emerged post-
Paleolithic. In a 2008, Prentice at al. proposed that the thrifty genes actually emerged 
with the switch to agriculture from hunter-gathering. They argue that famine was 
relatively rare before sedentary agriculture became a primary subsistence strategy. 
Berbesque et al.’s 2015 research supports this variation on the hypothesis, when they 
found that warm weather foragers experience significantly less food insecurity than their 
agriculturalist counterparts. Cold weather foragers were found to have more frequent 
periods of food insecurity, but are relatively recent in humans’ evolutionary history and 
had thus developed cultural adaptations to deal with availability issues. Increased fertility 
also accompanied agriculture. Regular cycles of feast and starvation worked together to 
create the genes by allowing more offspring to be produced during times of plenty, while 
selecting for individuals with a greater ability to survive lean times. Additionally, greater 
fat stores would be an advantage for reproduction during periods with lower food 
availability. Starvation halts fertility, particularly in females. Individuals with greater fat 
stores were more likely to be able to continue to reproduce during famine than their 
slimmer counterparts who would have less disposable energy with which to successfully 
reproduce.  
Recently, several articles sought to disprove the thrifty genotype hypothesis. 
Notable among these was a 2006 article by Benyshek and Watson titled “Exploring the 
Thrifty Genotype’s Food-Shortage Assumptions: A Cross-Cultural Comparison of 
Ethnographic Accounts of Food Security Among Foraging and Agricultural Societies” 
that exemplifies the results and conclusions of similar studies. The Benyshek and Watson 
article included a statistical cross-cultural study on 94 of the 118 societies contained with 
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the Human Relations Area Files (HRAF). The authors concluded that there is no 
significant difference in food security between hunter-gatherer groups and agriculturalists 
and, furthermore, that food insecurity is relatively rare in pre-industrial societies. (This 
ignores that there is still more food insecurity in pre-industrial societies than in modern, 
Western, industrial societies. There could be enough of a difference to drive the modern 
obesity epidemic.) Benyshek and Watson use this as evidence that the thrifty genotype 
hypothesis is not feasible. According to their results, there would not have been enough 
significant repeated episodes of feast and famine to drive natural selection in early 
humans. Instead, the authors propose that epigenetic programming could be solely 
responsible for obesity-related diseases. They do not offer an explanation for the rising 
rate of modern obesity.  
According to the authors, the cultures chosen from the HRAF were included 
because they had the most complete nutritional information data available and were 
representative of various modes of subsistence. However, it is important to note that 
hunter-gatherer groups in the HRAF do not exactly replicate how humans in the pre-
agricultural world would have lived, which brings into question how representative of the 
evolutionary environment they truly are. Modern hunter-gatherer groups are living in 
more extreme environments than they would have in the past, affecting their subsistence 
behaviors (Marlowe, 2005). They have been pushed out of traditional territories as 
agriculturalists or industrial interests have expanded their reach. Additionally, modern 
hunter-gatherers do not exist in a vacuum; they often have contact with agricultural or 
industrial societies in the form of trade. Trade introduces elements into the hunter-
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gatherer lifestyle that alter it from its traditional roots (Marlowe, 2005; Benyshek & 
Watson, 2006).  
Beyond behavioral differences, the Pleistocene and Holocene environments are 
different from each other. The Pleistocene was marked by a series of glaciation events 
that put incredible stress on all species. It saw the extinction of both mega fauna and 
Neandertals – both of which required huge amounts of energy to survive. Neandertals 
required, on average, 1.4 times more calories than anatomically modern humans (AMH). 
This helps explain how AMH were incredibly successful in this food-stressed 
environment; they simply needed less energy to survive (Froehle & Churchill, 2009). 
Humans spent enough time as hunter-gatherers in the Pleistocene (which was very 
different climatologically from the Holocene) that it would have likely affected the 
genetic profile, something that Benyshek & Watson do not seem to take into account. 
Additionally, the Holocene was marked by a climate amelioration that made 
agriculture possible (Richerson et al., 2001). Benyshek and Watson’s results found no 
differences in food insecurity between modern hunter-gatherers and agriculturalists. 
Other researchers have found that there are significant differences. With agriculture came 
rapid population growth – along with greater food insecurity and poor health (Prentice et 
al. 2008; Berbesque et al., 2015; Starling & Stock, 2007; Larsen, 2006; Larsen, 1995). 
Poor health as a result of less food and less high quality food also could have played a 
role in the evolution of the thrifty genotype. As discussed in the section on life history 
theory, when the body is stressed by disease or malnutrition, reproduction is less likely. 
Malnutrition often leads to disease because the body must choose to support maintenance 
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of basic bodily functions over immune function. The food insecurity that accompanies 
agriculture is where the thrifty genotype most likely emerged (Prentice et al. 2008).  
Hunter-gatherer groups may provide the best model for life in the evolutionary 
past – but they are the best model simply because no other models exist. The differences 
between the modern environment experienced by current hunter-gatherer groups and the 
evolutionary environment should be taken into account when considering research such 
as Benyshek and Watson’s that attempts to conflate the two. 
Besides the problem of using modern hunter-gatherer groups as a proxy for 
humans in the evolutionary environment, there is one major problem that would need to 
be addressed before completely discrediting the thrifty genotype hypothesis based on 
Benyshek and Watson’s results. As the authors themselves explain, they have not 
assessed whether even periodic and/or mild food insecurity can affect a population’s gene 
pool. Even supposedly slight differences in reproductive success or survivorship will 
eventually compound over time, causing a shift in the allele frequency of the genotype 
that controls mass and metabolism. This shift (however slight), when coupled with 
modern, Western, industrialized societies’ constant access to food could be one of the 
components of the obesity epidemic. Until this is tested, it is important to keep Benyshek 
and Watson’s criticisms in mind, while cautiously moving forward with the thrifty 
genotype hypothesis. Like most theoretical frameworks, the thrifty genotype hypothesis 
will likely be adjusted over time as more is learned, but current evidence suggests that it 
is the best model.  
 In direct opposition to the thrifty genotype hypothesis, the drifty genotype 
hypothesis proposes that humans’ predisposition to laying down fat came from random 
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drift. Speakman, the originator and staunchest supporter of the drifty gene hypothesis, 
believes that existing data for famine mortalities does not support the thrifty gene 
hypothesis (2008). Further, it is normally the very young or the very old that typically die 
during famine. The elderly are beyond reproductive years and the young have not yet had 
a chance to reproduce, thus their deaths cannot directly affect the group’s gene 
composition. Individuals beyond their reproductive years can indirectly affect a group’s 
gene pool by contributing resources such as childcare or extra food to their relatives who 
are still reproductively viable. Increased access to resources boosts individual fertility and 
decreases infant and childhood mortality (Pasternak et al., 1997). He does allow that 
individuals who are extremely lean are also more likely to perish from illness – a fact that 
has been confirmed by modern studies showing that disease survival rates are higher for 
people on the high end of the normal range or low end of the overweight range on the 
BMI scale. Speakman also takes issue with the mathematics of allele spread. Using 
Haldane’s calculations, Speakman posits that if thrifty genes emerged during the 
Paleolithic and conferred the advantage that researchers like Prentice et al. (2008) or Neel 
(1967) suggest, then many more people should be obese since the vast majority of the 
population should have the thrifty genotype.  
Instead, Speakman argues that there is an upper and lower intervention limit for 
weight. Below a certain weight, an organism risks starvation and the elimination from the 
gene pool. Above a certain weight, animals are much more likely to face predation risks 
because they are less likely to escape predators. Approximately 2 million years ago, 
humans lowered their predation risk through the development of weapons, living in 
groups, and (much later) fire. This allowed the upper intervention to edge upwards. Over 
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time, humans’ predation risk has decreased dramatically through the use of tools. With no 
real evolutionary pressure to stay lean in order to escape becoming a meal, gene drift 
allowed for obesity to creep in through random mutation. Speakman acknowledges that 
predation risk is only one proposed hypothesis through which gene drift would allow 
obesity to enter the population. Speakman also proposes another scenario in which 
variations in genes regulating fat oxidation always existed. However, without high 
dietary fat, they were never put to the test. In the modern environment with high dietary 
fat, people with a lesser ability to use their fat have become obese.  
 Although Speakman’s drifty gene hypothesis is at first intriguing, it is riddled 
with flaws. Speakman reasons that, according to calculations of gene spread, thrifty genes 
should be in the majority of the population if it confers as great of an adaptive advantage 
as proposed by other researchers. If this is true, a much greater portion of humanity 
should be overweight or obese. He ignores human agency as well as basic 
thermodynamics when he reaches this conclusion. People regularly choose to follow a 
certain diet in order to maximize their physical fitness (or at the very least avoid obesity). 
Even if a person carries the thrifty genotype, eating a balanced diet in which energy 
intake matches energy use will prevent obesity. Gaining weight despite matching caloric 
intake to expenditure literally defies the laws of physics. Additionally, he seems to have 
missed that there are still quite a few modern populations that regularly struggle with 
food insecurity. Possessing thrifty genes does not automatically doom an individual to 
being overweight or obese. His second argument that the majority of deaths during 
famines are irrelevant to selection because it is normally the very old and the very young 
that die discounts reproductive selection while focusing solely on viability selection. 
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Ultimately, there is a difference amongst individuals’ ability to reproduce based on their 
energy stores. Humans with greater stores would be able to produce more offspring 
during famine than their thinner peers, thereby contributing a larger percentage of the 
genes in the gene pool and demonstrating their reproductive selection advantage. 
Speakman’s drifty genotype hypothesis does not contribute to understanding modern 
obesity through critical evaluation of evolutionary forces. 
 The thrifty phenotype hypothesis is grounded in epigenetic research. Epigenetics 
posits that an individual’s fetal and pre-pubertal developmental environment produce 
cues for the body in order to prepare it for the post-natal environment (Gluckman & 
Hanson, 2008). For example, if a mother is in a food insecure environment, it prepares 
the growing fetus to survive in the same type of environment. It is advantageous to be 
able to lay down as much as fat as possible in these conditions. A mismatch between an 
individual’s developmentally adapted environment and his or her current environment 
creates a greater risk of becoming obese and developing obesity-related illnesses such as 
diabetes or cardiovascular disease (Gluckman & Hanson, 2008; Slomko et al., 2012).  
 The fetal environment is dictated both by the mother’s nutritional status during 
gestation as well as by the effects of her own developmental programming (Waterland & 
Michels, 2007; Kuzawa & Quinn, 2009). Researchers used Överkalix, a Swedish village 
with exceptional multi-generational records that detailed births, causes of death, and food 
accessibility in order to assess the impact of epigenetics on the mortality risk ratio for 
each individual in an isolated Swedish community. Studies covered several generations, 
spanning both famine and plenty periods. They found correlations between grandparents’ 
food supply and their grandchildren’s mortality rates due to cardiovascular disease 
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(CVD) and diabetes (Kaati et al., 2002; Bygren et al., 2014). Obesity is one of the 
primary risk factors for both CVD and diabetes (Hubert et al., 1983; Poirier et al., 2005: 
Mokdad et al., 2003; Wang et al., 2005). Although the results were sex specific, it seems 
clear that trans-generational epigenetic programming plays an important role in 
individuals’ disease and obesity risk (Kaati et al., 2002; Bygren et al., 2014). Other 
studies have found direct links between the mother’s health and her infant’s body weight 
(Kuzawa & Quinn, 2009; Gluckman & Hanson, 2008). Infants with high body weight 
born to women with obese BMIs or with uncontrolled gestational diabetes were more 
likely than their peers to become overweight or obese and suffer from associated diseases 
or disorders later in life (Heerwagen et al., 2010; Lillycrop & Burdge, 2011). Low infant 
body weight as a result of starvation experienced by the mother is strongly correlated 
with an increased risk of metabolic syndrome, diabetes, and cardiovascular disease when 
paired with a mismatched environment (i.e. when the mother had poor food security and 
her adult child had high access to food) (Ravelli et al., 1976; Yajnik & Deshmukh, 2008).  
 Epigenetic programming works through DNA methylation and acetylation, 
histone modulation, and DNA replication timing (Waterland & Michels, 2007). DNA 
methylation is the process whereby a methyl group is added to a sequence. The addition 
or subtraction of a methyl group alters gene expression. When DNA is replicated, it is 
methylated and then packaged into nucleosomes by binding histones to form chromatin 
(Conaway, 2012). The creation of chromatin is essential because unwound DNA would 
be far too long to fit within the nucleus (Widmaier et al., 2010). It is also important 
because the chromatin hold the epigenetic imprint (Conaway, 2012). Histone methylation 
further modifies the chromatin (Bannister & Kouzarides, 2011). In order to activate a 
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gene, the histone must be de-methylated so the correct portion of DNA is exposed for 
transcription and translation. During replication, the active and passive chromosomes are 
pulled apart and put back together at different times. This is known as DNA replication 
timing. Since the DNA replication timing dictates how chromatin is put together, it could 
potentially affect epigenetic states (Bannister & Kouzarides, 2011).  
 Although researchers often frame it as an either/or option, the thrifty genotype 
and thrifty phenotype hypotheses are not mutually exclusive. Studies have shown that 
there is no single gene controlling body weight; rather, it is polygenic. Genes with 
identified links to obesity include BMIQ1 through BMIQ6, FTO, BDNF, TMEM18, 
GNPDA2, NEGR1, NPC1, PCSK1, MTCH2, and SH2B1 (Hofker &Wijmenga, 2009; 
Benzinou et al., 2008). The direct effects of these genes on carriers are not necessarily 
large. For example, people with two copies of the FTO gene weigh on average 3 kg more 
than non-carriers; however, the extra kilos can be avoided by walking for 3.5 hours a 
week (Frayling et al., 2007). Of course, the genes do not work independently of 
epigenetics (Waterland & Michels, 2007). An individual’s epigenetic makeup dictates the 
degree of gene expression, directly affecting the gene’s ability to have an effect on body 
mass. Additionally, as discussed above, a person’s epigenetics could have a more global 
effect on metabolism based on developmental cues.  
 A combination of epigenetics and the thrifty genotype hypothesis provides this 
study’s theoretical framework for understanding evolutionary origins of obesity. Neither 
theory is mutually exclusive. In fact, it is likely that both the thrifty genotype and thrifty 
phenotype are working in concert to mediate body mass. The thrifty genotype works on 
an organism’s most basic genetic level by altering DNA. This is the long-term approach. 
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The shift towards an increasing frequency of genes promoting fat deposition happens 
over a long period of time as creatures with a better ability to store fat survive at a 
slightly greater rate than their thinner brethren. This could take centuries or millennia. 
The thrifty phenotype is the answer for short-term adaptations within a few generations. 
An individual may have quite a few genes predisposing them to fatness, but epigenetic 
changes dictate to a certain degree how much those genes are expressed.   
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Chapter IV: Materials and Methods  
Sample 
 IRB clearance was attained on May 26, 2014 and is in compliance with all federal 
and local regulations for the protection of human subjects (see Appendix A). The sample 
is made up 57 subjects. There were three different methods of recruitment: flyers, internet 
postings, and location-based. Flyers were posted around the city of Lincoln, Nebraska, 
with the majority placed on campus at the University of Nebraska – Lincoln (UNL). 
Roughly a quarter of all participants were recruited via flyers. Internet postings were 
made on Craigslist, an online classifieds website, and Reddit, a news aggregator site. 
Although Craigslist yielded zero participants, Reddit advertising resulted in three 
participants. The remaining participants were recruited in the Recreation Center located 
on UNL’s city campus. The overwhelming majority (73.7%) of participants are students 
at the University of Nebraska – Lincoln.  
Males represented 68.4% (39 participants) of the sample and females made up the 
remaining 31.6% (18 participants). The mean age of participants is 25.37 years and the 
median age is 24 years. The minimum age to participate was set at 19 years because the 
majority of the skeleton has finished developing by then. Although the last bone 
(clavicle) finishes fusion at age 25, the long bones, which are the most important skeletal 
component in terms of physical activity and endocrine interaction, have mostly finished 
growing. Additionally, the age of consent in Nebraska is 19. The maximum age cut-off 
was set at 45 years. The oldest participant in the study is 43 years old and youngest is 19 
years old, giving a range of 24 years. The oldest female in the study is 35 years old and is 
pre-menopausal, which allows her to data to remain in the study since her bone and 
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endocrine profile is unaffected by the natural drop in estrogen that accompanies 
menopause. All other participants above the age of 30 were men.  
Before joining the study, each prospective participant had to read and sign the 
informed consent. Subjects subsequently filled out a pre-health check questionnaire that 
assessed his or her fitness for the study. If participants failed to meet basic criteria, they 
were automatically excluded and all of their information was deleted in order to protect 
their confidentiality. Conditions regulating participant selection include no use of drugs. 
People using drugs not prescribed to them, suffering from alcoholism, or taking 
performance-enhancing drugs such as steroids were asked to self-exclude themselves. 
Other disqualifiers include broken bones or severely pulled tendons within the last nine 
months, pregnancy, menopause, eating disorders, and any endocrine disease (e.g. 
diabetes, thyroid disorders, poly cystic ovarian syndrome). Participants were screened for 
these health states because they all affect individuals’ endocrine profiles and/or bone 
physiology.  
In order to participate, subjects had to meet several health and exercise criteria. 
All participants must regularly exercise a minimum of 3.5 hours a week, which is in 
compliance with the National Institute of Health’s suggested baseline of at least 30 
minutes of exercise per day for every individual. Participants exercised an average of 5 
hours a week. Other minimum health requirements include being at a healthy weight 
(within normal BMI and/or waist-to-hip ratio ranges) and eating a healthy diet (according 
to the nutritional guidelines published online at www.nutrition.gov by the US Department 
of Agriculture).  
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Methods 
The study used four major tools: a questionnaire, bone density scan, multiplex 
hormone assay from blood samples, and basic anthropometric measures. The data were 
analyzed using IBM’s SPSS® v 21. The most important variables include leptin levels, 
osteocalcin levels, bone density measurements, anthropometric measurements, time spent 
physically active, time spent in sedentary activities, and typical types of exercise 
undertaken by each participant (See Table 1 for a complete listing of variables analyzed). 
Other variables, such as social and behavioral factors were also tested. Statistical analysis 
includes normality tests, correlation, and regression analysis. The questionnaire was 
developed to provide a more detailed examination of each individual’s typical physical 
activity patterns, diet, and general health. All the dietary data collected via the 
questionnaire were used primarily to screen participants for sufficiently nutritious diets. 
None were used for statistical assessment.  
Bone mineral density (BMD) was measured using a GE Lunar Achilles Insight® 
Bone Densitometer device at the calcaneus (Hawkinson et al. 2006). The calcaneus is a 
weight-bearing bone that is subject to the mechanical stresses that affect bone remodeling 
rates in humans. Studies have shown it to be an excellent site for diagnosing osteoporosis, 
indicating that it is an effective gauge of bone health (Forogh & Ghasemzadeh, 2005; 
Kayalar et al., 2009; Martini et al., 2004; Sweeney et al., 2002). This ultrasound machine 
was selected because it is effective, portable, radiation free, and relatively cheap 
(Hawkinson et al. 2006). Although it is not quite as effective as an axial DXA scanner, it 
still works well enough to provide legitimate data (Hawkinson et al. 2006). Internal 
validity for the particular unit used in this study was measured by taking the same 
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researcher’s bone density reading 20 times throughout the course of the study. The 
average T-score reading was 1.8, with a range of 1.5 to 1.9. This variation is within 
acceptable limits (Faulkner, 2011).  
Table 1: List of Variables Analyzed 
Sex Time Spent Running/Year (min & hrs) Total Time Sitting/Year (min & hrs) 
Stiffness Index Time Spent Strength Training/Year (min & hrs) Average Stress Level (Likert Scale, 1-5) 
T-Score Time Spent Biking/Year (min & hrs) Sunscreen Use (Likert Scale, 1-5) 
BUA Time Spent Walking/Year (min & hrs) Average Amount of Time Outside (Likert Scale, 1-5) 
SOS Time Spent Swimming/Year (min & hrs) Socioeconomic Status (Likert Scale, 1-5) 
Leptin Level (pg/mL) Total Time Exercising/Year (min & hrs) Leptin Level in Population (Normal BMI) 
Osteocalcin Level (pg/mL) Average Amount of Sleep/Night (hrs) Leptin Level in Population (Obese BMI) 
Waist-to-Hip Ratio (WHR) Time Sitting/Year for Work (min & hrs) Osteocalcin Level in Population (Normal BMI) 
Body Mass Index (BMI) Time Sitting/Year for Leisure (min & hrs)  
 
Three bone density measures were acquired: broadband ultrasound attenuation 
(BUA), speed-of-sound (SOS), and stiffness index; the subjects’ and t-score was also 
recorded. The heel ultrasonometer has a pre-determined BUA index that was created by 
passing ultrasound through various thicknesses of bone. When measuring an individual, 
the machine compares the BUA value taken from the participant against the known 
values for different thicknesses of bone, thereby arriving at an accurate assessment of 
density. SOS measures the speed at which an ultrasonic wave travels through a material. 
The speed of a sound wave is affected by the density, viscosity, elasticity, 
compressibility, and overall structure of the material through which it travels. By 
bouncing an ultrasound wave through an individual’s heel to a waiting receiver, one can 
determine bone density and structure. Essentially, BUA reveals how much of a signal is 
able to travel all the way through a material, while SOS shows how fast the signal travels. 
The stiffness index is a combination of BUA and SOS, which means it is an expression of 
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bone density and structure, and therefore overall bone quality. For the GE Lunar Achilles 
Insight®, the formula for stiffness is: 
Stiffness = [(0.28*SOS)+(0.67*BUA)] – 420 
The stiffness index is used to create the t-score. The t-score is a unit-less indicator of an 
individual’s bone quality that is determined by comparing the individual’s stiffness index 
against the stiffness index of a healthy 30-year-old of the same sex. A t-score of 0 means 
that the individual exactly matches that of the standard. A t-score higher than 0 means 
that the individual’s bone quality is higher than the standard and he or she is therefore at 
less risk of fracture due to osteoporosis. A t-score lower than 0 indicates that the subject 
has lower bone quality than the standard. Scores between +1 and -1 are considered 
normal. Scores from -1 to -2.5 indicate low bone mass. The threshold for osteoporosis is -
2.5 or less. A combination of all bone density measures allows for a more complete 
understanding of an individual’s BMD.  
Blood samples were used to assess hormone levels. Certified phlebotomists at the 
University of Nebraska – Lincoln’s Health Center drew the blood from participants. They 
were also responsible for spinning off and storing the plasma in a -20° C freezer. Serum 
samples were taken in the morning to help equalize the difference in leptin and 
osteocalcin’s circadian rhythms and after a minimum six-hour fast to minimize the effects 
of food on insulin levels.  
A multiplex assay was used to read hormone concentration. Assays are a common 
means of quantitatively assessing the amount of hormone present within a sample. 
Multiplex assays are distinguished by their ability to simultaneously measure many 
analytes at once, saving time and resources. I selected a Millipore® multiplex assay kit to 
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quantify the amount of leptin, osteocalcin, and insulin in each sample. This test 
established a baseline for hormones essential to regulating metabolism and bone 
processes.  
A MAGPIX® Multiplexing Instrument was used to read the assay results. The 
assay contains Luminex magnetic beads. The beads are dyed a specific color for each 
hormone and then coated in the corresponding antibodies. Each sample is measured a 
minimum of 50 times by the machine. If the hormone is present, it will bind to the beads. 
The MAGPIX® reader will then force the beads up through a tube using flow cytometry. 
Once in the tube, a green laser is used to excite the beads followed by a red laser 
classifying the beads. Once the beads are categorized, they are pushed in front of 
detectors that read and interpret them. The MAGPIX® provides a computerized readout 
of all the data gathered, including hormone levels measured in pg/mL.  
Each kit comes with a series of control beads with known values to build a 
standard curve. The standard curve allows the machine to determine how much of each 
hormone is in the participants’ samples by interpolation on the curve. If the detected 
values for the standard beads do not match the known values, then the kit failed and it is 
impossible to accurately read the unknown samples. Additionally, if the detected values 
create a messy standard curve, errors likely occurred during the assay or the kit is bad. 
The curve also specifies upper and lower detection limits.  
Part of the statistical analysis included comparing general population values of 
leptin and osteocalcin in normal and obese individuals to the hormone levels observed in 
this study’s participants. In order to accomplish this, population reference values were 
acquired by searching online databases of scholarly work (e.g. BioOne, Medline, 
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PubMed, and Web of Science) and compiling the results of previous studies. It should be 
noted that OC does not have the same popularity as leptin as a research topic so there are 
fewer available population means. See Appendix C for a complete list of population 
reference data and the citation information for the articles from which the information is 
drawn.  
Anthropometric data include weight, height, waist-to-hip ratio (WHR), and body 
mass index (BMI). Weight and height were measured with calibrated instruments at the 
University of Nebraska – Lincoln’s Health Center. BMI was calculated based on the 
weight and height measurements taken for the study.  
BMI = kilograms/meters2 
The World Health Organization’s guidelines were used to measure waist-to-hip ratio. 
Both BMI and WHR were used in this study in order to attain a more complete picture of 
each individual’s actual physical fitness. Often, BMI alone can be misleading when 
working with adults who are extremely physically fit because their increased muscle 
mass can put them in the ‘overweight’ or ‘obese’ categories despite being at peak 
physical fitness. The WHR is typically more reliable when assessing whether or not a 
person is at a healthy weight because it takes a person’s overall shape into account, 
whereas BMI does not. Instead of comparing what is typical for a certain height and 
weight range like BMI, WHR looks at an individual’s proportions. For example, a 
bodybuilder may fall into the overweight BMI category, but his or her WHR will still be 
normal. A healthy WHR for men is 0.90 or below and for women it is 0.80 or below. 
Although a few participants were technically overweight according to the BMI scale, all 
individuals had to have a healthy WHR in order to qualify for the study. 
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 In terms of statistics, several tests were used according to the nature of the data. 
Statistical analysis began with examining distribution and determining normality. 
Normally distributed data were then tested for correlations using Pearson’s correlation. 
Spearman’s rho and Kendall’s tau were used for assessing non-parametric data. An 
independent samples T-test was used for analyzing normally distributed continuous data 
and ranked ordinal data with only two groups. Mann-Whitney U, a nonparametric test for 
checking correlation between continuous and ranked ordinal variables with two groups, 
was used to examine whether hormone levels, time spent sitting, and time spent 
exercising varied across sex. Mann-Whitney U was also used to compare population 
hormone data against study hormone data. Kruskall-Wallis was then used to evaluate the 
non-parametric continuous data and ranked ordinal variables with more than two groups. 
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Chapter V: Results 
Statistical analysis was applied to leptin and osteocalcin levels, bone health 
measurements, anthropometric measurements, and time spent either physically active or 
sedentary. A total of 10 hypotheses were tested, all of which are listed below, along with 
a brief explanation of the results. Included in the statistical tests were distribution 
assessments, normality tests, and correlation (parametric and non-parametric). 
Statistically significant parametric correlations can be found in table 2 and statistically 
significant non-parametric correlations in tables 3 and 4.  
It should be noted that the insulin data were excluded from statistical analysis 
because the insulin detection beads failed, resulting in no available data for insulin, thus 
all hypotheses related to insulin were discarded. The osteocalcin and leptin assays were 
successful, although initially the standard curves for both were invalid at the upper end of 
the detection limit. For leptin, standard 7b’s expected value did not match the detected 
value. For osteocalcin, standards 5 through 7 were invalid. However, after eliminating the 
problematic standard values, the standard curves for both became viable. Leptin’s 
minimum detection limit was 47.5085 pg/mL and the maximum limit was 18,9729 
pg/mL. The minimum detection limit for osteocalcin was 137.1391 pg/mL and the 
maximum limit was 26,019 pg/mL. Since the problems were at the upper end of the 
spectrum, all the hormone analysis results for leptin and osteocalcin were viable for 
participants since they fell between confirmed standards. Control averages were slightly 
below the expected range, but were still usable.  
The following are a list of the hypotheses tested in this study with a brief 
summary of the results below. Significant relationships are marked with an asterisk.   
 51 
1. Leptin and osteocalcin have a significant relationship with each other. This study 
found no significant relationship between leptin and osteocalcin.  
2. Osteocalcin has a significant relationship with bone density measures.* 
Osteocalcin has a significant relationship with only one bone density measure: 
SOS.  
3. Leptin has a significant positive relationship with bone density measures. No 
relationship was found. 
4. Leptin has a significant negative relationship with waist-to-hip ratio and BMI. No 
relationship was found. 
5. Osteocalcin has a negative significant relationship with waist-to-hip ratio and 
BMI. No relationship was found. 
6. Leptin levels are significantly different than the general population.* Leptin levels 
were significantly different than that of the general population. Leptin levels 
amongst study participants were lower than amongst the general population, 
indicating that study participants had less fat and were likely fitter.  
7. Osteocalcin levels are significantly different than the general population. OC 
levels did not differ significantly between study participants and healthy members 
of the general population.  
8. Leptin levels are significantly different from obese samples.* Leptin levels for 
study participants were significantly lower than that of obese samples taken from 
the general population.  
9. Bone density measures have a significant positive relationship with waist-to-hip 
ratio and BMI.* BMI had significant positive relationships with all bone density 
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measures. A positive relationship is expected because more mass will result in 
greater stress on the bones, provoking a stronger bone turnover response when 
subjected to physical activity. There is no significant relationship between bone 
density and WHR. 
10. The amount of time an individual spends physically active and leptin have a 
significant negative relationship.* This was true for only two exercises: strength 
training and swimming. No other significant relationships were found. 
Distribution Analysis 
 Analysis began with determining whether or not each variable was normally 
distributed. This was done visually by creating a histogram when appropriate and 
quantitatively by applying the Shapiro-Wilk test (see Appendix C). The data for WHR, 
BMI, all bone density measures, and hours spent sitting were normally distributed. Leptin 
and osteocalcin levels as well as amount of time spent exercising had abnormal 
distributions. Efforts to transform the data proved fruitless so non-parametric tests were 
used to analyze the non-normally distributed data.  
Correlation 
 Analysis began with the normally distributed data and used Pearson’s correlation 
(see Table 2). As expected, all bone density measures were significantly and strongly 
correlated with each other (P<0.05). Additionally, WHR and BMI were also significantly 
correlated. BMI had a positive significant relationship with bone density but WHR did 
not. Next, continuous non-normally distributed data were tested for correlation using 
Kendall’s tau and Spearman’s rho. Tables 2 and 3 summarize the significant results of 
these tests. Leptin had a significant negative correlation with minutes spent strength 
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training and swimming per year (-0.204 and -0.263 respectively; P<0.05). There were no 
significant relationships between leptin and minutes spent walking, running, or biking per 
year. 
Table 2: Pearson’s correlation tests for bone density measures, WHR, and BMI 
 Waist-to-Hip 
Ratio 
BMI Stiffness 
Index 
T-Score BUA SOS 
Waist-to-Hip 
Ratio 
Pearson Correlation 1 .559** .209 .212 .210 .136 
Sig. (2-tailed)  .000 .121 .116 .120 .317 
N 57 57 56 56 56 56 
BMI 
Pearson Correlation .559** 1 .370** .380** .302* .309* 
Sig. (2-tailed) .000  .005 .004 .023 .020 
N 57 57 56 56 56 56 
Stiffness Index 
Pearson Correlation .209 .370** 1 .993** .813** .836** 
Sig. (2-tailed) .121 .005  .000 .000 .000 
N 56 56 56 56 56 56 
T-Score 
Pearson Correlation .212 .380** .993** 1 .819** .820** 
Sig. (2-tailed) .116 .004 .000  .000 .000 
N 56 56 56 56 56 56 
BUA 
Pearson Correlation .210 .302* .813** .819** 1 .361** 
Sig. (2-tailed) .120 .023 .000 .000  .006 
N 56 56 56 56 56 56 
SOS 
Pearson Correlation .136 .309* .836** .820** .361** 1 
Sig. (2-tailed) .317 .020 .000 .000 .006  
N 56 56 56 56 56 56 
* Correlation is significant at the 0.05 level (2-tailed). 
** Correlation is significant at the 0.01 level (2-tailed). 
 
Number of minutes spent strength training per year and two measures of bone 
density (stiffness index, T-score) also return expected results. The minutes strength 
training variable has a significant positive correlation with the stiffness index and the T-
score (0.195 and 0.202 respectively; P<0.05). Studies regularly show a significant 
positive correlation between strength training and higher bone density. There were no 
significant correlations between time spent strength training and BUA or SOS. There 
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were also no significant relationships between any other specific exercises (swimming, 
running, biking, and walking) or total amount of time exercising with bone density 
measures. 
                   Table 3:  Significant Non-Parametric Correlation Test Results 
 Leptin blood level 
in pg/mL 
Osteocalcin blood 
level in pg/mL 
Minutes 
walking/year 
Minutes strength 
training/year 
Kendall's 
tau 
Leptin blood 
level in pg/mL 
Correlation Coefficient 1.000 .073 .171 -.204* 
Sig. (2-tailed) . .434 .080 .032 
N 57 57 57 57 
Osteocalcin 
blood level in 
pg/mL 
Correlation Coefficient .073 1.000 -.260 .163 
Sig. (2-tailed) .434 . .007 .083 
N 57 57 57 57 
Minutes 
strength 
training/year 
Correlation Coefficient -.204* .163 -.258* 1.000 
Sig. (2-tailed) .032 .083 .009 . 
N 57 57 57 57 
Minutes spent 
walking/year 
Correlation Coefficient .171 -.260** 1.000 -.258** 
Sig. (2-tailed) .080 .007 . .009 
N 57 57 57 57 
Spearman's 
rho 
Leptin blood 
level in pg/mL 
Correlation Coefficient 1.000 .123 .231 -.295* 
Sig. (2-tailed) . .362 .084 .026 
N 57 57 57 57 
Osteocalcin 
blood level in 
pg/mL 
Correlation Coefficient .123 1.000 -.376 .255 
Sig. (2-tailed) .362 . .004 .056 
N 57 57 57 57 
Minutes 
strength 
training/year 
Correlation Coefficient -.295* .255 -.337* 1.000 
Sig. (2-tailed) .026 .056 .010 . 
N 57 57 57 57 
Minutes spent 
walking/year 
Correlation Coefficient .231 -.376** 1.000 -.337* 
Sig. (2-tailed) .084 .004 . .010 
N 57 57 57 57 
* Correlation is significant at the 0.05 level (2-tailed). 
** Correlation is significant at the 0.01 level (2-tailed). 
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Table 4: Significant Non-Parametric Correlation Test Results 
 Stiff Bone T-Score Minutes 
strength 
training/year 
Minutes spent 
walking/year 
Kendall's tau 
Stiff Bone 
Correlation Coefficient 1.000 .971** .195* -.159 
Sig. (2-tailed) . .000 .039 .103 
N 56 56 56 56 
T-Score 
Correlation Coefficient .971** 1.000 .202* -.176 
Sig. (2-tailed) .000 . .034 .071 
N 56 56 56 56 
Minutes strength 
training/year 
Correlation Coefficient .195* .202* 1.000 -.258** 
Sig. (2-tailed) .039 .034 . .009 
N 56 56 57 57 
Minutes spent 
walking/year 
Correlation Coefficient -.159 -.176 -.258** 1.000 
Sig. (2-tailed) .103 .071 .009 . 
N 56 56 57 57 
Spearman's rho 
Stiff Bone 
Correlation Coefficient 1.000 .991** .276* -.221 
Sig. (2-tailed) . .000 .040 .102 
N 56 56 56 56 
T-Score 
Correlation Coefficient .991** 1.000 .283* -.242 
Sig. (2-tailed) .000 . .035 .072 
N 56 56 56 56 
Minutes strength 
training/year 
Correlation Coefficient .276* .283* 1.000 -.337* 
Sig. (2-tailed) .040 .035 . .010 
N 56 56 57 57 
Minutes spent 
walking/year 
Correlation Coefficient -.221 -.242 -.337* 1.000 
Sig. (2-tailed) .102 .072 .010 . 
N 56 56 57 57 
* Correlation is significant at the 0.05 level (2-tailed). 
** Correlation is significant at the 0.01 level (2-tailed). 
 
Osteocalcin, like time spent strength training, also has a significant positive 
correlation (0.191; P<0.01) with SOS, which is expected. OC typically displays a positive 
relationship with bone density measures. Oddly, OC had no significant relationship with 
any other bone density measures. The reasons for this are unclear. Leptin also has no 
significant relationship with any bone density measures. This likely reflects the lack of a 
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significant relationship between OC and bone density, since leptin’s relationship with 
bone density measures are largely dependent on OC levels. Interestingly, there is a 
complete lack of correlation between leptin and OC. A negative correlation should exist 
between the two, but this study found none.  It is possible that there is another unknown 
confounding variable. Error within the hormone measurement could also have caused the 
negative correlation.   
WHR and BMI varied significantly according to sex. This is expected since WHR 
averages for females are different than the average for male (P<0.001). Men also tend to 
have slightly higher BMIs than women (P<0.001). No bone density measures varied 
according to sex. Although women lose bone density more rapidly than men post-
menopause, bone density would not vary across sex in the current sample since all 
women were pre-menopausal and exercised vigorously with regularity.  
Leptin and osteocalcin varied across sex, as predicted by the established literature 
(P =0.008 and P =0.022 respectively). The number of minutes spent strength training, 
walking, and swimming per year also varied across sex (P =0.003, P =0.001, and P 
=0.014 respectively). Men were more likely to participate in strength training than 
women, as well as bike more. See Appendix C for complete graphs. 
Mann-Whitney U was also used to compare population data against study data. 
To accomplish this, a new nominal variable was created to distinguish population data 
from study data. The dichotomous variable thus served as the non-continuous, categorical 
variable necessary for comparing the means of two differing populations. The Mann-
Whitney U test revealed that there were significant differences between the leptin levels 
of study participants and those of the general population. Participants generally had lower 
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leptin levels than the average ‘lean’ person. For the lean general population, the mean 
rank is 59.53 while for study participants it is 30.44. All studies from which population 
means were taken defined a ‘lean’ individual as someone with a BMI below 25. No 
studies from which population values were taken had stated physical fitness guideline for 
participants beyond BMI. The significant difference in means between study participants 
and the ‘lean’ general population are likely due to the added stipulation that participants 
for this study must be physically fit and active beyond the CDC recommended baseline 
for exercise. An even larger gap exists between study participants and the obese 
population, with study participants having lower leptin levels than their obese 
counterparts. The obese general population has a mean rank of 60.82 while study 
participants have a mean rank of 29.42. The difference in leptin levels between the 
general population and study participants confirms that fitter individuals have lower 
leptin levels, in accordance with lower body fat.  
It should be noted that the leptin population means were not drawn from the 
original data points but rather from the final published means. Several studies’ leptin 
averages were used to create separate data points for statistical analysis in this study. This 
means that the graph generated is lopsided since there are a fewer data points for the 
population mean. Despite this, the asymptotic significance is still P < 0.005 for both the 
‘lean’ and ‘obese’ general population, indicating that the means are truly statistically 
significantly different notwithstanding disparity in data points for each group. The Mann-
Whitney U test for osteocalcin found that there was no statistically significant difference 
between healthy members of the general population and study participants. 
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Regression 
The relationship between WHR and BMI as well as the relationships between all 
bone measures were excluded from the regression analysis since the significant 
correlation was caused by the variables’ internal relationship with one another. Linear 
regression analysis began with the only normally distributed data that has a significant 
relationship: BMI and all bone measures. BMI has a significant positive relationship with 
all bone measures. All bone variables were tested for a linear relationship with BMI, 
heteroscedasticity, normally distributed residuals, and autocorrelation. All variables 
passed the prerequisites for linear regression analysis. Linear regression established that 
BMI could statistically significantly predict stiffness index, t-score, SOS, and BUA (see 
table 4 for complete details). 
                Table 5: Bone Variables and BMI Linear Regression Analysis 
Dep. Variable R R2 Adj. 
R2 
Durbin-
Watson 
DoF F p Regression Equation 
Stiffness Index 0.370 0.137 0.121 1.872 1, 54 8.544 0.005 Stiffness index = 38.457 + (3.163*BMI) 
T-Score 0.380 0.144 0.128 1.909 1, 54 9.099 0.004 T-Score = -3.997 + (0.204*BMI) 
BUA 0.391 0.153 0.137 1.819 1, 53 9.504 0.020 BUA = 64.066 + (2.699*BMI) 
SOS 0.309 0.096 0.079 2.199 1, 54 5.702 0.003 SOS = 1462.720 + (5.940*BMI) 
 
Another linear regression test demonstrated that SOS could significantly predict OC, F 
(1, 53) = 9.809, P =0.003. SOS accounted for 14.0% of the explained variability in 
osteocalcin. The regression equation is: osteocalcin = -33049.886 + (22.936*SOS).  
 Several significant correlations failed to meet the basic assumptions for linear 
regression, likely because of their extreme distributions. There are currently no non-
parametric regression tests available on SPSS, so no regression analysis beyond testing 
for the standards of linear regression was carried out. The relationships that were not 
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analyzed include leptin levels and time strength training per year, leptin levels and time 
swimming per year, and osteocalcin levels and time spent walking per year. Two other 
relationships (time spent strength training and stiffness index, time spent strength training 
and t-score) satisfied the conditions for linear regression, but when tested they were no 
longer statistically significant at the 0.05 level. For the stiffness index, P = 0.074 with F 
(1, 54) = 3.329. P = 0.070 and F(1,54) = 3.421 for the T-score. Even if it were still 
significant, minutes spent strength training explains only a very small percentage (~4.0%) 
of the variability found within both the stiffness index and t-score, indicating that it is not 
a very useful measure of prediction.  
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Chapter VI: Discussion 
Significance of Results 
 This study attempted to test hypotheses about physical activity, leptin, 
osteocalcin, insulin, bone metabolism, and their relationships with each other that have 
downstream effects on body mass. The study design also sought to combine measures 
that had been tested independently before to create a more holistic understanding of what 
physical fitness might look like from an endocrine and bone biology perspective. For 
example, many studies in the past have measured leptin and osteocalcin or stress and 
leptin, but no study has measured all three at once. Using a combined approach yields 
more information on overall biological status, thus potentially giving greater insight into 
the evolutionary environment.  
 The study’s results support the literature that posits a relationship amongst bone 
strength, physical activity, and metabolic hormones. These connections are neatly 
summarized in Gordeladze & Reeseland (2003) and Wolf (2008). The most important 
findings include the relationship between OC and SOS; the relationship between time 
spent strength training and t-score and stiffness index; the relationship between time 
spent strength training and leptin; and the relationship between time spent swimming and 
leptin.  
 Although there were some unexpected results in the study, almost none directly 
contradict existing paradigms. Some of the relationships tested in this study that were 
expected to be significant were not. For example, this study did not find a significant 
relationship between either the amount of time spent sedentary or the amount of physical 
activity and increased bone robusticity. More exercise should cause the bones to 
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experience more stress and therefore greater density (Frost, 2003). More time sedentary 
could mean that there is less time spent exercising and therefore lower density. The 
reasons behind this inconsistency are unknown, although it was possibly caused by 
problems with the hormone analysis since certain data points had to be removed.  
 Additionally, sometimes closely related variables that were hypothesized to have 
similar correlation results had dissimilar findings. This can be seen with BMI and WHR 
when compared against bone health measures (stiffness index, SOS, BUA, T-score). BMI 
had a positive significant relationship with bone health measures, while WHR did not. 
Although this seems odd on the surface, this is perhaps because BMI more accurately 
captures weight than WHR since BMI is calculated using mass. As the mechanostat 
model theorizes, more force on bones results in greater deformation and remodeling 
(Frost, 2003). WHR, however, does not rely on mass measurements at all in order to 
assess general physical fitness; rather, it uses a ratio that focuses more on body 
composition. For this reason, WHR is often considered superior to BMI when gauging 
physical fitness and normality of body fat. (Srikanthan et al., 2009) BMI can be 
misleading in cases of individuals with a high degree of muscle mass relative to his or her 
height (Rothman, 2008). Potentially, the difference in what is being measured (weight 
and height v. ratio) could explain why BMI is positively correlated with bone density 
while WHR seems to have no relationship.  
However, even though certain relationships were not statistically significant, they 
often followed the same trends as more established studies. Potential reasons for this 
include small sample size or human error during the hormone analysis process. Only one 
relationship, a negative significant relationship between OC and walking, completely 
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opposed established relationships (Yamakazi et al., 2004; Kitareewan et al., 2011; 
Brooke-Wavell et al., 2001). A possible explanation is that people who walked more in 
this study had less time to exercise than other people since they were spending more time 
in transportation or were perhaps less able to accomplish other types of exercise. 
Ultimately, however, this study’s results agree with published research as well as 
providing a novel, combined approach to studying endocrine bases for obesity. 
Previously, most studies have only focused on one or two aspects of an individual’s 
overall weight management picture, such as diet and exercise or exercise and hormone 
profile. This study attempted to combine diet, exercise, hormone analysis, and 
anthropometrics to create a more holistic approach to the topic. Unfortunately, the dietary 
data were extremely difficult to work with – a common theme in nutritional research – 
but modification may make them more usable in the future.  
Interactions Among Systems Via Hormones 
Leptin and osteocalcin are of central importance to the physical activity-bone-
metabolic axis. Currently it is believed that leptin, a satiety hormone, acts on bone in two 
different ways (Gordeladze & Reeseland, 2003; Gordeladze, 2002; Reseland et al., 2001; 
Kalra et al., 2009). On a neuro-regulated systemic level, decreases in leptin correlate 
strongly with increases in circulating osteocalcin, along with increases in BMD (Aoki et 
al., 2011; Foresta et al., 2010; Gordeladze, 2002; Gordeladze & Reeseland, 2003; Kalra 
et al., 2009; Reseland et al., 2001). During physical activity, the body taps its fatty energy 
stores (Widmaier et al., 2010). Using fat decreases the amount of circulating leptin since 
there are fewer available cells to produce the hormone (Hadley & Levine, 2006). A drop 
in leptin signals to the brain that there is less energy available, suppressing satiety and 
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signaling the release of hunger hormones in order to restore lost energy stores (Friedman 
& Halass, 1998). Circulating leptin decreases OC, so decreases in leptin allow for OC 
levels to increase. Physical activity thus activates bone remodeling (explaining the 
positive relationship between strength training and stiffness index or t-score), which 
increases osteocalcin levels, while simultaneously decreasing circulating leptin in order 
to keep the brain apprised of overall energy reserves (Frost, 2003; Zhang et al., 2005; 
Gordeladze & Reeseland, 2003; Wolf, 2008). Bone remodeling typically results in 
increased bone strength. The significant positive relationship found in this study between 
SOS, a BMD measure, and OC reflects the relationship between bone turnover and 
osteocalcin (Lee et al., 2000). Bone metabolism, in turn, has a very important effect on 
the body’s ability to recognize and produce hormones that regulate blood sugar – one of 
the most essential functions of the body and one of the first impaired by being chronically 
overweight (Wolf, 2008).  
Despite physical activity reducing circulating leptin on a global level, the 
mechanical stress that accompanies exercise up-regulates leptin receptors in bone. 
Although there is less leptin available, increased receptivity means that the bone responds 
more strongly to available leptin. Leptin increases osteoblast differentiation and 
proliferation (Kalra et al., 2009), allowing for greater osteoblast action through increases 
in numbers and thus increasing osteocalcin production and secretion (Wolf, 2008). 
Higher OC levels leads to increased metabolic sensitivity in terms of insulin, which is 
important for effectively controlling weight (Cao, 2011; Gordeladze et al., 2002; 
Gordeladaze & Reeseland, 2003; Wolf, 2008).  
 
 64 
 
Insulin and osteocalcin work in an elegant feed-forward loop. Physical activity 
kicks off the loop by beginning osteocalcin production. On the cellular level, leptin 
encourages OC synthesis in the manner described above. Osteocalcin then stimulates the 
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proliferation of β-islet cells as well as the expression and production of insulin (Hwang et 
al., 2012). Insulin signaling in the osteoblast inhibits the production of osteoprotegrin and 
increases secretion of RANKL, a ligand critical to activating osteoclasts. This encourages 
osteoclast activity, creating a lower pH (4.5), which in turn allows for the 
decarboxylation and activation of osteocalcin. Decarboxylated osteocalcin, the active 
form of the hormone, is responsible for stimulating β-islet cells and increasing insulin 
sensitivity (Kwon et al., 2012; Reinehr & Roth, 2010). Insulin regulation and efficacy 
increases with greater production and release of osteocalcin (Hwang et al., 2012). 
The final piece of the leptin-insulin-OC axis is the interaction between leptin and 
insulin. Leptin serves as the check in the osteocalcin-insulin feed-forward loop by 
suppressing insulin production. On the neural level, leptin suppresses insulin production 
to prevent hypoglycemia. Leptin’s attenuating effect on insulin production disrupts the 
insulin-OC feed forward cycle (Hinoi et al., 2009). The exact mechanism whereby leptin 
is able to signal the central nervous system to mediate metabolic pathways in peripheral 
osteological tissue is still unknown, but evidence indicates leptin most likely works on 
the arcuate nucleus in the hypothalamus via an anorectic neuropeptide CART (cocaine 
amphetamine regulated transcript) (Takeda et al., 2002: Elefteriou et al., 2005; Karsenty, 
2006).  
There is evidence that leptin can work peripherally to decrease insulin secretion 
by acting directly on pancreatic β-islet cells to inhibit gene expression (Kieffer et al., 
1997; Havel, 2000; Karsenty, 2006). Additionally, leptin increases insulin sensitivity in 
peripheral tissues, thereby reducing the amount of insulin needed to regulate blood 
glucose and thus decreasing the possibility of insulin resistance. With increased insulin 
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sensitivity, the body is better able to detect when to release glucagon to countermand 
insulin’s effects. Interestingly, insulin stimulates the differentiation of preadipocytes into 
adipocytes are well as promoting lipogenesis. More adipocytes mean more leptin, which 
eventually helps diminish insulin production in the ways described above (Kahn & Flier, 
2000). All three hormones clearly play an important, interconnected, and complicated 
role in balancing metabolic regulation when supplied with the added stimuli of physical 
activity.  
Evolution, the Endocrine-Physical Activity-Bone Axis, and Modern Obesity 
In terms of this study, the thrifty genotype and thrifty phenotype hypotheses may 
explain obesity as well as the over-expression of leptin (and the resultant leptin 
insensitivity) in an increasingly larger portion of the population. From an evolutionary 
perspective, an individual may have quite a few genes predisposing them to fatness 
(thrifty genotype), but epigenetic changes dictate to a certain degree how much those 
genes are expressed (thrifty phenotype).  
The thrifty genotype hypothesis explains how the evolutionary environment 
selected for genes that enhanced energy storage abilities. An environment that is 
frequently food insecure would make the body better at recognizing a food deficit rather 
than a surfeit of food (Neel, 1989; Prentice et al., 2008). A lack of sufficient food was 
likely a much more typical scenario in the evolutionary environment than a constant 
overabundance of food (Neel, 1989; Prentice et al., 2008). A dearth of leptin, and the 
attendant food shortage it implies, is a much more dire situation in terms of survival than 
too much food. Thus, human bodies became geared towards identifying and surviving 
lean times, which shaped the way hormones developed. The study’s negative correlation 
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between strength training or swimming and leptin reflects this reality. Strength training 
uses fat in order to fuel the body during the workout (Widmaier et al., 2010). Decreased 
fat results in lower leptin (Zhang et al., 2005). Leptin depletion following physical 
activity triggers the hunger response and speaks to the body’s need to re-fuel itself in 
order to maintain energy stores against future use (Hadley & Levine, 2006; Elefteriou et 
al., 2005). As the principle energy indicator, leptin became especially adept at indicating 
energy sufficiency and shortage, but there does not appear to be a corresponding hormone 
to indicate energy overabundance. Indeed, in the evolutionary past there were likely few 
scenarios in which such a hormone might have been useful.  
Osteocalcin and insulin tie into the thrifty genotype as well. Leptin modifies 
osteoblasts on the cellular level in order to increase OC production (Kalra et al., 2009; 
Wolf, 2008). An excess of leptin indicates an excess of energy, signaling to the body that 
there is sufficient energy to devote to the growth or maintenance of the bones (Ahima & 
Flier, 2000). On a global level, leptin blocks the release of osteocalcin and insulin, 
causing the feed forward loop between insulin and OC to be interrupted (Gordeladze & 
Reeseland, 2003; Hinoi et al., 2009; Karsenty, 2006). This is a really important process 
from the evolutionary perspective. Blood sugar regulation is essential to survival. Excess 
blood sugar in the short term causes motor and mental impairments. In the long term, it 
causes kidney failure and nerve damage that will ultimately kill the sufferer (Widmaier et 
al., 2010). Insulin ensures blood glucose homeostasis (Hadley & Levine, 2006). The 
production of OC means that there is an excess of energy available, as a downstream 
effect of a leptin surplus up-regulating OC production on the cellular level (Kalra et al., 
2009). OC essentially primes the body to produce, secrete, and sense insulin post-
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exercise. The increased receptor sensitivity to insulin lasts beyond the production of OC, 
helping the body to more effectively regulate blood sugar (Hwang et al., 2012). With 
exercise, leptin levels drop precipitously, inciting hunger. After consuming food, an 
individual’s leptin levels rebound sufficiently to cut off the feed-forward loop between 
OC and insulin.  
Individuals with a more robust ability to accurately regulate blood sugar and 
monitor energy levels were more likely to survive, reproduce, and pass on their genes. 
Additionally, a greater ability to build bone in response to stress stimuli would have also 
marginally improved chances of survival by decreasing probability of fracture and shorter 
healing time in the event of fracture. A broken or fractured bone would have left an 
individual with a lesser ability to move, defend oneself, and feed oneself, making it much 
less likely that they would be able to pass on their genes in as a great a quantity. It is thus 
apparent that similar evolutionary pressures unite leptin, insulin, and osteocalcin into an 
efficacious triad centered on regulating metabolism (and therefore body mass) through 
physical activity and food availability as stimuli.  
While the thrifty genotype hypothesis helps explain the long-term genetic changes 
created by evolutionary pressures that cause humans to be pre-disposed to obesity, the 
thrifty phenotype hypothesis provides insight on short-term epigenetic adaptations that 
promote excess fat storage. This study’s results support current research showing that fit 
individuals have lower leptin levels than obese or overweight people (Blum et al., 1997; 
Kraemer et al., 2002; Masturba et al., 2002; Considine et al., 1996; Rahmani-nia et al., 
2008). It is posited that leptin overproduction can cause leptin insensitivity, leading to an 
inability to properly assess current energy availability and potentially encouraging 
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overconsumption of food since the brain perceives starvation (Münzberg & Myers, 
2005). This creates a self-sustaining cycle whereby an individual eats more since the 
orexigenic brain center is no longer naturally checked by leptin, creating greater fat stores 
that in turn produce ever increasing quantities of leptin that contribute to further receptor 
insensitivity. Leptin overproduction is closely associated with obesity and even being 
overweight (Münzberg & Myers, 2005; Friedman & Halaas, 1998; Elmquist et al., 1999). 
Additionally, people who are overweight or obese often fail to meet the CDC’s minimum 
physical activity standards (Centers for Disease Control, 2008). Osteocalcin deficiency 
from a lack of physical activity and the associated insulin insensitivity further exacerbate 
leptin overproduction since the sensitive feedback loops are disrupted or dysfunctional 
(Gordeladze & Reeseland, 2003; Wolf, 2008). 
When women with leptin insensitivity due to being overweight or obese become 
pregnant, their fetal environment may signal to the developing fetus that the environment 
is energy poor even if it is not because the brain’s inability to appropriately respond to 
leptin might create the illusion of starvation. This fetal programming helps explain why 
obese or overweight mothers have a higher probability of birthing overweight babies than 
women at a normal weight (Heerwagen et al., 2010; Lillycrop & Burdge, 2011). The 
baby is biologically prepared for food scarcity via the maternal cues. In epigenetic terms, 
these babies overexpress genes that promote fat deposition in order to better survive their 
supposedly food poor environment. The postnatal environment can continue the trends 
begun in the womb (Gluckman & Hanson, 2008; Slomko et al., 2012). Children 
belonging to overweight or obese parents are more likely to have unhealthy diets (Birch 
& Davison, 2001). This potentially leads to native leptin insensitivity during the 
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developmentally sensitive pre-pubertal period, causing epigenetic programming that 
exacerbates weight issues. These children go on to have an increased lifelong incidence 
of obesity compared to their peers who were born at a healthy weight. As adults, the 
overweight children pass on their flawed epigenetic programming to their own offspring, 
thus helping to perpetuate the cycle of obesity (Gluckman & Hanson, 2008).  
From an evolutionary perspective, this type of fetal program is advantageous 
because it would theoretically increase survival rates by modifying gene expression in 
accordance to environmental energy availability. In a modern environment, however, the 
thrifty genotype means that people are more likely to become overweight or obese, which 
causes epigenetic programming to be predicated on false cues due to endocrine 
dysfunction. The thrifty phenotype builds on the effects of the thrifty genotype, creating a 
dynamic that fuels the obesity epidemic.  
The thrifty genotype represents a long-term shift occurring over centuries or 
millennia in the human genome towards an increased frequency of genes that are more 
efficient at energy storage. Individuals with better mechanisms for fat accrual survive at a 
slightly greater rate than less fat-prone peers in energy uncertain contexts. The thrifty 
phenotype is a short-term adaptation that happens over the course of a few generations 
that affects gene expression rather than genetic composition. Initially, epigenetic changes 
that promoted fat deposition in energy poor environments would have increased 
survivorship. The modern environment can create circumstances that lead to endocrine 
dysfunction causing the body to receive false cues that result in the overexpression of 
energy storage genes.  
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Future Avenues of Investigation 
 This study has made an important contribution by creating a combined, holistic 
approach that simultaneously examines diet, exercise, and biological markers. However 
improvements may be made to future iterations of the experiment in order to draw solid 
conclusions both about the evolutionary origins of obesity as well as modern health 
implications. Additions that would better future studies include doubly labeled water 
calorimetry and food diaries for improved dietary tracking; an accelerometer and GPS for 
accurate activity recording; and regular, repeated blood draws over an extended period in 
order to enhance hormone profile analysis. Difficulties of incorporating these measures 
include increased costs in both money for purchasing materials as well as time for 
processing the resultant data.  
 Future studies would ideally look at the same variables over several different 
groups. Looking at close primate relatives such as chimpanzees or bonobos would help 
understand early human ancestors’ metabolic adaptations to the evolutionary 
environment. Changes, such as direct observation of activity rather than relying on self-
reporting, would need to be made to the protocol in order to take into account the 
limitations of non-human research. It would be interesting to look at both wild animals as 
well as their peers in captivity. Animals in captivity would have an added of advantage of 
having a controlled food supply that could, in future versions of the experiment, be 
modified in order to create a control group and intervention groups (e.g. low calorie diet 
and high calorie diet) that could really test the full effect of diet on endocrine factors of 
obesity and physical fitness.  
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In terms of human groups, there are many that would be interesting to study. 
Looking at hunter-gatherer groups would allow researchers to recreate the evolutionary 
environment with the associated activities as closely as is possible in the modern world. 
Humans spent the majority of their existence hunting and gathering, meaning that 
humans have had a lot of time to adapt to the evolutionary pressures of insecure food 
supply and regular activity in order to supply themselves with food. Additionally, it 
would be interesting to compare athletes who participate in high-impact sports (e.g. 
boxing, basketball, football, gymnastics etc.) against athletes who participate in low-
impact sports (e.g. swimming, biking, rowing, rock climbing, etc.) to see the effects of 
different types of activity stress on bones and the downstream endocrine and metabolic 
results. Overweight and obese groups would also be important to observe since their 
lifestyles are the farthest possible from the evolutionary environment.  
The final, but most complex set of groups are intervention groups. Four groups 
are required. Overweight individuals who undergo dietary intervention, overweight 
individuals who are given an exercise intervention, overweight individuals who follow a 
combined diet and exercise intervention plan, and fit individuals who stop exercising. 
Examining the long-term changes in endocrine factors and bone metabolism would 
demonstrate the direct effects of diet and exercise on bones, hormones, and metabolism. 
These recommendations would improve the quality of the data gathered as well as 
broaden the scope of the study. By diversifying the study groups, a truly complete picture 
of the endocrine-physical activity-bone axis will emerge. Additionally, by looking at a 
range of groups, it may become possible to truly compare the evolutionary environment 
to the modern environment. More work could also be done from a cellular biology 
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perspective to explore the exact signaling method between leptin and osteocalcin or 
osteocalcin and insulin. Another investigation in this arena could be looking at other 
potential functions of osteocalcin. OC appears to be an ancestral hormone and should 
therefore have more uses besides acting as an indicator of bone turnover or as an insulin 
enhancer. By supplementing the general lifestyle and endocrine data gathering with 
biochemical research, one can achieve a multi-faceted understanding of the importance of 
physical activity and bone metabolism as it relates to the obesity epidemic.  
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Chapter VII: Conclusion 
 Obesity is one of the most rapidly growing health epidemics in the modern world 
(World Health Organization, 2010). Beyond the health impacts, obesity takes a major toll 
on public health budgets and has a negative effect on the overall economy as workers 
take more time off in order to deal with health issues (Cawley & Meyerhoefer, 2012; 
Finkelstein et al., 2009; Trogdon et al., 2008). Trends show that obesity rates are 
climbing rapidly in first world countries. Third world countries are beginning to follow 
the same patterns as access to quick, calorically dense but nutritionally poor foods 
becomes more and more available. Research into obesity is in overall agreement (besides 
a few exceptions such as Pontzer et al. 2012) that the best means of prevention and 
treatment is diet and exercise (World Health Organization, 2010). Investigations into the 
evolutionary origins of obesity are important because they provide the causes for why 
humans are inclined towards obesity. Evolutionary research could also potentially help 
provide better weight loss and maintenance strategies beyond the general 
recommendations of diet and exercise by exploring the evolutionary origins of 
biochemical processes and tailoring intervention techniques to take maximum advantage 
of the quirks of the evolutionary process.  
 This study was important because it confirmed existing research into the 
evolutionary origins of obesity. Correlations between measures such as strength training 
and BMD or exercise and reduced leptin help demonstrate the reality of a physical 
activity-bone metabolism-endocrine axis. Additionally, activities under an individual’s 
control – such as strength training or swimming – can actually affect the endocrine 
system in a significant and beneficial way. Although less interesting, the reiteration of the 
 75 
correlation between variables such as BMI and WHR, all bone density measures with 
each other, and sex with hormone level readings is still important. Although all these 
relationships have been demonstrated before, testing the results of other researchers is an 
important part of the scientific process.  
 The use of a framework to guide research, in this case the thrifty genotype 
hypothesis, was especially useful. It helped provide some of the basic study questions by 
inspiring an interest in what fit people would look like in terms of both endocrinology 
and anthropometrics. For example, what kind of endocrine profile people who exercise 
regularly have? Are their anthropometrics tied to their hormone levels? How does bone 
mineral density affect hormones? By creating this sort of baseline data, it becomes 
possible to ask questions like: how do obese and fit individuals differ on an endocrine 
level? Or, can changes to obese individuals’ diet and exercise patterns effectively alter 
their endocrine-controlled metabolism sufficiently in order to ensure long-term weight 
maintenance and blood sugar regulation? These questions are beyond the scope of this 
study but will be part of important future investigations.  
 One of the most important things to emerge from the literature review for this 
study is the lack of multi-faceted studies that collect data from multiple parts of 
participants’ lives, such as diet, exercise, endocrine profile, and anthropometrics. Many 
studies look at two or three of the categories, but rarely look at all at once. Although not 
all the data collected were used in the ultimate analysis, the beginnings of a database now 
exist and it may be used in future studies.  
Although there were problems with some of the data that made it difficult to draw 
clear and solid conclusions, there were still several important results from this 
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investigation. Overall, the study created a fairly complete literature review on the 
hypotheses of the evolutionary origins of obesity, leptin, osteocalcin, insulin, bone 
metabolism, physical activity, and their effects on each other. The data collection and 
statistical analysis that were successful upheld the existing literature and 
recommendations for weight management. At the very least, exercise seems to have a 
real and important effect on an individual’s endocrine profile. The holistic approach of 
the study design is currently rare, but shows promise with adaptation for future studies’ 
methodology. As always, more research needs to be done in order to appropriately 
contextualize the findings of this study, but this study represents a good starting point, 
especially in terms of theory.  
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May 26, 2014  
 
Daniel Osborne 
Department of Anthropology 
834 OLDH, UNL, 68588-0368  
 
Maria Lapera 
Department of Anthropology 
 
IRB Number: 20140513842EP 
Project ID: 13842 
Project Title: Exploring the Physical Activity-Bone-Hormone Axis and Its Role in Obesity 
 
Dear Daniel: 
 
This letter is to officially notify you of the approval of your project by the Institutional Review Board (IRB) for the 
Protection of Human Subjects. It is the Board's opinion that you have provided adequate safeguards for the rights and 
welfare of the participants in this study based on the information provided. Your proposal is in compliance with this 
institution's Federal Wide Assurance 00002258 and the DHHS Regulations for the Protection of Human Subjects (45 
CFR 46). Your project was approved as an Expedited protocol, category 4, 6 & 7.  
 
Dates of EP Review: 04/19/2014 & 05/07/2014 
 
You are authorized to implement this study as of the Date of Final Approval: 05/26/2014. This approval is Valid 
Until: 05/25/2015. 
 
We wish to remind you that the principal investigator is responsible for reporting to this Board any of the following 
events within 48 hours of the event: 
* Any serious event (including on-site and off-site adverse events, injuries, side effects, deaths, or other problems) 
which in the opinion of the local investigator was unanticipated, involved risk to subjects or others, and was possibly 
related to the research procedures; 
* Any serious accidental or unintentional change to the IRB-approved protocol that involves risk or has the potential to 
recur; 
* Any publication in the literature, safety monitoring report, interim result or other finding that indicates an unexpected 
change to the risk/benefit ratio of the research; 
* Any breach in confidentiality or compromise in data privacy related to the subject or others; or 
* Any complaint of a subject that indicates an unanticipated risk or that cannot be resolved by the research staff. 
 
For projects which continue beyond one year from the starting date, the IRB will request continuing review and update 
of the research project. Your study will be due for continuing review as indicated above. The investigator must also 
advise the Board when this study is finished or discontinued by completing the enclosed Protocol Final Report form 
and returning it to the Institutional Review Board. 
 
If you have any questions, please contact the IRB office at 472-6965. 
 
Sincerely, 
 
Julia Torquati, Ph.D. 
Chair for the IRB 
 94 
Informed Consent Form 
        
 
                 DEPARTMENT OF ANTHROPOLOGY 
 
Consent to Participate in a Research Study 
EXPLORING THE RELATIONSHIP BETWEEN OSTEOCALCIN, LEPTIN, 
AND INSULIN IN FIT INDIVIDUALS WITH GOOD NUTRITIONAL STATUS 
 
Principal Investigator: Daniel Osborne, PhD, UNL-Anthropology 
Email: dosborne2@unl.edu  
Co-Investigator: Maria Gabriela Lapera, Master’s Candidate, UNL-Anthropology 
Email: mglapera@huskers.unl.edu Phone: 703-347-2371  
 
Daniel Osborne invites you to participate in a research study about the interaction 
between leptin and osteocalcin with the associated downstream effects on insulin. Please 
take whatever time you need to discuss the study with your family and friends, or anyone 
else you wish to. The decision to join, or not to join, is up to you. 
 
I am interested in studying the relationship amongst physical activity, bones, and 
hormones. More specifically, I want to understand the effect of daily, sustained vigorous 
activity on the hormones that act on and are produced by bones. Scientists have 
uncovered a relationship between leptin (a hormone that tells you when to stop eating) 
and the production of osteocalcin (a hormone produced by your bones when you 
exercise). We also know that osteocalcin makes the body more sensitive to insulin (a 
hormone that helps people regulate their blood sugar levels). As of now, no one knows 
exactly how physical activity, leptin, and osteocalcin interact. As a step towards that, I 
would like to understand what leptin and osteocalcin look like in an ideal system (i.e. a 
human consuming a high-quality diet who undertakes daily vigorous physical activity). 
By understanding what the levels should look like, we can better help people who 
struggle with obesity correct their hormonal issues to allow them a better chance of 
succeeding in returning to a more healthy weight. It might also help us understand 
humans’ evolutionary environment better.  
 
Subject Inclusion/Exclusion Criteria 
To participate in this study you must be an adult aged 19 years to 45 years. This study 
will accept participants of any sex and race/ethnicity.  Participants must be currently 
physically active, fit, have a good nutritional status, and in generally good health.  
 
People with known metabolic conditions (e.g. diabetes, metabolic syndrome), bone/tissue 
issues (e.g. broken bones, osteoporosis, arthritis, ACL tears, sprained ligament/tendon), 
or endocrine disorders cannot participate. Additionally, anyone currently pregnant or 
potentially pregnant cannot participate. Persons who have suffered from an eating 
disorder, experienced starvation/malnutrition in the past, or have had a long-term, serious 
illness are excluded. People with a history of drug use other than those prescribed for 
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medical reasons will be excluded. Anyone with a history of serious mental illness will 
also be excluded. Potential participants with any of the listed conditions will be asked to 
self-exclude themselves using a pre-study questionnaire. Their data will be destroyed. 
 
Description of Subject Involvement 
If you agree to be part of the study, you will be asked to fill out two questionnaires to 
assess your general health, exercise habits, and diet; have your weight, height, and waist-
to-hip ratio taken; undergo a blood draw; and have your bone density measured using a 
GE Lunar Achilles Insight Bone Densitometer device.  
 
The first questionnaire is to determine whether or not you would be a suitable participant 
in the study. It asks if you have any known endocrine or metabolic disorders, a history of 
drug use (including alcohol), any recently broken bones, or are pregnant. We think this 
will take you 10-15 minutes. If you have any of these conditions, you will be excluded 
from the study because all of these could affect the hormones we’re interested in 
studying. In regards to the alcohol, we will ask you how much you typically drink and 
how many years ago you started drinking. People who have been drinking in excess of a 
certain level for a long time will be excluded. If you have any conditions that would 
eliminate you from the study, all of your records will be destroyed. Please note: you will 
only be paid if you complete all steps of the procedure. If you are found ineligible after 
this step, you will not be paid. 
 
The second questionnaire is to assess general measures of health, exercise habits, and 
diet. We think this will take you 15-20 minutes. Since we are trying to understand how 
diet and physical activity play into hormone levels, it is important for researchers to know 
what your daily activities are like.  
 
A researcher will take your height, weight, and waist-to-hip ratio measurements. We 
anticipate this will take 5-10 minutes. These measurements will help us understand how 
your general health relates to your hormone levels and bone density.  
 
A researcher will measure your bone density at your calcaneus (heel bone) using a GE 
Lunar Achilles Insight Bone Densitometer. The device uses ultrasound and has no known 
risks. Ultrasound is a technology that uses harmless sound waves to ‘see’ inside of you. 
The probe emits sound waves that travel into your body. When they hit something solid, 
like bone, they are reflected back to the machine. The machine knows how long it took 
for the sound wave to come back. By measuring the time it took for the sound wave to 
come back, we’ll know how much bone is inside your heel bone. This process should 
take 10-15 minutes. This procedure will help researchers understand how much bone 
each participant has. 
 
A certified phlebotomist will then draw your blood from your arm using a syringe. We 
will take 4 mL of blood. This is equivalent to ¾ of a teaspoon of blood. This should take 
about 10-15 minutes. The blood will be tested to determine hormone levels. You will be 
given a snack (juice and cookies or chips) after your blood draw is complete. 
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At a maximum, your participation in the study should take two hours. It will likely take 
less time than this to complete the appointment. After this one-time appointment, you 
will not have any more time commitments. There are no costs to you for participating in 
the study.  
 
Benefits 
Participants can expect to receive their hormone (leptin/osteocalcin/insulin) profiles as 
well as their bone density readings. (Please keep in mind that the results of all tests are 
for research purposes only and should not be used for diagnosis or clinical purposes. If 
participants have concerns about their health, they should contact their physicians.) Your 
results will have to be picked up in person in order to make sure that your personal 
information remains security. If you do not pick up your report within 2 months of the 
conclusion of the study, they will be destroyed. A researcher will send you an email to set 
up an appointment to pick up your report. They will also have access to the final group 
analysis in the form of Maria Lapera’s thesis.  
 
Although you may not directly benefit from this study, others may eventually benefit 
from the information gathered in this study because it may provide greater insight into the 
causes of and potential solutions for obesity. 
 
Compensation 
You will be paid $15 for your time with a check that I’ll give you at the end of this data 
gathering session. You will only be paid if you complete all steps of the procedure. 
Potential participants that are disqualified from the study after the first questionnaire will 
not be eligible for any compensation. 
 
Risks and Discomforts 
There are a few minor risks associated with this study. Blood draws might cause pain, 
bruising at site of needle insertion, inflammation of the vein, infection, and fainting.  
 
You will be asked NOT to eat for the 6 hours preceding the blood draw.  
 
Confidentiality 
Every effort to ensure confidentiality will be made. Appointments for blood draws, 
interviews, and anthropometric measurements will be scheduled separately and with 
enough time to ensure that none overlap. Blood samples will only be handled by the 
phlebotomist and the researchers. 
 
Personal information will not be made available to anyone other than the researchers 
associated with the study and governmental offices or the Institutional Review Board 
who are charged with the responsibility of making sure that research procedures are in 
accordance with legal and ethical standards.  
 
All information related to the study will be kept on password-protected and encrypted 
computers. Any hard copies of data or reports will be kept in a locked room in a locked 
file cabinet to which only the researchers listed for this study have access. During the 
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study, all your questionnaires, measurements, and blood sample will be labeled with a 
code number rather than your name. The list that connects your name to the code number 
will be kept separately in locked file cabinet in a locked room or encrypted on a 
password-protected computer. Data will also be maintained on password protected 
computers and data will be encoded. After the study all hard copies will be destroyed. No 
records with identifying information will be kept, including the list linking your name 
with your code number.  
 
If you choose to leave the study before it is completed, all of your records, including 
personal information, will be destroyed. If you choose to do this, you MUST contact the 
investigator. You may leave the study at any time.  
 
Your blood will be temporarily stored at the UNL Health Center until it can be 
transported to a lab in Morrill Hall. The Morrill Hall lab is locked and the blood samples 
will be held in a locked refrigerator until it is time to test the samples. The samples will 
then be transported to a lab in Beadle where they will be under the direct supervision of a 
researcher at all times. Excess blood sample will be disposed of appropriately. Once the 
study is completed, your blood sample will be destroyed. 
 
Once your individual results have been delivered to you, all personal information will be 
deleted. You will be assigned a new designation (such as, "Individual 001") within the 
study. If your results must be described specifically in the eventual written analysis, you 
will be referred to using the new assigned designation (such as, "Individual 001") to 
protect your identity. Identifying information kept within study records should be 
removed by 6 months into the study at a maximum, with the exception of this document, 
which will be kept on file for 3 years, and a receipt for your compensation, which will be 
kept on file for 7 years. Neither of these documents will have your code number on it, so 
there will be no way to link your name with the data. While on file, it will be kept in a 
locked cabinet. Soft copies will be encrypted and kept on a password-protected computer. 
 
Future Use of Data 
Results and the data (without identifying information) can be kept and used by the 
researchers indefinitely. The researchers may share the data (without identifying 
information) with other researchers or institutions in the future.  
 
Only researchers associated with this study will have access to records and data with the 
exception of the personalized results that will be sent to you. 
 
Voluntary Nature of the Study 
Participating in this study is completely voluntary. Even if you decide to participate now, 
you may change your mind and stop at any time. If you decide to withdraw, all of your 
data will be deleted.  
 
Contact Information 
If you have questions about your rights as a research participant, wish to obtain 
information, ask questions, or discuss any concerns about this study with someone other 
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than the researchers, please contact the University of Nebraska – Lincoln Institutional 
Review Board. They may be reached between 9 am to 5 pm on Mondays through Fridays 
at 402-472-6965. The Institutional Review Board can also be reached at irb@unl.edu.  
 
Consent 
Subject 
The research project and the procedures associated with it have been explained to me. 
The experimental procedures have been identified and no guarantee has been given about 
the possible results. I will receive a signed copy of this consent form for my records.  
 
I agree to participate in this study. I am aware that my participation is voluntary and that I 
do not have to sign this form if I do not want to be part of this research study. I am aware 
that I may choose to drop out of the study at any time and have all my records destroyed 
after notifying the investigators.  
 
Signature of Subject:_____________________________ 
 
 
Date: __________________  Time: __________________ AM/PM 
 
Person Obtaining Consent 
I have explained to _________________________________________________ the 
nature and purpose of this study and the risks involved. I have answered and will answer 
all questions to the best of my ability. I will give a signed copy of the consent form to the 
subject.  
 
Signature of Person Obtaining Consent:_____________________________ 
 
 
Date: __________________  Time: __________________ AM/PM 
 
 
Investigator 
Signature of Investigator:_____________________________ 
 
 
Date: __________________  Time: __________________ AM/PM 
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Appendix B: Surveys 
 
Health Pre-Questionnaire 
 
Question YES NO 
METABOLIC DISORDERS   
Do you have diabetes?   
Do you have any other known metabolic disorder?   
   
ENDOCRINE DISORDERS   
Do you have any growth hormone related disorders?   
Do you have any thyroid issues?   
Do you have any adrenal issues?   
Do you have any problems regulating testosterone/estrogen?   
Do you have any problems with your pituitary?   
Do you have any problems with your parathyroid?   
Do you have any issues related to melanocortins, ACTH, CART, POMC?   
Do you have any other known endocrine disorders?   
   
MISCELLANEOUS   
Have you broken any bones recently (last year)?    
Have you sprained or strained any tendons, ligaments, or muscles recently (last year)?   
Are you pregnant or potentially pregnant?   
Do you have or have you ever had cancer?   
Have you ever suffered from an eating disorder or experienced starvation/malnutrition for 
an extended period? 
  
Have you ever had any type of hepatitis?    
Have you ever experienced depression or any other serious mental illness?   
Are you currently using drugs other than those required for medical reasons?   
ALCOHOL USE – please circle the letter corresponding to your answer. 
1. At what age did you begin drinking? ______________ years old 
2. How many standard drinks containing alcohol do you have on a typical day? 
a. 1 or 2 
b. 3 or 4 
c. 5 or 6 
d. 7 to 9 
e. 10 or more 
3. How often do you have six or more drinks on one occasion? 
a. Never 
b. Less than monthly 
c. Weekly 
d. Daily or almost daily
Other: 
1. How old are you? ________________ years old 
2. How many hours per week do you exercise? _______________ hrs/week 
3. Have you been working out for the above number of hours for greater than 6 months? YES  
 NO 
4. Do you feel that have a relatively healthy diet? YES  NO 
5. Are you a healthy weight? YES  NO 
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Study Questionnaire 
 
Activity and Diet Questionnaire 
Part 1 – Physical Activity 
Please circle all activities listed below that you have done more than 10 times in the last 
year. 
 
1. Jogging/Running (outdoor, 
treadmill) 
2. Swimming (laps, snorkeling) 
3. Bicycling (indoor, outdoor) 
4. Softball/Baseball 
5. Volleyball 
6. Bowling 
7. Basketball 
8. Skating (roller, ice, blading) 
9. Martial Arts 
10. Tai Chi 
11. Calisthenics/Toning Exercises 
12. Wood Chopping 
13. Water/Coal Hauling 
14. Walking for Exercise (outdoor, 
indoor) 
15. Football/Soccer 
16. Raquetball/Handball/Squash 
17. Horseback Riding 
18. Hunting 
19. Fishing 
20. Aerobic Dance/Step Aerobic 
21. Water Aerobics 
22. Dancing  
23. Gardening or Yard Work 
24. Badminton 
25. Strength/Weight Training 
26. Rock Climbing 
27. SCUBA diving 
28. Stair Master 
29. Fencing 
30. Hiking 
31. Tennis 
32. Golf 
33. Canoe/Row/Kayak 
34. Water Skiing  
35. Jumping Rope 
36. Ski/Snowboard 
37. Snow Shoeing 
38. Yoga 
39. Other
 
List each activity that you circled in the box below, check the months that you did each activity 
over the past year (12 months) and then estimate the average amount of time spent in that activity. 
Mark any activities for work with a “-W.” 
 
Activity 
J 
A 
N 
F
E
B 
M
A
R 
A
P
R 
M
A
Y 
J
U
N 
J
U
L 
A
U
G 
S
E
P 
O
C
T 
N
O
V 
D
E
C 
AVG # of 
times/ 
month 
Average # of 
minutes each 
time 
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1. Did you ever compete in an individual or team sport? If yes, how many total years did 
you participate? Please place a checkmark next to each sport in which you are still an 
active participant. 
Sport: _________________   ____ yrs            Sport: ________________   _______ yrs     
Sport: _________________   ____ yrs            Sport: ________________   _______ yrs     
Sport: _________________   ____ yrs            Sport: ________________   _______ yrs     
Sport: _________________   ____ yrs            Sport: ________________   _______ yrs     
 
2. Please briefly describe your workout (e.g.: strength training, cardio, interval training, 
etc.) and rate the level of intensity on a scale of 1-5 (1 = mild, slightly increased heart 
rate; 5 = strenuous, max heart rate, heavy breathing). Write 0 if you do not work out 
on a certain day. 
Monday  
Intensity:  1 2 3 4 5 
 
 
 
Tuesday 
Intensity:  1 2 3 4 5 
 
 
 
Wednesday 
Intensity:  1 2 3 4 5 
 
 
 
Thursday 
Intensity:  1 2 3 4 5 
 
 
 
Friday 
Intensity:  1 2 3 4 5 
 
 
 
Saturday 
Intensity:  1 2 3 4 5 
 
 
 
Sunday      
Intensity:  1 2 3 4 5 
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Part 2 – Leisure Time Activity 
1. In general, how many hours per day do you usually spend watching television?  
_________ hrs. 
 
2. In general, how many hours per day do you usually spend using a computer or another 
electronic device (e.g. iPAD, videogame) for fun?  _________ hrs. 
 
3. In general, how many hours per day do you usually spend using a computer or another 
electronic device for school or work?  _________ hrs. 
 
4. In general, how many hours of sleep do you get per night during a work night (i.e. 
Sunday through Thursday)?  ________ hrs. 
 
5. In general, how many hours of sleep do you get per night during a weekend night (i.e. 
Friday and Saturday)?  _________ hrs. 
 
Part 3 – Work Activity 
Have you had a job lasting longer than one month over this past year (from last June 2013 to this 
June 2014)? 
 
List all jobs that you have held over the past year for more than one month. Account for all 12 
months of the past year. If unemployed, disabled, retired, homemaker, and/or student during all or 
part of the past year, list as such. 
 
 
 
Job 
Name 
 
 
Job 
Code 
Walk/Bike 
to/from 
work 
(min/day) 
 
Avg  
 
Mon/Yr   
    
   Job  
 
Day/Wk 
 
Sched 
 
Hrs/Day 
Hrs 
spent 
sitting 
at work 
 
Check the 
category that 
best describes 
job activities 
when not sitting. 
 
  A          B          C 
            
          
          
          
          
 
Category A (includes all sitting 
activities) 
Sitting 
Standing still w/out heavy lifting 
Light cleaning – ironing, 
  cooking, washing, dusting 
Driving a bus, taxi, tractor 
Jewelry making/Weaving 
General office work 
Occasional/short distance walking 
 
 
Category B (includes most indoor 
activities) 
Carrying light loads 
Continuous walking 
Heavy cleaning – mopping, 
  sweeping, scrubbing, 
  vacuuming  
Gardening – planting, weeding 
Painting/plastering 
Plumbing/welding 
Electrical work 
Sheep herding 
Category C (heavy industrial work, 
outdoor construction, farming) 
Carrying moderate to heavy loads 
Heavy construction 
Farming – hoeing, digging, 
   mowing, raking 
Digging ditches, shoveling 
Chopping (ax), sawing wood 
Tree/pole climbing 
Water/coal/wood hauling 
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Job Codes 
 
Not employed outside the home 
1. Student 
2. Home maker 
3. Retired 
4. Disabled 
5. Unemployed 
 
Employee (or volunteer) 
6. Armed Services 
7. Office worker 
8. Non-office work 
 
Part 4 - Diet 
1. Do you take any dietary supplements?   YES      NO 
a. If so, how often?    DAILY    REGULARLY    OCCASIONALLY     NEVER 
b. Do you take multivitamins?  YES    NO 
c. Do you take protein supplements? YES    NO 
d. List the other dietary supplements you take: __________________________ 
 
2. Are you following any specific diet plan?    YES       NO 
a. If so, please give the name (e.g. Atkin’s, Paleo, South Beach) OR give a very 
brief description: 
 
 
b. Do you keep track of your daily caloric intake?  YES       NO 
o If so, what is your daily average caloric intake? _________ 
 
3. Meal habits: 
a. On average, how many days a week do you eat breakfast? ____ 
o If you do eat breakfast, on average how many are made from scratch at home? 
____ 
b. On average, how many days a week do you eat lunch? ____ 
o If you do eat lunch, on average how many are made from scratch at home? 
____ 
c. On average, how many days a week do you eat dinner? ____ 
o If you do eat dinner, on average how many are made from scratch at home? 
____ 
d. On average, how many times per day do you snack? ____ 
 
4. Meal breakdowns: 
a. In a typical day, how many of your meals or snacks include carbohydrates? _____ 
o Place a check next to the types of foods you normally eat: 
• ____ Bread, wraps, tortillas 
• ____ Cereal, oatmeal, granola bars 
• ____ Pasta 
• ____ Quinoa, couscous, rice 
• ____ Candy, chocolate, or baked goods 
• ____ Other:  
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b. In a typical day, how many of your meals or snacks include protein? ______ 
o  Place a check next to the types of foods you normally eat: 
• ____ Beef 
• ____ Ham or pork 
• ____ Chicken, turkey, quail, duck 
• ____ Lamb or goat 
• ____ Fish or shellfish 
• ____ Dairy 
• ____ Tofu 
•  ____Other plant proteins 
• ____ Other:  
 
c. In a typical day how many of your meals or snacks include vegetables? ______ 
o  Place a check next to the types of foods you normally eat: 
• ____ Fresh vegetables 
• ____ Frozen vegetables 
• ____ Dried vegetables 
• ____ Juice  
• ____ Canned vegetables 
• ____ Pureed vegetables (ex: baby food, home-made veggie smoothies) 
• ____ Other:  
 
d. In a typical day how many of your meals or snacks include fruit? ______ 
o  Place a check next to the types of foods you normally eat: 
• ____ Fresh fruit 
• ____ Frozen fruit 
• ____ Dried fruit 
• ____ Juice 
• ____ Canned fruit or fruit cups 
• ____ Pureed fruit (ex: apple sauce, home-made fruit smoothies) 
• ____ Other: 
Part 5 – Health 
1. Do you have any allergies?   YES     NO 
a. Seasonal: ______________________________________________________ 
b. Food: _________________________________________________________ 
c. Animal: _______________________________________________________ 
d. Other: ________________________________________________________ 
 
2. Do you have asthma?  YES    NO 
If you answered yes, circle the medications you use: 
Corticosteroid inhaler   Oral corticosteroids 
Short-acting beta2 (β2) agonist Anti-IgE 
Long-acting beta2 (β2) agonist Leukotriene modifiers 
Theophylline    Cromolyn 
  Other: ___________________________________________ 
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3. How would you rate your stress level on a scale of 1 to 5 (with 1 being totally 
unstressed and 5 being the most stressed)? 
 
     1               2  3  4  5 
 
4. How often do you spend time outside? 
a. Winter:     Never Occasionally      Sometimes      Often      Very Often 
b. Spring:      Never    Occasionally        Sometimes      Often       Very Often 
c. Summer:   Never Occasionally        Sometimes      Often       Very Often 
d. Fall:        Never        Occasionally        Sometimes      Often       Very Often 
 
5. Do you wear sunscreen when you’re outside for extended periods of time? 
Never     Occasionally Sometimes       Often    Very Often 
 
Part 6 - Background 
1. I am:  MALE          FEMALE         
a.   If you are female, at what age did you begin menstruating? _________years 
 
b. If you are female, do you take hormonal birth control?  YES NO 
 
2. Are you:  
Married  Single w/ Serious Partner Single     Divorced Separated 
 
3. What is your date of birth? __________________ 
 
4. How many full siblings do you have? _________ 
a. Write the birth order with the oldest on the left and youngest on the right. (Ex: If 
you have one older brother and two younger sisters, your birth order would be: 
Brother, Me, Sister, Sister.) 
 
 
5. How many half-siblings do you have? _________ 
 
6. Are your parents still together?  YES      NO      UNKNOWN 
a. If not, which term describes your parents’ situation: 
          Divorce  Separation   Widowed 
 
b. If they are no longer together, how old were you when they separated? _______ 
years  
 
7. Circle the socioeconomic group to which your family belonged while you were 
growing up:  
               lower            lower middle middle  upper middle  upper 
 
8.  Circle the socioeconomic group to which you now belong: 
 lower            lower middle middle  upper middle  upper 
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9. Please circle your race: 
White  Vietnamese   Filipino 
          
Black  Asian Indian   Samoan 
  
Japanese  Guamanian or Chamorro        Other Pacific Islander___________ 
 
Chinese  Other Asian _____________________ 
  
Korean  Native Hawaiian  American Indian/Alaska Native  
 
Other _____________________ 
 
10. If you are of Hispanic/Latino/Spanish descent, please specify the country or countries 
of origin. ________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Normality Tests and Distributions 
 
 
 
Table 2: Tests of Normality – WHR & BMI 
 Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Waist-to-hip ratio .071 57 .200* .985 57 .724 
BMI .064 57 .200* .985 57 .710 
*. This is a lower bound of the true significance. 
a. Lilliefors Significance Correction 
 
 
 
Table 1: Descriptives – WHR & BMI 
 Statistic Std. Error 
Waist-to-hip ratio 
Mean .78932 .008431 
95% Confidence Interval for Mean 
Lower Bound .77243  
Upper Bound .80620  
5% Trimmed Mean .78808  
Median .79100  
Variance .004  
Std. Deviation .063652  
Minimum .660  
Maximum .963  
Range .303  
Interquartile Range .079  
Skewness .216 .316 
Kurtosis .295 .623 
BMI 
Mean 24.061 .3705 
95% Confidence Interval for Mean 
Lower Bound 23.319  
Upper Bound 24.803  
5% Trimmed Mean 24.026  
Median 24.100  
Variance 7.822  
Std. Deviation 2.7969  
Minimum 18.7  
Maximum 30.9  
Range 12.2  
Interquartile Range 4.4  
Skewness .078 .316 
Kurtosis -.444 .623 
Figures 1-4: WHR scatterplots, boxplot, and hitsogram 
Figure 1                        Figure 2 
          
 
 
 
 
   Figure 3                Figure 4 
                    
 
 
 
 
 
 
 
 
 
 
 
Figures 5-8: BMI scatterplots, boxplot, and histogram 
      Figure 5          Figure 6 
         
 
 
 
   Figure 7             Figure 8 
                        
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Descriptives – Leptin & Osteocalcin 
 Statistic Std. Error 
Leptin blood level in pg/mL 
Mean 1791.8715 323.84837 
95% Confidence Interval for 
Mean 
Lower Bound 1143.1253  
Upper Bound 2440.6178  
5% Trimmed Mean 1440.8671  
Median 827.1449  
Variance 5978032.683  
Std. Deviation 2445.00157  
Minimum 46.00  
Maximum 11837.12  
Range 11791.12  
Interquartile Range 2463.79  
Skewness 2.320 .316 
Kurtosis 6.220 .623 
Osteocalcin blood level in 
pg/mL 
Mean 4201.4558 558.20396 
95% Confidence Interval for 
Mean 
Lower Bound 3083.2389  
Upper Bound 5319.6727  
5% Trimmed Mean 3753.1017  
Median 3643.0548  
Variance 17760724.915  
Std. Deviation 4214.34751  
Minimum 136.00  
Maximum 26020.00  
Range 25884.00  
Interquartile Range 4312.08  
Skewness 2.724 .316 
Kurtosis 11.864 .623 
 
 
Table 4: Tests of Normality – Leptin & Osteocalcin 
 Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Leptin blood level in pg/mL .238 57 .000 .718 57 .000 
Osteocalcin blood level in 
pg/mL 
.167 57 .000 .768 57 .000 
a. Lilliefors Significance Correction 
 
 
 
 
Figures 9-12: Leptin scatterplots, boxplot, and histogram 
Figure 9                                                Figure 10 
          
 
 
 
         Figure 11       Figure 12 
                 
 
 
 
 
 
 
 
 
 
 
Figures 13-16: Osteocalcin scatterplots, boxplot, and histogram 
     Figure 13          Figure 14 
        
 
 
 
      Figure 15          Figure 16 
                     
 
 
 
 
 
 
 
 
 
 
 
 
Table 5: Descriptives – Bone Health Measures 
 Statistic Std. Error 
Stiff Bone 
Mean 114.8571 3.11744 
95% Confidence Interval for 
Mean 
Lower Bound 108.6096  
Upper Bound 121.1046  
5% Trimmed Mean 114.7183  
Median 112.0000  
Variance 544.234  
Std. Deviation 23.32882  
Minimum 68.00  
Maximum 161.00  
Range 93.00  
Interquartile Range 36.75  
Skewness .161 .319 
Kurtosis -.882 .628 
T-Score 
Mean .9407 .19612 
95% Confidence Interval for 
Mean 
Lower Bound .5477  
Upper Bound 1.3337  
5% Trimmed Mean .9325  
Median .8000  
Variance 2.154  
Std. Deviation 1.46759  
Minimum -2.00  
Maximum 3.80  
Range 5.80  
Interquartile Range 2.31  
Skewness .136 .319 
Kurtosis -.933 .628 
BUA 
Mean 128.0116 2.74506 
95% Confidence Interval for 
Mean 
Lower Bound 122.5104  
Upper Bound 133.5128  
5% Trimmed Mean 128.4667  
Median 129.5850  
Variance 421.981  
Std. Deviation 20.54217  
Minimum 65.52  
Maximum 168.14  
Range 102.62  
Interquartile Range 28.83  
Skewness -.325 .319 
Kurtosis .335 .628 
 
 
Table 5 (continued) 
 Statistic Std. Error 
SOS 
Mean 1606.2116 7.00250 
95% Confidence Interval for 
Mean 
Lower Bound 1592.1783  
Upper Bound 1620.2449  
5% Trimmed Mean 1604.2343  
Median 1599.8750  
Variance 2745.958  
Std. Deviation 52.40189  
Minimum 1529.94  
Maximum 1724.82  
Range 194.88  
Interquartile Range 81.19  
Skewness .497 .319 
Kurtosis -.620 .628 
 
 
Table 6: Tests of Normality – Bone Health Measures 
 Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Stiff Bone .068 56 .200* .974 56 .257 
T-Score .074 56 .200* .972 56 .228 
BUA .061 56 .200* .983 56 .626 
SOS .104 56 .196 .949 56 .019 
*. This is a lower bound of the true significance. 
a. Lilliefors Significance Correction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 17-20: Stiff Bone scatterplots, boxplot, and histogram 
 
   Figure 17          Figure 18 
          
 
 
 
 
    Figure 19         Figure 20 
                 
 
 
 
 
 
 
 
 
 
 
 
Figures 21-24: T-Score scatterplots, boxplot, and histogram 
     Figure 21          Figure 22 
       
 
 
 
 
 
     Figure 23       Figure 24 
              
 
 
 
 
 
 
 
 
 
 
Figures 25-28: BUA scatterplots, boxplot, and histogram 
       Figure 25          Figure 26 
    
 
 
 
 
 
 
   Figure 27         Figure 28 
               
 
 
 
 
 
 
 
 
 
 
Figures 29-32: SOS scatterplots, boxplot, and histogram 
        Figure 29          Figure 30 
    
 
 
 
 
 
 
     Figure 31                   Figure 32    
  
               
 
 
 
 
 
 
 
 
 
 
 
Table 7: Descriptives – Time Spent Exercising (minutes) 
 Statistic Std. Error 
Minutes spent running per year 
Mean 5347.7895 928.57074 
95% Confidence Interval for 
Mean 
Lower Bound 3487.6388  
Upper Bound 7207.9402  
5% Trimmed Mean 4368.1871  
Median 3600.0000  
Variance 49147886.383  
Std. Deviation 7010.55535  
Minimum .00  
Maximum 42000.00  
Range 42000.00  
Interquartile Range 4230.00  
Skewness 3.213 .316 
Kurtosis 13.235 .623 
Minutes strength training per 
year 
Mean 8300.1754 1335.00740 
95% Confidence Interval for 
Mean 
Lower Bound 5625.8342  
Upper Bound 10974.5166  
5% Trimmed Mean 7187.4464  
Median 5400.0000  
Variance 101587951.754  
Std. Deviation 10079.08487  
Minimum .00  
Maximum 43200.00  
Range 43200.00  
Interquartile Range 11310.00  
Skewness 1.574 .316 
Kurtosis 2.187 .623 
Minutes spent biking per year 
Mean 2821.3158 690.29293 
95% Confidence Interval for 
Mean 
Lower Bound 1438.4929  
Upper Bound 4204.1387  
5% Trimmed Mean 1928.6550  
Median .0000  
Variance 27160746.898  
Std. Deviation 5211.59735  
Minimum .00  
Maximum 25200.00  
Range 25200.00  
Interquartile Range 4060.00  
Skewness 3.098 .316 
Kurtosis 10.877 .623 
 
 
 
Table 7 (continued) 
 Statistic Std. Error 
Minutes spent walking per year 
Mean 5561.7544 1165.97677 
95% Confidence Interval for 
Mean 
Lower Bound 3226.0222  
Upper Bound 7897.4865  
5% Trimmed Mean 4558.6745  
Median 1280.0000  
Variance 77491604.010  
Std. Deviation 8802.93156  
Minimum .00  
Maximum 43200.00  
Range 43200.00  
Interquartile Range 8550.00  
Skewness 2.068 .316 
Kurtosis 4.918 .623 
Minutes spent swimming per 
year 
Mean 1002.7193 587.77020 
95% Confidence Interval for 
Mean 
Lower Bound -174.7259  
Upper Bound 2180.1645  
5% Trimmed Mean 259.3957  
Median .0000  
Variance 19692007.206  
Std. Deviation 4437.56771  
Minimum .00  
Maximum 32400.00  
Range 32400.00  
Interquartile Range 235.00  
Skewness 6.657 .316 
Kurtosis 46.859 .623 
Total minutes spent exercising 
per year 
Mean 23033.7544 2230.12515 
95% Confidence Interval for 
Mean 
Lower Bound 18566.2769  
Upper Bound 27501.2319  
5% Trimmed Mean 21553.9376  
Median 18480.0000  
Variance 283487115.760  
Std. Deviation 16837.07563  
Minimum 3240.00  
Maximum 82800.00  
Range 79560.00  
Interquartile Range 22140.00  
Skewness 1.337 .316 
Kurtosis 1.944 .623 
 
 
 
Table 8: Tests of Normality – Time Spent Exercising (minutes) 
 Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Minutes spent running per year .251 57 .000 .652 57 .000 
Minutes strength training per 
year 
.205 57 .000 .803 57 .000 
Minutes spent biking per year .294 57 .000 .583 57 .000 
Minutes spent walking per year .290 57 .000 .681 57 .000 
Minutes spent swimming per 
year 
.411 57 .000 .229 57 .000 
Total minutes spent exercising 
per year 
.151 57 .002 .885 57 .000 
a. Lilliefors Significance Correction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 33-36: Minutes Spent Running/Year scatterplots, boxplot, and histogram 
     Figure 33          Figure 34 
    
 
    Figure 35       Figure 36 
               
 
 
 
 
 
 
 
 
 
 
 
 
Figures 37-40: Minutes Spent Strength Training/Year scatterplots, boxplot, and histogram 
   Figure 37          Figure 38 
    
 
 
 
   Figure 39       Figure 40 
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 41-44: Minutes Spent Biking/Year scatterplots, boxplot, and histogram 
 
      Figure 41          Figure 42 
    
 
 
 
          Figure 43          Figure 44 
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 45-49: Minutes Spent Walking/Year scatterplots, boxplot, and histogram 
        Figure 45                     Figure 46 
    
 
 
 
 
 
      Figure 47       Figure 48 
               
 
 
 
 
 
 
 
 
 
 
 
 
Figures 49-52: Minutes Spent Swimming/Year scatterplots, boxplot, and histogram 
      Figure 49          Figure 50 
    
 
 
 
 
       Figure 51                 Figure 52 
          
 
 
 
 
 
 
 
 
 
 
 
 
Figures 52-55: Total Minutes Spent Exercising/Year scatterplots, boxplot, and histogram 
        Figure 52         Figure 53 
   
 
 
          Figure 54       Figure 55 
             
 
 
 
 
 
 
 
 
 
 
 
 
Table 9: Descriptives – Time Spent Exercising (hours) 
 Statistic Std. Error 
Hours Spent Running Per Year 
Mean 89.1298 15.47618 
95% Confidence Interval for 
Mean 
Lower Bound 58.1273  
Upper Bound 120.1323  
5% Trimmed Mean 72.8031  
Median 60.0000  
Variance 13652.191  
Std. Deviation 116.84259  
Minimum .00  
Maximum 700.00  
Range 700.00  
Interquartile Range 70.50  
Skewness 3.213 .316 
Kurtosis 13.235 .623 
Hours Spent Strength Training 
Per Year 
Mean 89.1298 15.47618 
95% Confidence Interval for 
Mean 
Lower Bound 58.1273  
Upper Bound 120.1323  
5% Trimmed Mean 72.8031  
Median 60.0000  
Variance 13652.191  
Std. Deviation 116.84259  
Minimum .00  
Maximum 700.00  
Range 700.00  
Interquartile Range 70.50  
Skewness 3.213 .316 
Kurtosis 13.235 .623 
Hours Spent Biking Per Year 
Mean 47.0219 11.50488 
95% Confidence Interval for 
Mean 
Lower Bound 23.9749  
Upper Bound 70.0690  
5% Trimmed Mean 32.1442  
Median .0000  
Variance 7544.650  
Std. Deviation 86.85994  
Minimum .00  
Maximum 420.00  
Range 420.00  
Interquartile Range 67.67  
Skewness 3.098 .316 
Kurtosis 10.877 .623 
 
 
 
Table 9  (continued) 
 Statistic Std. Error 
Hours Spent Walking Per Year 
Mean 92.6958 19.43295 
95% Confidence Interval for 
Mean 
Lower Bound 53.7669  
Upper Bound 131.6247  
5% Trimmed Mean 75.9778  
Median 21.3300  
Variance 21525.464  
Std. Deviation 146.71559  
Minimum .00  
Maximum 720.00  
Range 720.00  
Interquartile Range 142.50  
Skewness 2.068 .316 
Kurtosis 4.918 .623 
Hours Spent Swimming Per 
Year 
Mean 16.7119 9.79617 
95% Confidence Interval for 
Mean 
Lower Bound -2.9122  
Upper Bound 36.3360  
5% Trimmed Mean 4.3232  
Median .0000  
Variance 5470.004  
Std. Deviation 73.95947  
Minimum .00  
Maximum 540.00  
Range 540.00  
Interquartile Range 3.92  
Skewness 6.657 .316 
Kurtosis 46.859 .623 
Total Hours Spent Exercising 
Per Year 
Mean 334.6893 42.94474 
95% Confidence Interval for 
Mean 
Lower Bound 248.6606  
Upper Bound 420.7180  
5% Trimmed Mean 293.0596  
Median 240.0000  
Variance 105122.305  
Std. Deviation 324.22570  
Minimum 18.00  
Maximum 1735.33  
Range 1717.33  
Interquartile Range 333.08  
Skewness 2.247 .316 
Kurtosis 6.370 .623 
 
 
 
Table 10: Time Spent Exercising (hours) 
 Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Hours Spent Running Per Year .251 57 .000 .652 57 .000 
Hours Spent Strength Training 
Per Year 
.251 57 .000 .652 57 .000 
Hours Spent Biking Per Year .294 57 .000 .583 57 .000 
Hours Spent Walking Per Year .290 57 .000 .681 57 .000 
Hours Spent Swimming Per 
Year 
.411 57 .000 .229 57 .000 
Total Hours Spent Exercising 
Per Year 
.202 57 .000 .776 57 .000 
a. Lilliefors Significance Correction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 56-59: Hours Spent Running/Year scatterplots, boxplot, and histogram 
                        Figure 56                   Figure 57 
    
 
 
 
 
 
        Figure 58       Figure 59 
               
 
 
 
 
 
 
 
 
 
 
 
Figures 60-63: Hours Spent Strength Training/Year scatterplots, boxplot, and histogram 
      Figure 60                      Figure 61 
     
 
 
 
 
       Figure 62       Figure 63 
               
 
 
 
 
 
 
 
 
 
Figures 64-67: Hours Spent Biking/Year scatterplots, boxplot, and histogram 
        Figure 64          Figure 65 
       
 
 
 
 
    Figure 66          Figure 67 
               
 
 
 
 
 
 
 
 
 
 
Figures 68-71: Hours Spent Walking/Year scatterplots, boxplot, and histogram 
         Figure 68          Figure 69 
     
 
 
 
 
       Figure 70          Figure 71 
                
 
 
 
 
 
 
 
 
 
 
Figures 71-74: Hours Spent Swimming/Year scatterplots, boxplot, and histogram 
    Figure 71                 Figure 72 
     
 
 
 
 
 
Figure 73          Figure 74 
               
 
 
 
 
 
 
 
 
 
 
 
 
Figures 75-78: Hours Spent Exercising/Year scatterplots, boxplot, and histogram 
    Figure 75                           Figure 76 
             
 
 
 
    Figure 77                           Figure 78 
             
 
 
 
 
 
 
 
 
 
 
 
 
Table 11: Descriptives – Sedentary Time (minutes) 
 Statistic Std. Error 
Minutes Spent Sitting Per Year 
for Work 
Mean 19145.7895 1940.38977 
95% Confidence Interval for 
Mean 
Lower Bound 15258.7217  
Upper Bound 23032.8573  
5% Trimmed Mean 18426.7836  
Median 15120.0000  
Variance 214611410.526  
Std. Deviation 14649.62151  
Minimum .00  
Maximum 54000.00  
Range 54000.00  
Interquartile Range 21300.00  
Skewness .545 .316 
Kurtosis -.495 .623 
Minutes Spent Sitting Per Year 
for Leisure 
Mean 54596.7684 4152.91514 
95% Confidence Interval for 
Mean 
Lower Bound 46277.4797  
Upper Bound 62916.0571  
5% Trimmed Mean 52946.6807  
Median 43831.2000  
Variance 983062136.131  
Std. Deviation 31353.82171  
Minimum .00  
Maximum 142451.40  
Range 142451.40  
Interquartile Range 32873.40  
Skewness .801 .316 
Kurtosis .715 .623 
Total Minutes Spent Sitting Per 
Year 
Mean 73742.5579 4593.68743 
95% Confidence Interval for 
Mean 
Lower Bound 64540.2962  
Upper Bound 82944.8196  
5% Trimmed Mean 72917.1754  
Median 70875.6000  
Variance 1202811957.958  
Std. Deviation 34681.57952  
Minimum 8359.20  
Maximum 156693.60  
Range 148334.40  
Interquartile Range 50045.10  
Skewness .412 .316 
Kurtosis -.273 .623 
 
 
 
Table 12: Tests of Normality – Sedentary Time (minutes) 
 Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Minutes Spent Sitting Per Year 
for Work 
.120 57 .041 .937 57 .005 
Minutes Spent Sitting Per Year 
for Leisure 
.161 57 .001 .938 57 .006 
Total Minutes Spent Sitting Per 
Year 
.086 57 .200* .979 57 .419 
*. This is a lower bound of the true significance. 
a. Lilliefors Significance Correction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 79-82: Total Work Minutes Spent Sitting/Year scatterplots, boxplot, and histogram 
     Figure 79                      Figure 80 
             
 
 
 
Figure 81        Figure 82 
             
 
 
 
 
 
 
 
 
 
 
 
Figures 83-86: Total Leisure Minutes Spent Sitting/Year scatterplots, boxplot, and histogram 
     Figure 83                       Figure 84 
           
 
 
 
Figure 85        Figure 86 
             
 
 
 
 
 
 
 
 
 
 
 
Figures 87-90: Total Minutes Spent Sitting/Year scatterplots, boxplot, and histogram 
Figure 87                                             Figure 88 
             
 
 
 
Figure 89        Figure 91 
             
 
 
 
 
 
 
 
 
 
 
 
 
Table 13: Descriptives – Sedentary Time (hours) 
 Statistic Std. Error 
Average Number of Hours Slept 
Per Night 
Mean 7.4474 .13877 
95% Confidence Interval for 
Mean 
Lower Bound 7.1694  
Upper Bound 7.7254  
5% Trimmed Mean 7.5027  
Median 7.5000  
Variance 1.098  
Std. Deviation 1.04768  
Minimum 4.25  
Maximum 9.00  
Range 4.75  
Interquartile Range 1.00  
Skewness -.773 .316 
Kurtosis .579 .623 
Total Work Hours Spent Sitting 
Per Year 
Mean 319.0965 32.33983 
95% Confidence Interval for 
Mean 
Lower Bound 254.3120  
Upper Bound 383.8810  
5% Trimmed Mean 307.1131  
Median 252.0000  
Variance 59614.281  
Std. Deviation 244.16036  
Minimum .00  
Maximum 900.00  
Range 900.00  
Interquartile Range 355.00  
Skewness .545 .316 
Kurtosis -.495 .623 
Total Leisure Hours Spent 
Sitting Per Year 
Mean 909.9460 69.21529 
95% Confidence Interval for 
Mean 
Lower Bound 771.2911  
Upper Bound 1048.6009  
5% Trimmed Mean 882.4447  
Median 730.5200  
Variance 273073.108  
Std. Deviation 522.56397  
Minimum .00  
Maximum 2374.19  
Range 2374.19  
Interquartile Range 547.89  
Skewness .801 .316 
Kurtosis .715 .623 
 
 
 
Table 13 (continued)  
 Statistic Std. Error 
Total Hours Spent Sitting Per 
Year 
Mean 1229.0425 76.56150 
95% Confidence Interval for 
Mean 
Lower Bound 1075.6713  
Upper Bound 1382.4136  
5% Trimmed Mean 1215.2863  
Median 1181.2600  
Variance 334114.815  
Std. Deviation 578.02666  
Minimum 139.32  
Maximum 2611.56  
Range 2472.25  
Interquartile Range 834.09  
Skewness .412 .316 
Kurtosis -.273 .623 
 
 
Table 14: Tests of Normality – Sedentary Time (hours) 
 Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Average Number of Hours Slept 
Per Night 
.169 57 .000 .943 57 .010 
Total Work Hours Spent Sitting 
Per Year 
.120 57 .041 .937 57 .005 
Total Leisure Hours Spent 
Sitting Per Year 
.161 57 .001 .938 57 .006 
Total Hours Spent Sitting Per 
Year 
.086 57 .200* .979 57 .419 
*. This is a lower bound of the true significance. 
a. Lilliefors Significance Correction 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 92-95: Average Number of Hours Slept/Night scatterplots, boxplot, and histogram 
     Figure 92           Figure 93 
        
 
 
 
      Figure 94            Figure 95 
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 96-99: Total Work Hours Spent Sitting/Year scatterplots, boxplot, and histogram 
    Figure 96              Figure 97 
        
 
 
 
Figure 98           Figure 99 
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 100-103: Total Leisure Hours Spent Sitting/Year scatterplots, boxplot, and histogram 
     Figure 100                  Figure 101 
 
 
 
 
     Figure 102           Figure 103 
               
 
 
 
 
 
 
 
 
 
 
 
 
Figures 104-107: Total Hours Spent Sitting/Year scatterplots, boxplot, and histogram 
        Figure 104                  Figure 105 
               
 
 
 
        Figure 106           Figure 107 
                 
 
 
 
 
 
 
 
 
 
 
Pearson’s Correlation 
 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
Table 15: Pearson’s Correlation – Bone Health Measures 
 Stiff Bone T-Score BUA SOS 
Stiff Bone 
Pearson Correlation 1 .993** .813** .836** 
Sig. (2-tailed)  .000 .000 .000 
N 56 56 56 56 
T-Score 
Pearson Correlation .993** 1 .819** .820** 
Sig. (2-tailed) .000  .000 .000 
N 56 56 56 56 
BUA 
Pearson Correlation .813** .819** 1 .361** 
Sig. (2-tailed) .000 .000  .006 
N 56 56 56 56 
SOS 
Pearson Correlation .836** .820** .361** 1 
Sig. (2-tailed) .000 .000 .006  
N 56 56 56 56 
 
 
 
 
Table 16: Pearson’s Correlation – WHR & BMI 
 Waist-to-hip ratio BMI 
Waist-to-hip ratio 
Pearson Correlation 1 .559** 
Sig. (2-tailed)  .000 
N 57 57 
BMI 
Pearson Correlation .559** 1 
Sig. (2-tailed) .000  
N 57 57 
 
 
 
 
 
 
 
 
 
 
Table 17: Pearson’s Correlation –WHR, BMI, and Bone Health Measures 
 Waist-to-hip 
ratio 
BMI Stiff Bone T-Score BUA SOS 
Waist-to-hip ratio 
Pearson Correlation 1 .559** .209 .212 .210 .136 
Sig. (2-tailed)  .000 .121 .116 .120 .317 
N 57 57 56 56 56 56 
BMI 
Pearson Correlation .559** 1 .370** .380** .302* .309* 
Sig. (2-tailed) .000  .005 .004 .023 .020 
N 57 57 56 56 56 56 
Stiff Bone 
Pearson Correlation .209 .370** 1 .993** .813** .836** 
Sig. (2-tailed) .121 .005  .000 .000 .000 
N 56 56 56 56 56 56 
T-Score 
Pearson Correlation .212 .380** .993** 1 .819** .820** 
Sig. (2-tailed) .116 .004 .000  .000 .000 
N 56 56 56 56 56 56 
BUA 
Pearson Correlation .210 .302* .813** .819** 1 .361** 
Sig. (2-tailed) .120 .023 .000 .000  .006 
N 56 56 56 56 56 56 
SOS 
Pearson Correlation .136 .309* .836** .820** .361** 1 
Sig. (2-tailed) .317 .020 .000 .000 .006  
N 56 56 56 56 56 56 
 
 
Table 18: Pearson’s Correlation –WHR, BMI, and Total Time Sedentary Per Year 
 Waist-to-hip ratio BMI Total Hours Spent 
Sitting Per Year 
Total Minutes 
Spent Sitting Per 
Year 
Waist-to-hip ratio 
Pearson Correlation 1 .559** .060 .060 
Sig. (2-tailed)  .000 .656 .656 
N 57 57 57 57 
BMI 
Pearson Correlation .559** 1 .114 .114 
Sig. (2-tailed) .000  .398 .398 
N 57 57 57 57 
Total Hours Spent Sitting Per 
Year 
Pearson Correlation .060 .114 1 1.000** 
Sig. (2-tailed) .656 .398  .000 
N 57 57 57 57 
Total Minutes Spent Sitting Per 
Year 
Pearson Correlation .060 .114 1.000** 1 
Sig. (2-tailed) .656 .398 .000  
N 57 57 57 57 
 
 
 
 
 
Table 19: Pearson’s Correlation –Bone Health Measures and Total Time Sedentary Per Year 
 Stiff Bone T-Score BUA SOS Total Hours 
Spent Sitting 
Per Year 
Total Minutes 
Spent Sitting 
Per Year 
Stiff Bone 
Pearson Correlation 1 .993** .813** .836** .169 .169 
Sig. (2-tailed)  .000 .000 .000 .212 .212 
N 56 56 56 56 56 56 
T-Score 
Pearson Correlation .993** 1 .819** .820** .168 .168 
Sig. (2-tailed) .000  .000 .000 .215 .215 
N 56 56 56 56 56 56 
BUA 
Pearson Correlation .813** .819** 1 .361** .156 .156 
Sig. (2-tailed) .000 .000  .006 .250 .250 
N 56 56 56 56 56 56 
SOS 
Pearson Correlation .836** .820** .361** 1 .122 .122 
Sig. (2-tailed) .000 .000 .006  .371 .371 
N 56 56 56 56 56 56 
Total Hours Spent Sitting 
Per Year 
Pearson Correlation .169 .168 .156 .122 1 1.000** 
Sig. (2-tailed) .212 .215 .250 .371  .000 
N 56 56 56 56 57 57 
Total Minutes Spent 
Sitting Per Year 
Pearson Correlation .169 .168 .156 .122 1.000** 1 
Sig. (2-tailed) .212 .215 .250 .371 .000  
N 56 56 56 56 57 57 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kendall’s Tau and Spearman’s Rho 
 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
 
Table 20: Kendall’s and Spearman’s Correlation – Leptin and Osteocalcin 
 Leptin blood level 
in pg/mL 
Osteocalcin blood 
level in pg/mL 
Kendall's tau_b 
Leptin blood level in pg/mL 
Correlation Coefficient 1.000 .073 
Sig. (2-tailed) . .434 
N 57 57 
Osteocalcin blood level in 
pg/mL 
Correlation Coefficient .073 1.000 
Sig. (2-tailed) .434 . 
N 57 57 
Spearman's rho 
Leptin blood level in pg/mL 
Correlation Coefficient 1.000 .123 
Sig. (2-tailed) . .362 
N 57 57 
Osteocalcin blood level in 
pg/mL 
Correlation Coefficient .123 1.000 
Sig. (2-tailed) .362 . 
N 57 57 
 
 
 
 
 
 
 
 
 
Table 21: Kendall’s Correlation – Time Spent Exercising Per Year (minutes) 
 Minutes spent 
running per 
year 
Minutes 
strength 
training per 
year 
Minutes spent 
biking per year 
Minutes spent 
walking per 
year 
Minutes spent 
swimming per 
year 
Total minutes 
spent 
exercising per 
year 
Kendall's tau_b 
Minutes spent running per 
year 
Correlation Coefficient 1.000 .078 -.262** .099 .007 .230* 
Sig. (2-tailed) . .405 .008 .307 .944 .012 
N 57 57 57 57 57 57 
Minutes strength training 
per year 
Correlation Coefficient .078 1.000 -.044 -.258** .041 .286** 
Sig. (2-tailed) .405 . .660 .009 .699 .002 
N 57 57 57 57 57 57 
Minutes spent biking per 
year 
Correlation Coefficient -.262** -.044 1.000 .258* -.318** .244* 
Sig. (2-tailed) .008 .660 . .013 .004 .013 
N 57 57 57 57 57 57 
Minutes spent walking per 
year 
Correlation Coefficient .099 -.258** .258* 1.000 -.331** .333** 
Sig. (2-tailed) .307 .009 .013 . .003 .001 
N 57 57 57 57 57 57 
Minutes spent swimming 
per year 
Correlation Coefficient .007 .041 -.318** -.331** 1.000 -.103 
Sig. (2-tailed) .944 .699 .004 .003 . .321 
N 57 57 57 57 57 57 
Total minutes spent 
exercising per year 
Correlation Coefficient .230* .286** .244* .333** -.103 1.000 
Sig. (2-tailed) .012 .002 .013 .001 .321 . 
N 57 57 57 57 57 57 
 
 
 
 
 
 
 
 
Table 22: Spearman’s Correlation – Time Spent Exercising Per Year (minutes) 
 Minutes spent 
running per 
year 
Minutes 
strength 
training per 
year 
Minutes spent 
biking per year 
Minutes spent 
walking per 
year 
Minutes spent 
swimming per 
year 
Total minutes 
spent 
exercising per 
year 
Spearman's rho 
Minutes spent running per 
year 
Correlation Coefficient 1.000 .107 -.331* .139 .016 .352** 
Sig. (2-tailed) . .427 .012 .302 .906 .007 
N 57 57 57 57 57 57 
Minutes strength training 
per year 
Correlation Coefficient .107 1.000 -.061 -.337* .043 .342** 
Sig. (2-tailed) .427 . .650 .010 .752 .009 
N 57 57 57 57 57 57 
Minutes spent biking per 
year 
Correlation Coefficient -.331* -.061 1.000 .319* -.378** .340** 
Sig. (2-tailed) .012 .650 . .016 .004 .010 
N 57 57 57 57 57 57 
Minutes spent walking per 
year 
Correlation Coefficient .139 -.337* .319* 1.000 -.401** .451** 
Sig. (2-tailed) .302 .010 .016 . .002 .000 
N 57 57 57 57 57 57 
Minutes spent swimming 
per year 
Correlation Coefficient .016 .043 -.378** -.401** 1.000 -.128 
Sig. (2-tailed) .906 .752 .004 .002 . .343 
N 57 57 57 57 57 57 
Total minutes spent 
exercising per year 
Correlation Coefficient .352** .342** .340** .451** -.128 1.000 
Sig. (2-tailed) .007 .009 .010 .000 .343 . 
N 57 57 57 57 57 57 
 
 
 
 
 
 
 
 
 
Table 23: Kendall’s Correlation – Time Spent Exercising Per Year (hours) 
 Hours Spent 
Running Per 
Year 
Hours Spent 
Strength 
Training Per 
Year 
Hours Spent 
Biking Per 
Year 
Hours Spent 
Walking Per 
Year 
Hours Spent 
Swimming Per 
Year 
Total Hours 
Spent 
Exercising Per 
Year 
Kendall's tau_b 
Hours Spent Running Per 
Year 
Correlation Coefficient 1.000 1.000** -.262** .099 .007 .453** 
Sig. (2-tailed) . . .008 .307 .944 .000 
N 57 57 57 57 57 57 
Hours Spent Strength 
Training Per Year 
Correlation Coefficient 1.000** 1.000 -.262** .099 .007 .453** 
Sig. (2-tailed) . . .008 .307 .944 .000 
N 57 57 57 57 57 57 
Hours Spent Biking Per 
Year 
Correlation Coefficient -.262** -.262** 1.000 .258* -.318** .160 
Sig. (2-tailed) .008 .008 . .013 .004 .103 
N 57 57 57 57 57 57 
Hours Spent Walking Per 
Year 
Correlation Coefficient .099 .099 .258* 1.000 -.331** .515** 
Sig. (2-tailed) .307 .307 .013 . .003 .000 
N 57 57 57 57 57 57 
Hours Spent Swimming Per 
Year 
Correlation Coefficient .007 .007 -.318** -.331** 1.000 -.032 
Sig. (2-tailed) .944 .944 .004 .003 . .754 
N 57 57 57 57 57 57 
Total Hours Spent 
Exercising Per Year 
Correlation Coefficient .453** .453** .160 .515** -.032 1.000 
Sig. (2-tailed) .000 .000 .103 .000 .754 . 
N 57 57 57 57 57 57 
 
 
 
 
 
 
 
 
 
Table 24: Spearman’s Correlation – Time Spent Exercising Per Year (hours) 
 Hours Spent 
Running Per 
Year 
Hours Spent 
Strength 
Training Per 
Year 
Hours Spent 
Biking Per 
Year 
Hours Spent 
Walking Per 
Year 
Hours Spent 
Swimming Per 
Year 
Total Hours 
Spent 
Exercising Per 
Year 
Spearman's rho 
Hours Spent Running Per 
Year 
Correlation Coefficient 1.000 1.000** -.331* .139 .016 .563** 
Sig. (2-tailed) . . .012 .302 .906 .000 
N 57 57 57 57 57 57 
Hours Spent Strength 
Training Per Year 
Correlation Coefficient 1.000** 1.000 -.331* .139 .016 .563** 
Sig. (2-tailed) . . .012 .302 .906 .000 
N 57 57 57 57 57 57 
Hours Spent Biking Per 
Year 
Correlation Coefficient -.331* -.331* 1.000 .319* -.378** .209 
Sig. (2-tailed) .012 .012 . .016 .004 .119 
N 57 57 57 57 57 57 
Hours Spent Walking Per 
Year 
Correlation Coefficient .139 .139 .319* 1.000 -.401** .620** 
Sig. (2-tailed) .302 .302 .016 . .002 .000 
N 57 57 57 57 57 57 
Hours Spent Swimming Per 
Year 
Correlation Coefficient .016 .016 -.378** -.401** 1.000 -.035 
Sig. (2-tailed) .906 .906 .004 .002 . .795 
N 57 57 57 57 57 57 
Total Hours Spent 
Exercising Per Year 
Correlation Coefficient .563** .563** .209 .620** -.035 1.000 
Sig. (2-tailed) .000 .000 .119 .000 .795 . 
N 57 57 57 57 57 57 
 
 
 
 
 
 
 
 
Table 25: Kendall’s and Spearman’s Correlation – Sedentary Time (minutes) 
 Minutes Spent 
Sitting Per Year for 
Work 
Minutes Spent 
Sitting Per Year for 
Leisure 
Total Minutes Spent 
Sitting Per Year 
Kendall's tau_b 
Minutes Spent Sitting Per Year for 
Work 
Correlation Coefficient 1.000 .053 .328** 
Sig. (2-tailed) . .585 .000 
N 57 57 57 
Minutes Spent Sitting Per Year for 
Leisure 
Correlation Coefficient .053 1.000 .774** 
Sig. (2-tailed) .585 . .000 
N 57 57 57 
Total Minutes Spent Sitting Per 
Year 
Correlation Coefficient .328** .774** 1.000 
Sig. (2-tailed) .000 .000 . 
N 57 57 57 
Spearman's rho 
Minutes Spent Sitting Per Year for 
Work 
Correlation Coefficient 1.000 .066 .442** 
Sig. (2-tailed) . .624 .001 
N 57 57 57 
Minutes Spent Sitting Per Year for 
Leisure 
Correlation Coefficient .066 1.000 .901** 
Sig. (2-tailed) .624 . .000 
N 57 57 57 
Total Minutes Spent Sitting Per 
Year 
Correlation Coefficient .442** .901** 1.000 
Sig. (2-tailed) .001 .000 . 
N 57 57 57 
 
 
 
 
 
 
 
 
 
 
Table 26: Kendall’s and Spearman’s Correlation – Sedentary Time (hours) 
 Average Number of 
Hours Slept Per 
Night 
Total Work Hours 
Spent Sitting Per 
Year 
Total Leisure Hours 
Spent Sitting Per 
Year 
Total Hours Spent 
Sitting Per Year 
Kendall's tau_b 
Average Number of Hours Slept 
Per Night 
Correlation Coefficient 1.000 .074 .011 .061 
Sig. (2-tailed) . .440 .910 .518 
N 57 57 57 57 
Total Work Hours Spent Sitting 
Per Year 
Correlation Coefficient .074 1.000 .053 .328** 
Sig. (2-tailed) .440 . .585 .000 
N 57 57 57 57 
Total Leisure Hours Spent Sitting 
Per Year 
Correlation Coefficient .011 .053 1.000 .774** 
Sig. (2-tailed) .910 .585 . .000 
N 57 57 57 57 
Total Hours Spent Sitting Per Year 
Correlation Coefficient .061 .328** .774** 1.000 
Sig. (2-tailed) .518 .000 .000 . 
N 57 57 57 57 
Spearman's rho 
Average Number of Hours Slept 
Per Night 
Correlation Coefficient 1.000 .109 .003 .090 
Sig. (2-tailed) . .419 .982 .504 
N 57 57 57 57 
Total Work Hours Spent Sitting 
Per Year 
Correlation Coefficient .109 1.000 .066 .442** 
Sig. (2-tailed) .419 . .624 .001 
N 57 57 57 57 
Total Leisure Hours Spent Sitting 
Per Year 
Correlation Coefficient .003 .066 1.000 .901** 
Sig. (2-tailed) .982 .624 . .000 
N 57 57 57 57 
Total Hours Spent Sitting Per Year 
Correlation Coefficient .090 .442** .901** 1.000 
Sig. (2-tailed) .504 .001 .000 . 
N 57 57 57 57 
 
 
 
 
Table 27: Kendall’s and Spearman’s Correlation – Leptin, Osteocalcin, WHR, and BMI 
 Leptin blood level in 
pg/mL 
Osteocalcin blood 
level in pg/mL 
Waist-to-hip ratio BMI 
Kendall's tau_b 
Leptin blood level in pg/mL 
Correlation Coefficient 1.000 .073 -.011 .119 
Sig. (2-tailed) . .434 .906 .200 
N 57 57 57 57 
Osteocalcin blood level in pg/mL 
Correlation Coefficient .073 1.000 .049 .066 
Sig. (2-tailed) .434 . .596 .469 
N 57 57 57 57 
Waist-to-hip ratio 
Correlation Coefficient -.011 .049 1.000 .467** 
Sig. (2-tailed) .906 .596 . .000 
N 57 57 57 57 
BMI 
Correlation Coefficient .119 .066 .467** 1.000 
Sig. (2-tailed) .200 .469 .000 . 
N 57 57 57 57 
Spearman's rho 
Leptin blood level in pg/mL 
Correlation Coefficient 1.000 .123 -.046 .173 
Sig. (2-tailed) . .362 .736 .199 
N 57 57 57 57 
Osteocalcin blood level in pg/mL 
Correlation Coefficient .123 1.000 .075 .088 
Sig. (2-tailed) .362 . .579 .516 
N 57 57 57 57 
Waist-to-hip ratio 
Correlation Coefficient -.046 .075 1.000 .670** 
Sig. (2-tailed) .736 .579 . .000 
N 57 57 57 57 
BMI 
Correlation Coefficient .173 .088 .670** 1.000 
Sig. (2-tailed) .199 .516 .000 . 
N 57 57 57 57 
 
 
 
 
 
Table 28: Kendall’s Correlation – Leptin, Osteocalcin, and Bone Health Measures 
 Leptin blood level 
in pg/mL 
Osteocalcin blood 
level in pg/mL 
Stiff Bone T-Score BUA SOS 
Kendall's tau_b 
Leptin blood level in 
pg/mL 
Correlation Coefficient 1.000 .073 -.039 -.043 -.066 -.009 
Sig. (2-tailed) . .434 .675 .649 .477 .921 
N 57 57 56 56 56 56 
Osteocalcin blood level 
in pg/mL 
Correlation Coefficient .073 1.000 .128 .123 .029 .191* 
Sig. (2-tailed) .434 . .166 .186 .750 .038 
N 57 57 56 56 56 56 
Stiff Bone 
Correlation Coefficient -.039 .128 1.000 .971** .696** .711** 
Sig. (2-tailed) .675 .166 . .000 .000 .000 
N 56 56 56 56 56 56 
T-Score 
Correlation Coefficient -.043 .123 .971** 1.000 .709** .693** 
Sig. (2-tailed) .649 .186 .000 . .000 .000 
N 56 56 56 56 56 56 
BUA 
Correlation Coefficient -.066 .029 .696** .709** 1.000 .403** 
Sig. (2-tailed) .477 .750 .000 .000 . .000 
N 56 56 56 56 56 56 
SOS 
Correlation Coefficient -.009 .191* .711** .693** .403** 1.000 
Sig. (2-tailed) .921 .038 .000 .000 .000 . 
N 56 56 56 56 56 56 
 
 
Table 29: Spearman’s Correlation – Leptin, Osteocalcin, and Bone Health Measures 
 Leptin blood level 
in pg/mL 
Osteocalcin blood 
level in pg/mL 
Stiff Bone T-Score BUA SOS 
Spearman's rho 
Leptin blood level 
in pg/mL 
Correlation Coefficient 1.000 .123 -.061 -.059 -.088 -.007 
Sig. (2-tailed) . .362 .656 .663 .518 .959 
N 57 57 56 56 56 56 
Osteocalcin blood 
level in pg/mL 
Correlation Coefficient .123 1.000 .192 .180 .041 .295* 
Sig. (2-tailed) .362 . .157 .185 .765 .027 
N 57 57 56 56 56 56 
Stiff Bone 
Correlation Coefficient -.061 .192 1.000 .991** .863** .866** 
Sig. (2-tailed) .656 .157 . .000 .000 .000 
N 56 56 56 56 56 56 
T-Score 
Correlation Coefficient -.059 .180 .991** 1.000 .868** .850** 
Sig. (2-tailed) .663 .185 .000 . .000 .000 
N 56 56 56 56 56 56 
BUA 
Correlation Coefficient -.088 .041 .863** .868** 1.000 .514** 
Sig. (2-tailed) .518 .765 .000 .000 . .000 
N 56 56 56 56 56 56 
SOS 
Correlation Coefficient -.007 .295* .866** .850** .514** 1.000 
Sig. (2-tailed) .959 .027 .000 .000 .000 . 
N 56 56 56 56 56 56 
 
 
 
 
 
 
 
 
 
Table 30: Kendall’s Correlation – Leptin, Osteocalcin, and Time Spent Exercising/Year (minutes) 
 Leptin blood 
level in pg/mL 
Osteocalcin 
blood level 
in pg/mL 
Minutes 
spent 
running per 
year 
Minutes 
strength 
training per 
year 
Minutes 
spent biking 
per year 
Minutes 
spent 
walking per 
year 
Minutes 
spent 
swimming 
per year 
Total 
minutes 
exercising 
per year 
Kendall's 
tau_b 
Leptin blood 
level in pg/mL 
Correlation Coefficient 1.000 .073 -.014 -.204* .027 .171 -.263* -.069 
Sig. (2-tailed) . .434 .879 .032 .789 .080 .012 .455 
N 57 57 57 57 57 57 57 57 
Osteocalcin 
blood level in 
pg/mL 
Correlation Coefficient .073 1.000 -.052 .163 -.031 -.260** .154 -.077 
Sig. (2-tailed) .434 . .572 .083 .756 .007 .138 .401 
N 57 57 57 57 57 57 57 57 
Minutes spent 
running per year 
Correlation Coefficient -.014 -.052 1.000 .078 -.262** .099 .007 .230* 
Sig. (2-tailed) .879 .572 . .405 .008 .307 .944 .012 
N 57 57 57 57 57 57 57 57 
Minutes 
strength training 
per year 
Correlation Coefficient -.204* .163 .078 1.000 -.044 -.258** .041 .286** 
Sig. (2-tailed) .032 .083 .405 . .660 .009 .699 .002 
N 57 57 57 57 57 57 57 57 
Minutes spent 
biking per year 
Correlation Coefficient .027 -.031 -.262** -.044 1.000 .258* -.318** .244* 
Sig. (2-tailed) .789 .756 .008 .660 . .013 .004 .013 
N 57 57 57 57 57 57 57 57 
Minutes spent 
walking per 
year 
Correlation Coefficient .171 -.260** .099 -.258** .258* 1.000 -.331** .333** 
Sig. (2-tailed) .080 .007 .307 .009 .013 . .003 .001 
N 57 57 57 57 57 57 57 57 
Minutes spent 
swimming per 
year 
Correlation Coefficient -.263* .154 .007 .041 -.318** -.331** 1.000 -.103 
Sig. (2-tailed) .012 .138 .944 .699 .004 .003 . .321 
N 57 57 57 57 57 57 57 57 
Total minutes 
spent exercising 
per year 
Correlation Coefficient -.069 -.077 .230* .286** .244* .333** -.103 1.000 
Sig. (2-tailed) .455 .401 .012 .002 .013 .001 .321 . 
N 57 57 57 57 57 57 57 57 
 
 
 
 
Table 31: Spearman’s Correlation – Leptin, Osteocalcin, and Time Spent Exercising/Year (minutes) 
 Leptin blood 
level in 
pg/mL 
Osteocalcin 
blood level 
in pg/mL 
Minutes 
spent 
running per 
year 
Minutes 
strength 
training per 
year 
Minutes 
spent biking 
per year 
Minutes 
spent 
walking per 
year 
Minutes 
spent 
swimming 
per year 
Total 
minutes 
exercising 
per year 
Spearman's 
rho 
Leptin blood 
level in pg/mL 
Correlation Coefficient 1.000 .123 -.015 -.295* .038 .231 -.340** -.099 
Sig. (2-tailed) . .362 .909 .026 .780 .084 .010 .465 
N 57 57 57 57 57 57 57 57 
Osteocalcin 
blood level in 
pg/mL 
Correlation Coefficient .123 1.000 -.090 .255 -.039 -.376** .212 -.127 
Sig. (2-tailed) .362 . .505 .056 .773 .004 .113 .345 
N 57 57 57 57 57 57 57 57 
Minutes spent 
running per 
year 
Correlation Coefficient -.015 -.090 1.000 .107 -.331* .139 .016 .352** 
Sig. (2-tailed) .909 .505 . .427 .012 .302 .906 .007 
N 57 57 57 57 57 57 57 57 
Minutes 
strength 
training per 
year 
Correlation Coefficient -.295* .255 .107 1.000 -.061 -.337* .043 .342** 
Sig. (2-tailed) .026 .056 .427 . .650 .010 .752 .009 
N 
57 57 57 57 57 57 57 57 
Minutes spent 
biking per year 
Correlation Coefficient .038 -.039 -.331* -.061 1.000 .319* -.378** .340** 
Sig. (2-tailed) .780 .773 .012 .650 . .016 .004 .010 
N 57 57 57 57 57 57 57 57 
Minutes spent 
walking per 
year 
Correlation Coefficient .231 -.376** .139 -.337* .319* 1.000 -.401** .451** 
Sig. (2-tailed) .084 .004 .302 .010 .016 . .002 .000 
N 57 57 57 57 57 57 57 57 
Minutes spent 
swimming per 
year 
Correlation Coefficient -.340** .212 .016 .043 -.378** -.401** 1.000 -.128 
Sig. (2-tailed) .010 .113 .906 .752 .004 .002 . .343 
N 57 57 57 57 57 57 57 57 
Total minutes 
exercising per 
year 
Correlation Coefficient -.099 -.127 .352** .342** .340** .451** -.128 1.000 
Sig. (2-tailed) .465 .345 .007 .009 .010 .000 .343 . 
N 57 57 57 57 57 57 57 57 
 
 
 
Table 32: Kendall’s Correlation – Leptin, Osteocalcin, and Time Spent Exercising/Year (hours) 
 Leptin blood 
level in 
pg/mL 
Osteocalcin 
blood level 
in pg/mL 
Hours Spent 
Running Per 
Year 
Hours Spent 
Strength 
Training Per 
Year 
Hours Spent 
Biking Per 
Year 
Hours Spent 
Walking Per 
Year 
Hours Spent 
Swimming 
Per Year 
Total Hours 
Exercising 
Per Year 
Kendall's 
tau_b 
Leptin blood level 
in pg/mL 
Correlation Coefficient 1.000 .073 -.014 -.014 .027 .171 -.263* .050 
Sig. (2-tailed) . .434 .879 .879 .789 .080 .012 .589 
N 57 57 57 57 57 57 57 57 
Osteocalcin blood 
level in pg/mL 
Correlation Coefficient .073 1.000 -.052 -.052 -.031 -.260** .154 -.207* 
Sig. (2-tailed) .434 . .572 .572 .756 .007 .138 .024 
N 57 57 57 57 57 57 57 57 
Hours Spent 
Running Per Year 
Correlation Coefficient -.014 -.052 1.000 1.000** -.262** .099 .007 .453** 
Sig. (2-tailed) .879 .572 . . .008 .307 .944 .000 
N 57 57 57 57 57 57 57 57 
Hours Spent 
Strength Training 
Per Year 
Correlation Coefficient -.014 -.052 1.000** 1.000 -.262** .099 .007 .453** 
Sig. (2-tailed) .879 .572 . . .008 .307 .944 .000 
N 57 57 57 57 57 57 57 57 
Hours Spent 
Biking Per Year 
Correlation Coefficient .027 -.031 -.262** -.262** 1.000 .258* -.318** .160 
Sig. (2-tailed) .789 .756 .008 .008 . .013 .004 .103 
N 57 57 57 57 57 57 57 57 
Hours Spent 
Walking Per Year 
Correlation Coefficient .171 -.260** .099 .099 .258* 1.000 -.331** .515** 
Sig. (2-tailed) .080 .007 .307 .307 .013 . .003 .000 
N 57 57 57 57 57 57 57 57 
Hours Spent 
Swimming Per 
Year 
Correlation Coefficient -.263* .154 .007 .007 -.318** -.331** 1.000 -.032 
Sig. (2-tailed) .012 .138 .944 .944 .004 .003 . .754 
N 57 57 57 57 57 57 57 57 
Total Hours Spent 
Exercising Per 
Year 
Correlation Coefficient .050 -.207* .453** .453** .160 .515** -.032 1.000 
Sig. (2-tailed) .589 .024 .000 .000 .103 .000 .754 . 
N 57 57 57 57 57 57 57 57 
 
 
 
 
Table 33: Spearman’s Correlation – Leptin, Osteocalcin, and Time Spent Exercising/Year (hours) 
 Leptin blood 
level in 
pg/mL 
Osteocalcin 
blood level 
in pg/mL 
Hours Spent 
Running Per 
Year 
Hours Spent 
Strength 
Training Per 
Year 
Hours Spent 
Biking Per 
Year 
Hours Spent 
Walking Per 
Year 
Hours Spent 
Swimming 
Per Year 
Total Hours 
Exercising 
Per Year 
Spearman's 
rho 
Leptin blood 
level in pg/mL 
Correlation Coefficient 1.000 .123 -.015 -.015 .038 .231 -.340** .070 
Sig. (2-tailed) . .362 .909 .909 .780 .084 .010 .605 
N 57 57 57 57 57 57 57 57 
Osteocalcin 
blood level in 
pg/mL 
Correlation Coefficient .123 1.000 -.090 -.090 -.039 -.376** .212 -.302* 
Sig. (2-tailed) .362 . .505 .505 .773 .004 .113 .022 
N 57 57 57 57 57 57 57 57 
Hours Spent 
Running Per 
Year 
Correlation Coefficient -.015 -.090 1.000 1.000** -.331* .139 .016 .563** 
Sig. (2-tailed) .909 .505 . . .012 .302 .906 .000 
N 57 57 57 57 57 57 57 57 
Hours Spent 
Strength 
Training Per 
Year 
Correlation Coefficient -.015 -.090 1.000** 1.000 -.331* .139 .016 .563** 
Sig. (2-tailed) .909 .505 . . .012 .302 .906 .000 
N 
57 57 57 57 57 57 57 57 
Hours Spent 
Biking Per Year 
Correlation Coefficient .038 -.039 -.331* -.331* 1.000 .319* -.378** .209 
Sig. (2-tailed) .780 .773 .012 .012 . .016 .004 .119 
N 57 57 57 57 57 57 57 57 
Hours Spent 
Walking Per 
Year 
Correlation Coefficient .231 -.376** .139 .139 .319* 1.000 -.401** .620** 
Sig. (2-tailed) .084 .004 .302 .302 .016 . .002 .000 
N 57 57 57 57 57 57 57 57 
Hours Spent 
Swimming Per 
Year 
Correlation Coefficient -.340** .212 .016 .016 -.378** -.401** 1.000 -.035 
Sig. (2-tailed) .010 .113 .906 .906 .004 .002 . .795 
N 57 57 57 57 57 57 57 57 
Total Hours 
Exercising Per 
Year 
Correlation Coefficient .070 -.302* .563** .563** .209 .620** -.035 1.000 
Sig. (2-tailed) .605 .022 .000 .000 .119 .000 .795 . 
N 57 57 57 57 57 57 57 57 
 
 
 
 
Table 34: Kendall’s Correlation – Leptin, Osteocalcin, and Sedentary Time (minutes) 
 Leptin blood 
level in pg/mL 
Osteocalcin 
blood level in 
pg/mL 
Minutes Spent 
Sitting Per Year 
for Work 
Minutes Spent 
Sitting Per Year 
for Leisure 
Total Minutes 
Spent Sitting Per 
Year 
Kendall's tau_b 
Leptin blood level in pg/mL 
Correlation Coefficient 1.000 .073 -.006 .064 .077 
Sig. (2-tailed) . .434 .950 .514 .406 
N 57 57 57 57 57 
Osteocalcin blood level in 
pg/mL 
Correlation Coefficient .073 1.000 .024 -.151 -.119 
Sig. (2-tailed) .434 . .798 .116 .195 
N 57 57 57 57 57 
Minutes Spent Sitting Per Year 
for Work 
Correlation Coefficient -.006 .024 1.000 .053 .328** 
Sig. (2-tailed) .950 .798 . .585 .000 
N 57 57 57 57 57 
Minutes Spent Sitting Per Year 
for Leisure 
Correlation Coefficient .064 -.151 .053 1.000 .774** 
Sig. (2-tailed) .514 .116 .585 . .000 
N 57 57 57 57 57 
Total Minutes Spent Sitting 
Per Year 
Correlation Coefficient .077 -.119 .328** .774** 1.000 
Sig. (2-tailed) .406 .195 .000 .000 . 
N 57 57 57 57 57 
 
 
 
 
 
 
 
 
 
 
 
 
Table 35: Spearman’s Correlation – Leptin, Osteocalcin, and Sedentary Time (minutes) 
 Leptin blood 
level in pg/mL 
Osteocalcin 
blood level in 
pg/mL 
Minutes Spent 
Sitting Per Year 
for Work 
Minutes Spent 
Sitting Per Year 
for Leisure 
Total Minutes 
Spent Sitting Per 
Year 
Spearman's rho 
Leptin blood level in pg/mL 
Correlation Coefficient 1.000 .123 -.001 .086 .098 
Sig. (2-tailed) . .362 .997 .525 .470 
N 57 57 57 57 57 
Osteocalcin blood level in 
pg/mL 
Correlation Coefficient .123 1.000 .051 -.210 -.166 
Sig. (2-tailed) .362 . .707 .118 .218 
N 57 57 57 57 57 
Minutes Spent Sitting Per 
Year for Work 
Correlation Coefficient -.001 .051 1.000 .066 .442** 
Sig. (2-tailed) .997 .707 . .624 .001 
N 57 57 57 57 57 
Minutes Spent Sitting Per 
Year for Leisure 
Correlation Coefficient .086 -.210 .066 1.000 .901** 
Sig. (2-tailed) .525 .118 .624 . .000 
N 57 57 57 57 57 
Total Minutes Spent Sitting 
Per Year 
Correlation Coefficient .098 -.166 .442** .901** 1.000 
Sig. (2-tailed) .470 .218 .001 .000 . 
N 57 57 57 57 57 
 
 
 
 
 
 
 
 
 
 
 
Table 36: Kendall’s Correlation – Leptin, Osteocalcin, and Sedentary Time (hours) 
 Leptin blood 
level in pg/mL 
Osteocalcin 
blood level in 
pg/mL 
Average 
Number of 
Hours Slept Per 
Night 
Total Work 
Hours Spent 
Sitting Per Year 
Total Leisure 
Hours Spent 
Sitting Per Year 
Total Hours 
Spent Sitting 
Per Year 
Kendall's tau_b 
Leptin blood level in 
pg/mL 
Correlation Coefficient 1.000 .073 .252** -.006 .064 .077 
Sig. (2-tailed) . .434 .009 .950 .514 .406 
N 57 57 57 57 57 57 
Osteocalcin blood level in 
pg/mL 
Correlation Coefficient .073 1.000 .082 .024 -.151 -.119 
Sig. (2-tailed) .434 . .393 .798 .116 .195 
N 57 57 57 57 57 57 
Average Number of Hours 
Slept Per Night 
Correlation Coefficient .252** .082 1.000 .074 .011 .061 
Sig. (2-tailed) .009 .393 . .440 .910 .518 
N 57 57 57 57 57 57 
Total Work Hours Spent 
Sitting Per Year 
Correlation Coefficient -.006 .024 .074 1.000 .053 .328** 
Sig. (2-tailed) .950 .798 .440 . .585 .000 
N 57 57 57 57 57 57 
Total Leisure Hours Spent 
Sitting Per Year 
Correlation Coefficient .064 -.151 .011 .053 1.000 .774** 
Sig. (2-tailed) .514 .116 .910 .585 . .000 
N 57 57 57 57 57 57 
Total Hours Spent Sitting 
Per Year 
Correlation Coefficient .077 -.119 .061 .328** .774** 1.000 
Sig. (2-tailed) .406 .195 .518 .000 .000 . 
N 57 57 57 57 57 57 
 
 
 
 
 
 
 
 
 
Table 37: Spearman’s Correlation – Leptin, Osteocalcin, and Sedentary Time (hours) 
 Leptin blood 
level in pg/mL 
Osteocalcin 
blood level in 
pg/mL 
Average 
Number of 
Hours Slept Per 
Night 
Total Work 
Hours Spent 
Sitting Per Year 
Total Leisure 
Hours Spent 
Sitting Per Year 
Total Hours 
Spent Sitting 
Per Year 
Spearman's rho 
Leptin blood level in 
pg/mL 
Correlation Coefficient 1.000 .123 .348** -.001 .086 .098 
Sig. (2-tailed) . .362 .008 .997 .525 .470 
N 57 57 57 57 57 57 
Osteocalcin blood level in 
pg/mL 
Correlation Coefficient .123 1.000 .114 .051 -.210 -.166 
Sig. (2-tailed) .362 . .398 .707 .118 .218 
N 57 57 57 57 57 57 
Average Number of Hours 
Slept Per Night 
Correlation Coefficient .348** .114 1.000 .109 .003 .090 
Sig. (2-tailed) .008 .398 . .419 .982 .504 
N 57 57 57 57 57 57 
Total Work Hours Spent 
Sitting Per Year 
Correlation Coefficient -.001 .051 .109 1.000 .066 .442** 
Sig. (2-tailed) .997 .707 .419 . .624 .001 
N 57 57 57 57 57 57 
Total Leisure Hours Spent 
Sitting Per Year 
Correlation Coefficient .086 -.210 .003 .066 1.000 .901** 
Sig. (2-tailed) .525 .118 .982 .624 . .000 
N 57 57 57 57 57 57 
Total Hours Spent Sitting 
Per Year 
Correlation Coefficient .098 -.166 .090 .442** .901** 1.000 
Sig. (2-tailed) .470 .218 .504 .001 .000 . 
N 57 57 57 57 57 57 
 
 
 
 
 
 
 
Table 38: Kendall’s Correlation – Bone Health Measures and Time Spent Exercising/Year (minutes) 
 Stiff 
Bone 
T-Score BUA SOS Min 
running/year 
Min strength 
training/year 
Min 
bike/year 
Min 
walk/year 
Min 
swim/year 
Total min 
exercise/year 
Kendall's 
tau_b 
Stiff Bone 
Correlation Coefficient 1.000 .971** .696** .711** .080 .195* .002 -.159 .068 .080 
Sig. (2-tailed) . .000 .000 .000 .392 .039 .988 .103 .518 .385 
N 56 56 56 56 56 56 56 56 56 56 
T-Score 
Correlation Coefficient .971** 1.000 .709** .693** .061 .202* .017 -.176 .061 .071 
Sig. (2-tailed) .000 . .000 .000 .510 .034 .862 .071 .560 .445 
N 56 56 56 56 56 56 56 56 56 56 
BUA 
Correlation Coefficient .696** .709** 1.000 .403** -.031 .184 .014 -.152 .072 .032 
Sig. (2-tailed) .000 .000 . .000 .740 .051 .886 .116 .489 .724 
N 56 56 56 56 56 56 56 56 56 56 
SOS 
Correlation Coefficient .711** .693** .403** 1.000 .158 .154 -.022 -.150 .059 .097 
Sig. (2-tailed) .000 .000 .000 . .088 .101 .826 .123 .573 .289 
N 56 56 56 56 56 56 56 56 56 56 
Minutes spent 
running per year 
Correlation Coefficient .080 .061 -.031 .158 1.000 .078 -.262** .099 .007 .230* 
Sig. (2-tailed) .392 .510 .740 .088 . .405 .008 .307 .944 .012 
N 56 56 56 56 57 57 57 57 57 57 
Minutes strength 
training per year 
Correlation Coefficient .195* .202* .184 .154 .078 1.000 -.044 -.258** .041 .286** 
Sig. (2-tailed) .039 .034 .051 .101 .405 . .660 .009 .699 .002 
N 56 56 56 56 57 57 57 57 57 57 
Minutes spent 
biking per year 
Correlation Coefficient .002 .017 .014 -.022 -.262** -.044 1.000 .258* -.318** .244* 
Sig. (2-tailed) .988 .862 .886 .826 .008 .660 . .013 .004 .013 
N 56 56 56 56 57 57 57 57 57 57 
Minutes spent 
walking per year 
Correlation Coefficient -.159 -.176 -.152 -.150 .099 -.258** .258* 1.000 -.331** .333** 
Sig. (2-tailed) .103 .071 .116 .123 .307 .009 .013 . .003 .001 
N 56 56 56 56 57 57 57 57 57 57 
Minutes spent 
swimming per year 
Correlation Coefficient .068 .061 .072 .059 .007 .041 -.318** -.331** 1.000 -.103 
Sig. (2-tailed) .518 .560 .489 .573 .944 .699 .004 .003 . .321 
N 56 56 56 56 57 57 57 57 57 57 
Total minutes 
spent exercising 
per year 
Correlation Coefficient .080 .071 .032 .097 .230* .286** .244* .333** -.103 1.000 
Sig. (2-tailed) .385 .445 .724 .289 .012 .002 .013 .001 .321 . 
N 56 56 56 56 57 57 57 57 57 57 
Table 39: Spearman’s Correlation – Bone Health Measures and Time Spent Exercising/Year (minutes) 
 Stiff 
Bone 
T-Score BUA SOS Min run per 
year 
Min strength 
training per year 
Min bike per 
year 
Min walk 
per year 
Min swim 
per year 
Total min 
exercise/year 
Spearman's 
rho 
Stiff Bone 
Correlation Coefficient 1.000 .991** .863** .866** .107 .276* -.005 -.221 .083 .118 
Sig. (2-tailed) . .000 .000 .000 .434 .040 .971 .102 .543 .385 
N 56 56 56 56 56 56 56 56 56 56 
T-Score 
Correlation Coefficient .991** 1.000 .868** .850** .080 .283* .012 -.242 .075 .105 
Sig. (2-tailed) .000 . .000 .000 .557 .035 .928 .072 .582 .441 
N 56 56 56 56 56 56 56 56 56 56 
BUA 
Correlation Coefficient .863** .868** 1.000 .514** -.054 .247 .006 -.217 .097 .054 
Sig. (2-tailed) .000 .000 . .000 .694 .066 .963 .109 .478 .692 
N 56 56 56 56 56 56 56 56 56 56 
SOS 
Correlation Coefficient .866** .850** .514** 1.000 .241 .233 -.036 -.202 .080 .154 
Sig. (2-tailed) .000 .000 .000 . .073 .084 .792 .135 .559 .258 
N 56 56 56 56 56 56 56 56 56 56 
Minutes spent 
running per year 
Correlation Coefficient .107 .080 -.054 .241 1.000 .107 -.331* .139 .016 .352** 
Sig. (2-tailed) .434 .557 .694 .073 . .427 .012 .302 .906 .007 
N 56 56 56 56 57 57 57 57 57 57 
Minutes 
strength training 
per year 
Correlation Coefficient .276* .283* .247 .233 .107 1.000 -.061 -.337* .043 .342** 
Sig. (2-tailed) .040 .035 .066 .084 .427 . .650 .010 .752 .009 
N 56 56 56 56 57 57 57 57 57 57 
Minutes spent 
biking per year 
Correlation Coefficient -.005 .012 .006 -.036 -.331* -.061 1.000 .319* -.378** .340** 
Sig. (2-tailed) .971 .928 .963 .792 .012 .650 . .016 .004 .010 
N 56 56 56 56 57 57 57 57 57 57 
Minutes spent 
walking per year 
Correlation Coefficient -.221 -.242 -.217 -.202 .139 -.337* .319* 1.000 -.401** .451** 
Sig. (2-tailed) .102 .072 .109 .135 .302 .010 .016 . .002 .000 
N 56 56 56 56 57 57 57 57 57 57 
Minutes spent 
swimming per 
year 
Correlation Coefficient .083 .075 .097 .080 .016 .043 -.378** -.401** 1.000 -.128 
Sig. (2-tailed) .543 .582 .478 .559 .906 .752 .004 .002 . .343 
N 56 56 56 56 57 57 57 57 57 57 
Total minutes 
spent exercising 
per year 
Correlation Coefficient .118 .105 .054 .154 .352** .342** .340** .451** -.128 1.000 
Sig. (2-tailed) .385 .441 .692 .258 .007 .009 .010 .000 .343 . 
N 56 56 56 56 57 57 57 57 57 57 
Table 40: Kendall’s Correlation – Bone Health Measures and Time Spent Exercising/Year (hours) 
 Stiff 
Bone 
T-
Score 
BUA SOS Hours 
Run/Year 
Hours Strength 
Training/Year 
Hours 
Bike/Year 
Hours Spent 
Walk/Year 
Hours 
Swim/Year 
Total Hours 
Exercise/Year 
Kendall's 
tau_b 
Stiff Bone 
Correlation Coefficient 1.000 .971** .696** .711** .080 .080 .002 -.159 .068 -.011 
Sig. (2-tailed) . .000 .000 .000 .392 .392 .988 .103 .518 .904 
N 56 56 56 56 56 56 56 56 56 56 
T-Score 
Correlation Coefficient .971** 1.000 .709** .693** .061 .061 .017 -.176 .061 -.027 
Sig. (2-tailed) .000 . .000 .000 .510 .510 .862 .071 .560 .766 
N 56 56 56 56 56 56 56 56 56 56 
BUA 
Correlation Coefficient .696** .709** 1.000 .403** -.031 -.031 .014 -.152 .072 -.060 
Sig. (2-tailed) .000 .000 . .000 .740 .740 .886 .116 .489 .516 
N 56 56 56 56 56 56 56 56 56 56 
SOS 
Correlation Coefficient .711** .693** .403** 1.000 .158 .158 -.022 -.150 .059 .027 
Sig. (2-tailed) .000 .000 .000 . .088 .088 .826 .123 .573 .767 
N 56 56 56 56 56 56 56 56 56 56 
Hours Spent 
Running Per 
Year 
Correlation Coefficient .080 .061 -.031 .158 1.000 1.000** -.262** .099 .007 .453** 
Sig. (2-tailed) .392 .510 .740 .088 . . .008 .307 .944 .000 
N 56 56 56 56 57 57 57 57 57 57 
Hours Strength 
Training Per 
Year 
Correlation Coefficient .080 .061 -.031 .158 1.000** 1.000 -.262** .099 .007 .453** 
Sig. (2-tailed) .392 .510 .740 .088 . . .008 .307 .944 .000 
N 56 56 56 56 57 57 57 57 57 57 
Hours Spent 
Biking Per Year 
Correlation Coefficient .002 .017 .014 -.022 -.262** -.262** 1.000 .258* -.318** .160 
Sig. (2-tailed) .988 .862 .886 .826 .008 .008 . .013 .004 .103 
N 56 56 56 56 57 57 57 57 57 57 
Hours Spent 
Walking Per 
Year 
Correlation Coefficient -.159 -.176 -.152 -.150 .099 .099 .258* 1.000 -.331** .515** 
Sig. (2-tailed) .103 .071 .116 .123 .307 .307 .013 . .003 .000 
N 56 56 56 56 57 57 57 57 57 57 
Hours Spent 
Swimming Per 
Year 
Correlation Coefficient .068 .061 .072 .059 .007 .007 -.318** -.331** 1.000 -.032 
Sig. (2-tailed) .518 .560 .489 .573 .944 .944 .004 .003 . .754 
N 56 56 56 56 57 57 57 57 57 57 
Total Hours 
Exercising Per 
Year 
Correlation Coefficient -.011 -.027 -.060 .027 .453** .453** .160 .515** -.032 1.000 
Sig. (2-tailed) .904 .766 .516 .767 .000 .000 .103 .000 .754 . 
N 56 56 56 56 57 57 57 57 57 57 
Table 41: Spearman’s Correlation – Bone Health Measures and Time Spent Exercising/Year (hours) 
 Stiff 
Bone 
T-Score BUA SOS Hours 
Run/Year 
Hours Strength 
Training/Year 
Hours 
Bike/Year 
Hours 
Walk/Year 
Hours 
Swim/Year 
Total Hours 
Exercise/Year 
Spearman's 
rho 
Stiff Bone 
Correlation Coefficient 1.000 .991** .863** .866** .107 .107 -.005 -.221 .083 -.024 
Sig. (2-tailed) . .000 .000 .000 .434 .434 .971 .102 .543 .861 
N 56 56 56 56 56 56 56 56 56 56 
T-Score 
Correlation Coefficient .991** 1.000 .868** .850** .080 .080 .012 -.242 .075 -.049 
Sig. (2-tailed) .000 . .000 .000 .557 .557 .928 .072 .582 .719 
N 56 56 56 56 56 56 56 56 56 56 
BUA 
Correlation Coefficient .863** .868** 1.000 .514** -.054 -.054 .006 -.217 .097 -.082 
Sig. (2-tailed) .000 .000 . .000 .694 .694 .963 .109 .478 .550 
N 56 56 56 56 56 56 56 56 56 56 
SOS 
Correlation Coefficient .866** .850** .514** 1.000 .241 .241 -.036 -.202 .080 .038 
Sig. (2-tailed) .000 .000 .000 . .073 .073 .792 .135 .559 .780 
N 56 56 56 56 56 56 56 56 56 56 
Hours Spent 
Running Per 
Year 
Correlation Coefficient .107 .080 -.054 .241 1.000 1.000** -.331* .139 .016 .563** 
Sig. (2-tailed) .434 .557 .694 .073 . . .012 .302 .906 .000 
N 56 56 56 56 57 57 57 57 57 57 
Hours 
Strength 
Training Per 
Year 
Correlation Coefficient .107 .080 -.054 .241 1.000** 1.000 -.331* .139 .016 .563** 
Sig. (2-tailed) .434 .557 .694 .073 . . .012 .302 .906 .000 
N 
56 56 56 56 57 57 57 57 57 57 
Hours Spent 
Biking Per 
Year 
Correlation Coefficient -.005 .012 .006 -.036 -.331* -.331* 1.000 .319* -.378** .209 
Sig. (2-tailed) .971 .928 .963 .792 .012 .012 . .016 .004 .119 
N 56 56 56 56 57 57 57 57 57 57 
Hours Spent 
Walking Per 
Year 
Correlation Coefficient -.221 -.242 -.217 -.202 .139 .139 .319* 1.000 -.401** .620** 
Sig. (2-tailed) .102 .072 .109 .135 .302 .302 .016 . .002 .000 
N 56 56 56 56 57 57 57 57 57 57 
Hours Spent 
Swimming Per 
Year 
Correlation Coefficient .083 .075 .097 .080 .016 .016 -.378** -.401** 1.000 -.035 
Sig. (2-tailed) .543 .582 .478 .559 .906 .906 .004 .002 . .795 
N 56 56 56 56 57 57 57 57 57 57 
Total Hours 
Exercising Per 
Year 
Correlation Coefficient -.024 -.049 -.082 .038 .563** .563** .209 .620** -.035 1.000 
Sig. (2-tailed) .861 .719 .550 .780 .000 .000 .119 .000 .795 . 
N 56 56 56 56 57 57 57 57 57 57 
Table 42 Kendall’s Correlation – Bone Health Measures and Sedentary Time (minutes) 
 Stiff Bone T-Score BUA SOS Minutes Spent 
Sitting Per Year 
for Work 
Minutes Spent 
Sitting Per Year 
for Leisure 
Total Minutes 
Spent Sitting 
Per Year 
Kendall's tau_b 
Stiff Bone 
Correlation Coefficient 1.000 .971** .696** .711** .030 .081 .100 
Sig. (2-tailed) . .000 .000 .000 .750 .405 .279 
N 56 56 56 56 56 56 56 
T-Score 
Correlation Coefficient .971** 1.000 .709** .693** .030 .093 .105 
Sig. (2-tailed) .000 . .000 .000 .750 .340 .258 
N 56 56 56 56 56 56 56 
BUA 
Correlation Coefficient .696** .709** 1.000 .403** .013 .121 .096 
Sig. (2-tailed) .000 .000 . .000 .887 .212 .296 
N 56 56 56 56 56 56 56 
SOS 
Correlation Coefficient .711** .693** .403** 1.000 .053 .049 .081 
Sig. (2-tailed) .000 .000 .000 . .571 .616 .381 
N 56 56 56 56 56 56 56 
Minutes Spent Sitting Per 
Year for Work 
Correlation Coefficient .030 .030 .013 .053 1.000 .053 .328** 
Sig. (2-tailed) .750 .750 .887 .571 . .585 .000 
N 56 56 56 56 57 57 57 
Minutes Spent Sitting Per 
Year for Leisure 
Correlation Coefficient .081 .093 .121 .049 .053 1.000 .774** 
Sig. (2-tailed) .405 .340 .212 .616 .585 . .000 
N 56 56 56 56 57 57 57 
Total Minutes Spent Sitting 
Per Year 
Correlation Coefficient .100 .105 .096 .081 .328** .774** 1.000 
Sig. (2-tailed) .279 .258 .296 .381 .000 .000 . 
N 56 56 56 56 57 57 57 
 
 
 
 
 
 
 
Table 43: Spearman’s Correlation – Bone Health Measures and Sedentary Time (minutes) 
 Stiff Bone T-Score BUA SOS Minutes Spent 
Sitting Per Year 
for Work 
Minutes Spent 
Sitting Per Year 
for Leisure 
Total Minutes 
Spent Sitting 
Per Year 
Spearman's rho 
Stiff Bone 
Correlation Coefficient 1.000 .991** .863** .866** .042 .110 .141 
Sig. (2-tailed) . .000 .000 .000 .761 .422 .300 
N 56 56 56 56 56 56 56 
T-Score 
Correlation Coefficient .991** 1.000 .868** .850** .044 .118 .149 
Sig. (2-tailed) .000 . .000 .000 .750 .385 .274 
N 56 56 56 56 56 56 56 
BUA 
Correlation Coefficient .863** .868** 1.000 .514** .022 .163 .160 
Sig. (2-tailed) .000 .000 . .000 .872 .231 .240 
N 56 56 56 56 56 56 56 
SOS 
Correlation Coefficient .866** .850** .514** 1.000 .078 .062 .116 
Sig. (2-tailed) .000 .000 .000 . .565 .651 .395 
N 56 56 56 56 56 56 56 
Minutes Spent Sitting Per 
Year for Work 
Correlation Coefficient .042 .044 .022 .078 1.000 .066 .442** 
Sig. (2-tailed) .761 .750 .872 .565 . .624 .001 
N 56 56 56 56 57 57 57 
Minutes Spent Sitting Per 
Year for Leisure 
Correlation Coefficient .110 .118 .163 .062 .066 1.000 .901** 
Sig. (2-tailed) .422 .385 .231 .651 .624 . .000 
N 56 56 56 56 57 57 57 
Total Minutes Spent Sitting 
Per Year 
Correlation Coefficient .141 .149 .160 .116 .442** .901** 1.000 
Sig. (2-tailed) .300 .274 .240 .395 .001 .000 . 
N 56 56 56 56 57 57 57 
 
 
 
 
 
Table 44: Kendall’s Correlation – Bone Health Measures and Sedentary Time (hours) 
 Stiff Bone T-Score BUA SOS Average 
Number of 
Hours Slept 
Per Night 
Total Work 
Hours Spent 
Sitting Per 
Year 
Total Leisure 
Hours Spent 
Sitting Per 
Year 
Total Hours 
Spent Sitting 
Per Year 
Kendall's tau_b 
Stiff Bone 
Correlation Coefficient 1.000 .971** .696** .711** .077 .030 .081 .100 
Sig. (2-tailed) . .000 .000 .000 .424 .750 .405 .279 
N 56 56 56 56 56 56 56 56 
T-Score 
Correlation Coefficient .971** 1.000 .709** .693** .061 .030 .093 .105 
Sig. (2-tailed) .000 . .000 .000 .525 .750 .340 .258 
N 56 56 56 56 56 56 56 56 
BUA 
Correlation Coefficient .696** .709** 1.000 .403** .085 .013 .121 .096 
Sig. (2-tailed) .000 .000 . .000 .376 .887 .212 .296 
N 56 56 56 56 56 56 56 56 
SOS 
Correlation Coefficient .711** .693** .403** 1.000 .041 .053 .049 .081 
Sig. (2-tailed) .000 .000 .000 . .669 .571 .616 .381 
N 56 56 56 56 56 56 56 56 
Average Number of 
Hours Slept Per Night 
Correlation Coefficient .077 .061 .085 .041 1.000 .074 .011 .061 
Sig. (2-tailed) .424 .525 .376 .669 . .440 .910 .518 
N 56 56 56 56 57 57 57 57 
Total Work Hours Spent 
Sitting Per Year 
Correlation Coefficient .030 .030 .013 .053 .074 1.000 .053 .328** 
Sig. (2-tailed) .750 .750 .887 .571 .440 . .585 .000 
N 56 56 56 56 57 57 57 57 
Total Leisure Hours 
Spent Sitting Per Year 
Correlation Coefficient .081 .093 .121 .049 .011 .053 1.000 .774** 
Sig. (2-tailed) .405 .340 .212 .616 .910 .585 . .000 
N 56 56 56 56 57 57 57 57 
Total Hours Spent Sitting 
Per Year 
Correlation Coefficient .100 .105 .096 .081 .061 .328** .774** 1.000 
Sig. (2-tailed) .279 .258 .296 .381 .518 .000 .000 . 
N 56 56 56 56 57 57 57 57 
 
 
 
Table 45: Spearman’s Correlation – Bone Health Measures and Sedentary Time (hours) 
 Stiff 
Bone 
T-Score BUA SOS Average 
Number of 
Hours Slept 
Per Night 
Total Work 
Hours Spent 
Sitting Per 
Year 
Total Leisure 
Hours Spent 
Sitting Per 
Year 
Total Hours 
Spent Sitting 
Per Year 
Spearman's rho 
Stiff Bone 
Correlation Coefficient 1.000 .991** .863** .866** .115 .042 .110 .141 
Sig. (2-tailed) . .000 .000 .000 .399 .761 .422 .300 
N 56 56 56 56 56 56 56 56 
T-Score 
Correlation Coefficient .991** 1.000 .868** .850** .095 .044 .118 .149 
Sig. (2-tailed) .000 . .000 .000 .484 .750 .385 .274 
N 56 56 56 56 56 56 56 56 
BUA 
Correlation Coefficient .863** .868** 1.000 .514** .118 .022 .163 .160 
Sig. (2-tailed) .000 .000 . .000 .384 .872 .231 .240 
N 56 56 56 56 56 56 56 56 
SOS 
Correlation Coefficient .866** .850** .514** 1.000 .060 .078 .062 .116 
Sig. (2-tailed) .000 .000 .000 . .662 .565 .651 .395 
N 56 56 56 56 56 56 56 56 
Average Number of 
Hours Slept Per Night 
Correlation Coefficient .115 .095 .118 .060 1.000 .109 .003 .090 
Sig. (2-tailed) .399 .484 .384 .662 . .419 .982 .504 
N 56 56 56 56 57 57 57 57 
Total Work Hours 
Spent Sitting Per Year 
Correlation Coefficient .042 .044 .022 .078 .109 1.000 .066 .442** 
Sig. (2-tailed) .761 .750 .872 .565 .419 . .624 .001 
N 56 56 56 56 57 57 57 57 
Total Leisure Hours 
Spent Sitting Per Year 
Correlation Coefficient .110 .118 .163 .062 .003 .066 1.000 .901** 
Sig. (2-tailed) .422 .385 .231 .651 .982 .624 . .000 
N 56 56 56 56 57 57 57 57 
Total Hours Spent 
Sitting Per Year 
Correlation Coefficient .141 .149 .160 .116 .090 .442** .901** 1.000 
Sig. (2-tailed) .300 .274 .240 .395 .504 .001 .000 . 
N 56 56 56 56 57 57 57 57 
 
 
 
 
Table 46: Kendall’s Correlation – WHR, BMI, and Time Spent Exercising/Year (minutes) 
 Waist-to-hip 
ratio 
BMI Minutes 
spent 
running per 
year 
Minutes 
strength 
training per 
year 
Minutes 
spent biking 
per year 
Minutes 
spent 
walking per 
year 
Minutes 
spent 
swimming 
per year 
Total minutes 
spent 
exercising per 
year 
Kendall's 
tau_b 
Waist-to-hip ratio 
Correlation Coefficient 1.000 .467** -.073 .241** -.078 -.109 -.043 .033 
Sig. (2-tailed) . .000 .428 .010 .428 .257 .676 .715 
N 57 57 57 57 57 57 57 57 
BMI 
Correlation Coefficient .467** 1.000 -.034 .283** -.077 -.048 -.014 .115 
Sig. (2-tailed) .000 . .715 .003 .437 .617 .896 .208 
N 57 57 57 57 57 57 57 57 
Minutes spent 
running per year 
Correlation Coefficient -.073 -.034 1.000 .078 -.262** .099 .007 .230* 
Sig. (2-tailed) .428 .715 . .405 .008 .307 .944 .012 
N 57 57 57 57 57 57 57 57 
Minutes strength 
training per year 
Correlation Coefficient .241** .283** .078 1.000 -.044 -.258** .041 .286** 
Sig. (2-tailed) .010 .003 .405 . .660 .009 .699 .002 
N 57 57 57 57 57 57 57 57 
Minutes spent 
biking per year 
Correlation Coefficient -.078 -.077 -.262** -.044 1.000 .258* -.318** .244* 
Sig. (2-tailed) .428 .437 .008 .660 . .013 .004 .013 
N 57 57 57 57 57 57 57 57 
Minutes spent 
walking per year 
Correlation Coefficient -.109 -.048 .099 -.258** .258* 1.000 -.331** .333** 
Sig. (2-tailed) .257 .617 .307 .009 .013 . .003 .001 
N 57 57 57 57 57 57 57 57 
Minutes spent 
swimming per 
year 
Correlation Coefficient -.043 -.014 .007 .041 -.318** -.331** 1.000 -.103 
Sig. (2-tailed) .676 .896 .944 .699 .004 .003 . .321 
N 57 57 57 57 57 57 57 57 
Total minutes 
spent exercising 
per year 
Correlation Coefficient .033 .115 .230* .286** .244* .333** -.103 1.000 
Sig. (2-tailed) .715 .208 .012 .002 .013 .001 .321 . 
N 57 57 57 57 57 57 57 57 
 
 
 
 
Table 47: Spearman’s Correlation – WHR, BMI, and Time Spent Exercising/Year (minutes) 
 Waist-to-hip 
ratio 
BMI Minutes 
spent 
running per 
year 
Minutes 
strength 
training per 
year 
Minutes 
spent biking 
per year 
Minutes 
spent 
walking per 
year 
Minutes 
spent 
swimming 
per year 
Total minutes 
spent 
exercising per 
year 
Spearman's 
rho 
Waist-to-hip ratio 
Correlation Coefficient 1.000 .670** -.110 .336* -.110 -.138 -.035 .057 
Sig. (2-tailed) . .000 .417 .011 .417 .306 .796 .673 
N 57 57 57 57 57 57 57 57 
BMI 
Correlation Coefficient .670** 1.000 -.059 .388** -.102 -.073 -.024 .148 
Sig. (2-tailed) .000 . .664 .003 .451 .587 .858 .272 
N 57 57 57 57 57 57 57 57 
Minutes spent 
running per year 
Correlation Coefficient -.110 -.059 1.000 .107 -.331* .139 .016 .352** 
Sig. (2-tailed) .417 .664 . .427 .012 .302 .906 .007 
N 57 57 57 57 57 57 57 57 
Minutes strength 
training per year 
Correlation Coefficient .336* .388** .107 1.000 -.061 -.337* .043 .342** 
Sig. (2-tailed) .011 .003 .427 . .650 .010 .752 .009 
N 57 57 57 57 57 57 57 57 
Minutes spent 
biking per year 
Correlation Coefficient -.110 -.102 -.331* -.061 1.000 .319* -.378** .340** 
Sig. (2-tailed) .417 .451 .012 .650 . .016 .004 .010 
N 57 57 57 57 57 57 57 57 
Minutes spent 
walking per year 
Correlation Coefficient -.138 -.073 .139 -.337* .319* 1.000 -.401** .451** 
Sig. (2-tailed) .306 .587 .302 .010 .016 . .002 .000 
N 57 57 57 57 57 57 57 57 
Minutes spent 
swimming per 
year 
Correlation Coefficient -.035 -.024 .016 .043 -.378** -.401** 1.000 -.128 
Sig. (2-tailed) .796 .858 .906 .752 .004 .002 . .343 
N 57 57 57 57 57 57 57 57 
Total minutes 
spent exercising 
per year 
Correlation Coefficient .057 .148 .352** .342** .340** .451** -.128 1.000 
Sig. (2-tailed) .673 .272 .007 .009 .010 .000 .343 . 
N 57 57 57 57 57 57 57 57 
 
 
 
 
 
 Table 48: Kendall’s Correlation – WHR, BMI, and Time Spent Exercising/Year (hours)  
 Waist-to-
hip ratio 
BMI Hours Spent 
Running Per 
Year 
Hours 
Strength 
Training Per 
Year 
Hours Spent 
Biking Per 
Year 
Hours Spent 
Walking Per 
Year 
Hours Spent 
Swimming 
Per Year 
Total Hours 
Spent 
Exercising 
Per Year 
Kendall's 
tau_b 
Waist-to-hip ratio 
Correlation Coefficient 1.000 .467** -.073 -.073 -.078 -.109 -.043 -.115 
Sig. (2-tailed) . .000 .428 .428 .428 .257 .676 .208 
N 57 57 57 57 57 57 57 57 
BMI 
Correlation Coefficient .467** 1.000 -.034 -.034 -.077 -.048 -.014 -.086 
Sig. (2-tailed) .000 . .715 .715 .437 .617 .896 .345 
N 57 57 57 57 57 57 57 57 
Hours Spent Running 
Per Year 
Correlation Coefficient -.073 -.034 1.000 1.000** -.262** .099 .007 .453** 
Sig. (2-tailed) .428 .715 . . .008 .307 .944 .000 
N 57 57 57 57 57 57 57 57 
Hours Spent Strength 
Training Per Year 
Correlation Coefficient -.073 -.034 1.000** 1.000 -.262** .099 .007 .453** 
Sig. (2-tailed) .428 .715 . . .008 .307 .944 .000 
N 57 57 57 57 57 57 57 57 
Hours Spent Biking Per 
Year 
Correlation Coefficient -.078 -.077 -.262** -.262** 1.000 .258* -.318** .160 
Sig. (2-tailed) .428 .437 .008 .008 . .013 .004 .103 
N 57 57 57 57 57 57 57 57 
Hours Spent Walking 
Per Year 
Correlation Coefficient -.109 -.048 .099 .099 .258* 1.000 -.331** .515** 
Sig. (2-tailed) .257 .617 .307 .307 .013 . .003 .000 
N 57 57 57 57 57 57 57 57 
Hours Spent 
Swimming Per Year 
Correlation Coefficient -.043 -.014 .007 .007 -.318** -.331** 1.000 -.032 
Sig. (2-tailed) .676 .896 .944 .944 .004 .003 . .754 
N 57 57 57 57 57 57 57 57 
Total Hours Spent 
Exercising Per Year 
Correlation Coefficient -.115 -.086 .453** .453** .160 .515** -.032 1.000 
Sig. (2-tailed) .208 .345 .000 .000 .103 .000 .754 . 
N 57 57 57 57 57 57 57 57 
 
 
 
 Table 49: Spearman’s Correlation – WHR, BMI, and Time Spent Exercising/Year (hours)  
 Waist-to-hip 
ratio 
BMI Hours Spent 
Running Per 
Year 
Hours 
Strength 
Training Per 
Year 
Hours Spent 
Biking Per 
Year 
Hours Spent 
Walking Per 
Year 
Hours Spent 
Swimming 
Per Year 
Total Hours 
Spent 
Exercising 
Per Year 
Spearman's rho 
Waist-to-hip ratio 
Correlation Coefficient 1.000 .670** -.110 -.110 -.110 -.138 -.035 -.158 
Sig. (2-tailed) . .000 .417 .417 .417 .306 .796 .242 
N 57 57 57 57 57 57 57 57 
BMI 
Correlation Coefficient .670** 1.000 -.059 -.059 -.102 -.073 -.024 -.128 
Sig. (2-tailed) .000 . .664 .664 .451 .587 .858 .343 
N 57 57 57 57 57 57 57 57 
Hours Spent 
Running Per Year 
Correlation Coefficient -.110 -.059 1.000 1.000** -.331* .139 .016 .563** 
Sig. (2-tailed) .417 .664 . . .012 .302 .906 .000 
N 57 57 57 57 57 57 57 57 
Hours Spent 
Strength Training 
Per Year 
Correlation Coefficient -.110 -.059 1.000** 1.000 -.331* .139 .016 .563** 
Sig. (2-tailed) .417 .664 . . .012 .302 .906 .000 
N 57 57 57 57 57 57 57 57 
Hours Spent 
Biking Per Year 
Correlation Coefficient -.110 -.102 -.331* -.331* 1.000 .319* -.378** .209 
Sig. (2-tailed) .417 .451 .012 .012 . .016 .004 .119 
N 57 57 57 57 57 57 57 57 
Hours Spent 
Walking Per Year 
Correlation Coefficient -.138 -.073 .139 .139 .319* 1.000 -.401** .620** 
Sig. (2-tailed) .306 .587 .302 .302 .016 . .002 .000 
N 57 57 57 57 57 57 57 57 
Hours Spent 
Swimming Per 
Year 
Correlation Coefficient -.035 -.024 .016 .016 -.378** -.401** 1.000 -.035 
Sig. (2-tailed) .796 .858 .906 .906 .004 .002 . .795 
N 57 57 57 57 57 57 57 57 
Total Hours Spent 
Exercising Per 
Year 
Correlation Coefficient -.158 -.128 .563** .563** .209 .620** -.035 1.000 
Sig. (2-tailed) .242 .343 .000 .000 .119 .000 .795 . 
N 57 57 57 57 57 57 57 57 
 
 
Table 50: Kendall’s Correlation – WHR, BMI, and Sedentary Time (minutes) 
 Waist-to-hip ratio BMI Minutes Spent 
Sitting Per Year 
for Work 
Minutes Spent 
Sitting Per Year 
for Leisure 
Total Minutes 
Spent Sitting Per 
Year 
Kendall's tau_b 
Waist-to-hip ratio 
Correlation Coefficient 1.000 .467** -.101 .051 .045 
Sig. (2-tailed) . .000 .273 .595 .625 
N 57 57 57 57 57 
BMI 
Correlation Coefficient .467** 1.000 -.008 .076 .091 
Sig. (2-tailed) .000 . .934 .430 .321 
N 57 57 57 57 57 
Minutes Spent Sitting Per Year 
for Work 
Correlation Coefficient -.101 -.008 1.000 .053 .328** 
Sig. (2-tailed) .273 .934 . .585 .000 
N 57 57 57 57 57 
Minutes Spent Sitting Per Year 
for Leisure 
Correlation Coefficient .051 .076 .053 1.000 .774** 
Sig. (2-tailed) .595 .430 .585 . .000 
N 57 57 57 57 57 
Total Minutes Spent Sitting Per 
Year 
Correlation Coefficient .045 .091 .328** .774** 1.000 
Sig. (2-tailed) .625 .321 .000 .000 . 
N 57 57 57 57 57 
 
 
 
 
 
 
 
 
 
 
 
 
Table 51: Spearman’s Correlation – WHR, BMI, and Sedentary Time (minutes) 
 Waist-to-hip ratio BMI Minutes Spent 
Sitting Per Year 
for Work 
Minutes Spent 
Sitting Per Year 
for Leisure 
Total Minutes 
Spent Sitting Per 
Year 
Spearman's rho 
Waist-to-hip ratio 
Correlation Coefficient 1.000 .670** -.122 .065 .056 
Sig. (2-tailed) . .000 .366 .629 .679 
N 57 57 57 57 57 
BMI 
Correlation Coefficient .670** 1.000 -.004 .100 .128 
Sig. (2-tailed) .000 . .977 .458 .343 
N 57 57 57 57 57 
Minutes Spent Sitting Per Year 
for Work 
Correlation Coefficient -.122 -.004 1.000 .066 .442** 
Sig. (2-tailed) .366 .977 . .624 .001 
N 57 57 57 57 57 
Minutes Spent Sitting Per Year 
for Leisure 
Correlation Coefficient .065 .100 .066 1.000 .901** 
Sig. (2-tailed) .629 .458 .624 . .000 
N 57 57 57 57 57 
Total Minutes Spent Sitting Per 
Year 
Correlation Coefficient .056 .128 .442** .901** 1.000 
Sig. (2-tailed) .679 .343 .001 .000 . 
N 57 57 57 57 57 
 
 
 
 
 
 
 
 
 
 
 
 
Table 52: Kendall’s Correlation – WHR, BMI, and Sedentary Time (hours) 
 Waist-to-hip 
ratio 
BMI Average 
Number of 
Hours Slept Per 
Night 
Total Work 
Hours Spent 
Sitting Per Year 
Total Leisure 
Hours Spent 
Sitting Per Year 
Total Hours 
Spent Sitting 
Per Year 
Kendall's tau_b 
Waist-to-hip ratio 
Correlation Coefficient 1.000 .467** .095 -.101 .051 .045 
Sig. (2-tailed) . .000 .317 .273 .595 .625 
N 57 57 57 57 57 57 
BMI 
Correlation Coefficient .467** 1.000 .120 -.008 .076 .091 
Sig. (2-tailed) .000 . .209 .934 .430 .321 
N 57 57 57 57 57 57 
Average Number of Hours 
Slept Per Night 
Correlation Coefficient .095 .120 1.000 .074 .011 .061 
Sig. (2-tailed) .317 .209 . .440 .910 .518 
N 57 57 57 57 57 57 
Total Work Hours Spent 
Sitting Per Year 
Correlation Coefficient -.101 -.008 .074 1.000 .053 .328** 
Sig. (2-tailed) .273 .934 .440 . .585 .000 
N 57 57 57 57 57 57 
Total Leisure Hours Spent 
Sitting Per Year 
Correlation Coefficient .051 .076 .011 .053 1.000 .774** 
Sig. (2-tailed) .595 .430 .910 .585 . .000 
N 57 57 57 57 57 57 
Total Hours Spent Sitting 
Per Year 
Correlation Coefficient .045 .091 .061 .328** .774** 1.000 
Sig. (2-tailed) .625 .321 .518 .000 .000 . 
N 57 57 57 57 57 57 
 
 
 
 
 
 
 
 
 
Table 53: Spearman’s Correlation – WHR, BMI, and Sedentary Time (hours) 
 Waist-to-hip 
ratio 
BMI Average 
Number of 
Hours Slept Per 
Night 
Total Work 
Hours Spent 
Sitting Per Year 
Total Leisure 
Hours Spent 
Sitting Per Year 
Total Hours 
Spent Sitting 
Per Year 
Spearman's rho 
Waist-to-hip ratio 
Correlation Coefficient 1.000 .670** .123 -.122 .065 .056 
Sig. (2-tailed) . .000 .360 .366 .629 .679 
N 57 57 57 57 57 57 
BMI 
Correlation Coefficient .670** 1.000 .159 -.004 .100 .128 
Sig. (2-tailed) .000 . .239 .977 .458 .343 
N 57 57 57 57 57 57 
Average Number of Hours 
Slept Per Night 
Correlation Coefficient .123 .159 1.000 .109 .003 .090 
Sig. (2-tailed) .360 .239 . .419 .982 .504 
N 57 57 57 57 57 57 
Total Work Hours Spent 
Sitting Per Year 
Correlation Coefficient -.122 -.004 .109 1.000 .066 .442** 
Sig. (2-tailed) .366 .977 .419 . .624 .001 
N 57 57 57 57 57 57 
Total Leisure Hours Spent 
Sitting Per Year 
Correlation Coefficient .065 .100 .003 .066 1.000 .901** 
Sig. (2-tailed) .629 .458 .982 .624 . .000 
N 57 57 57 57 57 57 
Total Hours Spent Sitting 
Per Year 
Correlation Coefficient .056 .128 .090 .442** .901** 1.000 
Sig. (2-tailed) .679 .343 .504 .001 .000 . 
N 57 57 57 57 57 57 
 
 
 
 
 
 
 
 
Table 54: Kendall’s Correlation – Sedentary Time and Time Spent Exercising/Year (minutes) 
 Minutes 
spent 
running 
per year 
Minutes 
strength 
training per 
year 
Minutes 
spent 
biking per 
year 
Minutes 
spent 
walking per 
year 
Minutes 
spent 
swimming 
per year 
Total 
minutes 
exercising 
per year 
Minutes 
Sitting Per 
Year for 
Work 
Minutes 
Sitting Per 
Year for 
Leisure 
Total 
Minutes 
Sitting Per 
Year 
Kendall's 
tau_b 
Minutes spent 
running per year 
Correlation Coefficient 1.000 .078 -.262** .099 .007 .230* .011 .112 .097 
Sig. (2-tailed) . .405 .008 .307 .944 .012 .907 .246 .289 
N 57 57 57 57 57 57 57 57 57 
Minutes strength 
training per year 
Correlation Coefficient .078 1.000 -.044 -.258** .041 .286** -.008 -.108 -.104 
Sig. (2-tailed) .405 . .660 .009 .699 .002 .933 .272 .264 
N 57 57 57 57 57 57 57 57 57 
Minutes spent 
biking per year 
Correlation Coefficient -.262** -.044 1.000 .258* -.318** .244* -.004 -.026 -.014 
Sig. (2-tailed) .008 .660 . .013 .004 .013 .965 .799 .888 
N 57 57 57 57 57 57 57 57 57 
Minutes spent 
walking per year 
Correlation Coefficient .099 -.258** .258* 1.000 -.331** .333** -.058 .160 .117 
Sig. (2-tailed) .307 .009 .013 . .003 .001 .548 .115 .225 
N 57 57 57 57 57 57 57 57 57 
Minutes spent 
swimming per 
year 
Correlation Coefficient .007 .041 -.318** -.331** 1.000 -.103 -.020 -.088 -.107 
Sig. (2-tailed) .944 .699 .004 .003 . .321 .848 .416 .300 
N 57 57 57 57 57 57 57 57 57 
Total minutes 
spent exercising 
per year 
Correlation Coefficient .230* .286** .244* .333** -.103 1.000 -.088 .035 .003 
Sig. (2-tailed) .012 .002 .013 .001 .321 . .341 .716 .978 
N 57 57 57 57 57 57 57 57 57 
Minutes Spent 
Sitting Per Year 
for Work 
Correlation Coefficient .011 -.008 -.004 -.058 -.020 -.088 1.000 .053 .328** 
Sig. (2-tailed) .907 .933 .965 .548 .848 .341 . .585 .000 
N 57 57 57 57 57 57 57 57 57 
Minutes Spent 
Sitting Per Year 
for Leisure 
Correlation Coefficient .112 -.108 -.026 .160 -.088 .035 .053 1.000 .774** 
Sig. (2-tailed) .246 .272 .799 .115 .416 .716 .585 . .000 
N 57 57 57 57 57 57 57 57 57 
Total Minutes 
Spent Sitting Per 
Year 
Correlation Coefficient .097 -.104 -.014 .117 -.107 .003 .328** .774** 1.000 
Sig. (2-tailed) .289 .264 .888 .225 .300 .978 .000 .000 . 
N 57 57 57 57 57 57 57 57 57 
Table 55: Spearman’s Correlation – Sedentary Time and Time Spent Exercising/Year (minutes) 
 Minutes 
spent 
running per 
year 
Minutes 
strength 
training per 
year 
Minutes 
spent 
biking per 
year 
Minutes 
spent 
walking per 
year 
Minutes 
spent 
swimming 
per year 
Total 
minutes 
exercising 
per year 
Minutes 
Sitting Per 
Year for 
Work 
Minutes 
Sitting Per 
Year for 
Leisure 
Total 
Minutes 
Sitting Per 
Year 
Spearman's 
rho 
Minutes spent 
running per year 
Correlation Coefficient 1.000 .107 -.331* .139 .016 .352** .009 .164 .144 
Sig. (2-tailed) . .427 .012 .302 .906 .007 .947 .222 .285 
N 57 57 57 57 57 57 57 57 57 
Minutes 
strength training 
per year 
Correlation Coefficient .107 1.000 -.061 -.337* .043 .342** .004 -.160 -.150 
Sig. (2-tailed) .427 . .650 .010 .752 .009 .977 .234 .265 
N 57 57 57 57 57 57 57 57 57 
Minutes spent 
biking per year 
Correlation Coefficient -.331* -.061 1.000 .319* -.378** .340** .000 -.036 -.016 
Sig. (2-tailed) .012 .650 . .016 .004 .010 1.000 .793 .905 
N 57 57 57 57 57 57 57 57 57 
Minutes spent 
walking per 
year 
Correlation Coefficient .139 -.337* .319* 1.000 -.401** .451** -.075 .203 .167 
Sig. (2-tailed) .302 .010 .016 . .002 .000 .578 .130 .215 
N 57 57 57 57 57 57 57 57 57 
Minutes spent 
swimming per 
year 
Correlation Coefficient .016 .043 -.378** -.401** 1.000 -.128 -.024 -.113 -.145 
Sig. (2-tailed) .906 .752 .004 .002 . .343 .859 .403 .282 
N 57 57 57 57 57 57 57 57 57 
Total minutes 
spent exercising 
per year 
Correlation Coefficient .352** .342** .340** .451** -.128 1.000 -.139 .030 -.017 
Sig. (2-tailed) .007 .009 .010 .000 .343 . .304 .823 .901 
N 57 57 57 57 57 57 57 57 57 
Minutes Spent 
Sitting Per Year 
for Work 
Correlation Coefficient .009 .004 .000 -.075 -.024 -.139 1.000 .066 .442** 
Sig. (2-tailed) .947 .977 1.000 .578 .859 .304 . .624 .001 
N 57 57 57 57 57 57 57 57 57 
Minutes Spent 
Sitting Per Year 
for Leisure 
Correlation Coefficient .164 -.160 -.036 .203 -.113 .030 .066 1.000 .901** 
Sig. (2-tailed) .222 .234 .793 .130 .403 .823 .624 . .000 
N 57 57 57 57 57 57 57 57 57 
Total Minutes 
Spent Sitting 
Per Year 
Correlation Coefficient .144 -.150 -.016 .167 -.145 -.017 .442** .901** 1.000 
Sig. (2-tailed) .285 .265 .905 .215 .282 .901 .001 .000 . 
N 57 57 57 57 57 57 57 57 57 
Table 56: Kendall’s Correlation – Sedentary Time and Time Spent Exercising/Year (hours) 
 Hours 
Spent 
Running 
Per Year 
Hours 
Strength 
Training 
Per Year 
Hours 
Spent 
Biking Per 
Year 
Hours 
Spent 
Walking 
Per Year 
Hours 
Spent 
Swimming 
Per Year 
Total Hours 
Spent 
Exercising 
Per Year 
Total Work 
Hours 
Sitting Per 
Year 
Total Leisure 
Hours Sitting 
Per Year 
Total Hours 
Sitting Per 
Year 
Kendall's 
tau_b 
Hours Spent 
Running Per 
Year 
Correlation Coefficient 1.000 1.000** -.262** .099 .007 .453** .011 .112 .097 
Sig. (2-tailed) . . .008 .307 .944 .000 .907 .246 .289 
N 57 57 57 57 57 57 57 57 57 
Hours Strength 
Training Per 
Year 
Correlation Coefficient 1.000** 1.000 -.262** .099 .007 .453** .011 .112 .097 
Sig. (2-tailed) . . .008 .307 .944 .000 .907 .246 .289 
N 57 57 57 57 57 57 57 57 57 
Hours Spent 
Biking Per Year 
Correlation Coefficient -.262** -.262** 1.000 .258* -.318** .160 -.004 -.026 -.014 
Sig. (2-tailed) .008 .008 . .013 .004 .103 .965 .799 .888 
N 57 57 57 57 57 57 57 57 57 
Hours Spent 
Walking Per 
Year 
Correlation Coefficient .099 .099 .258* 1.000 -.331** .515** -.058 .160 .117 
Sig. (2-tailed) .307 .307 .013 . .003 .000 .548 .115 .225 
N 57 57 57 57 57 57 57 57 57 
Hours Spent 
Swimming Per 
Year 
Correlation Coefficient .007 .007 -.318** -.331** 1.000 -.032 -.020 -.088 -.107 
Sig. (2-tailed) .944 .944 .004 .003 . .754 .848 .416 .300 
N 57 57 57 57 57 57 57 57 57 
Total Hours 
Exercising Per 
Year 
Correlation Coefficient .453** .453** .160 .515** -.032 1.000 -.104 .114 .054 
Sig. (2-tailed) .000 .000 .103 .000 .754 . .258 .235 .554 
N 57 57 57 57 57 57 57 57 57 
Total Work 
Hours Spent 
Sitting Per Year 
Correlation Coefficient .011 .011 -.004 -.058 -.020 -.104 1.000 .053 .328** 
Sig. (2-tailed) .907 .907 .965 .548 .848 .258 . .585 .000 
N 57 57 57 57 57 57 57 57 57 
Total Leisure 
Hours Spent 
Sitting Per Year 
Correlation Coefficient .112 .112 -.026 .160 -.088 .114 .053 1.000 .774** 
Sig. (2-tailed) .246 .246 .799 .115 .416 .235 .585 . .000 
N 57 57 57 57 57 57 57 57 57 
Total Hours 
Spent Sitting 
Per Year 
Correlation Coefficient .097 .097 -.014 .117 -.107 .054 .328** .774** 1.000 
Sig. (2-tailed) .289 .289 .888 .225 .300 .554 .000 .000 . 
N 57 57 57 57 57 57 57 57 57 
Table 57: Spearman’s Correlation – Sedentary Time and Time Spent Exercising/Year (hours) 
 Hours 
Spent 
Running 
Per Year 
Hours 
Strength 
Training 
Per Year 
Hours 
Spent 
Biking Per 
Year 
Hours 
Spent 
Walking 
Per Year 
Hours 
Spent 
Swimming 
Per Year 
Total Hours 
Spent 
Exercising 
Per Year 
Total Work 
Hours 
Sitting Per 
Year 
Total Leisure 
Hours Sitting 
Per Year 
Total 
Hours 
Sitting Per 
Year 
Spearman's 
rho 
Hours Spent 
Running Per 
Year 
Correlation Coefficient 1.000 1.000** -.331* .139 .016 .563** .009 .164 .144 
Sig. (2-tailed) . . .012 .302 .906 .000 .947 .222 .285 
N 57 57 57 57 57 57 57 57 57 
Hours Strength 
Training Per 
Year 
Correlation Coefficient 1.000** 1.000 -.331* .139 .016 .563** .009 .164 .144 
Sig. (2-tailed) . . .012 .302 .906 .000 .947 .222 .285 
N 57 57 57 57 57 57 57 57 57 
Hours Spent 
Biking Per Year 
Correlation Coefficient -.331* -.331* 1.000 .319* -.378** .209 .000 -.036 -.016 
Sig. (2-tailed) .012 .012 . .016 .004 .119 1.000 .793 .905 
N 57 57 57 57 57 57 57 57 57 
Hours Spent 
Walking Per 
Year 
Correlation Coefficient .139 .139 .319* 1.000 -.401** .620** -.075 .203 .167 
Sig. (2-tailed) .302 .302 .016 . .002 .000 .578 .130 .215 
N 57 57 57 57 57 57 57 57 57 
Hours Spent 
Swimming Per 
Year 
Correlation Coefficient .016 .016 -.378** -.401** 1.000 -.035 -.024 -.113 -.145 
Sig. (2-tailed) .906 .906 .004 .002 . .795 .859 .403 .282 
N 57 57 57 57 57 57 57 57 57 
Total Hours 
Exercising Per 
Year 
Correlation Coefficient .563** .563** .209 .620** -.035 1.000 -.151 .149 .078 
Sig. (2-tailed) .000 .000 .119 .000 .795 . .261 .267 .562 
N 57 57 57 57 57 57 57 57 57 
Total Work 
Hours Spent 
Sitting Per Year 
Correlation Coefficient .009 .009 .000 -.075 -.024 -.151 1.000 .066 .442** 
Sig. (2-tailed) .947 .947 1.000 .578 .859 .261 . .624 .001 
N 57 57 57 57 57 57 57 57 57 
Total Leisure 
Hours Spent 
Sitting Per Year 
Correlation Coefficient .164 .164 -.036 .203 -.113 .149 .066 1.000 .901** 
Sig. (2-tailed) .222 .222 .793 .130 .403 .267 .624 . .000 
N 57 57 57 57 57 57 57 57 57 
Total Hours 
Spent Sitting 
Per Year 
Correlation Coefficient .144 .144 -.016 .167 -.145 .078 .442** .901** 1.000 
Sig. (2-tailed) .285 .285 .905 .215 .282 .562 .001 .000 . 
N 57 57 57 57 57 57 57 57 57 
Independent Samples T-Test 
 
 
Table 58: WHR and BMI vs. Sex Group Statistics 
 Male or female N Mean Std. Deviation Std. Error Mean 
Waist-to-hip ratio 
Male 39 .81913 .049098 .007862 
Female 18 .72472 .038745 .009132 
BMI 
Male 39 24.913 2.7083 .4337 
Female 18 22.216 2.0253 .4774 
 
 
 
Table 59: Independent Samples Test for WHR and BMI vs. Sex 
 Levene's Test for Equality of 
Variances 
t-test for Equality of Means 
F Sig. t df Sig. (2-tailed) Mean 
Difference 
Std. Error 
Difference 
95% Confidence Interval of 
the Difference 
Lower Upper 
Waist-to-hip ratio 
Equal variances assumed .326 .570 7.179 55 .000 .094406 .013150 .068054 .120758 
Equal variances not 
assumed 
  7.834 41.371 .000 .094406 .012050 .070077 .118735 
BMI 
Equal variances assumed 1.149 .289 3.761 55 .000 2.6973 .7172 1.2599 4.1346 
Equal variances not 
assumed 
  4.182 43.411 .000 2.6973 .6450 1.3970 3.9976 
(See Table 1 for descriptives, Table 2 for tests of normality, and figures 1-8 for associated scatterplots, boxplots, and histograms.)  
 
 
 
 
 
 
 
 
Table 60: Bone Health Measures vs. Sex Group Statistics 
 Male or female N Mean Std. Deviation Std. Error Mean 
Stiff Bone 
Male 38 118.6316 21.65631 3.51312 
Female 18 106.8889 25.31656 5.96717 
T-Score 
Male 38 1.1876 1.35654 .22006 
Female 18 .4194 1.59347 .37559 
BUA 
Male 38 131.4095 18.70800 3.03484 
Female 18 120.8383 22.87356 5.39135 
SOS 
Male 38 1611.5750 54.84931 8.89773 
Female 18 1594.8889 46.21839 10.89378 
 
 
 
Table 61: Bone Health Measures vs. Sex Independent Samples Test 
 Levene's Test for Equality of 
Variances 
t-test for Equality of Means 
F Sig. t df Sig. (2-tailed) Mean 
Difference 
Std. Error 
Difference 
95% Confidence Interval of the 
Difference 
Lower Upper 
Stiff Bone 
Equal variances assumed .512 .477 1.794 54 .078 11.74269 6.54437 -1.37798 24.86336 
Equal variances not 
assumed 
  1.696 29.215 .101 11.74269 6.92453 -2.41504 25.90042 
T-Score 
Equal variances assumed .549 .462 1.870 54 .067 .76819 .41070 -.05522 1.59159 
Equal variances not 
assumed 
  1.765 29.100 .088 .76819 .43531 -.12198 1.65835 
BUA 
Equal variances assumed 2.364 .130 1.837 54 .072 10.57114 5.75486 -.96667 22.10895 
Equal variances not 
assumed 
  1.709 28.180 .099 10.57114 6.18683 -2.09836 23.24064 
SOS 
Equal variances assumed .687 .411 1.115 54 .270 16.68611 14.96070 -13.30828 46.68050 
Equal variances not 
assumed 
  1.186 39.227 .243 16.68611 14.06571 -11.75921 45.13143 
(See Table 5 for descriptives, Table 6 for tests of normality, and figures 17-32 for associated scatterplots, boxplots, and histograms.)  
 
Mann-Whitney U Tests 
 
Table 62: Leptin and Osteocalcin vs. Sex 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 108: Leptin vs. Sex 
 
 
 
 
 
 
 
Figure 109: Osteocalcin vs. Sex 
 
 
 
 
 
 
 
 
 
 
Table 63: Time Spent Exercising Per Year (Minutes) Vs. Sex 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 110: Time Spent Running Per Year (Minutes) Vs. Sex 
 
 
 
 
 
 
 
Figure 111: Time Spent Strength Training Per Year (Minutes) Vs. Sex 
 
 
 
 
 
 
 
 
 
 
Figure 112: Time Spent Biking Per Year (Minutes) Vs. Sex 
 
 
 
 
 
 
 
 
 
 
Figure 113: Time Spent Walking Per Year (Minutes) Vs. Sex 
 
 
 
 
 
 
 
 
 
 
Figure 114: Time Spent Swimming Per Year (Minutes) Vs. Sex 
 
 
 
 
 
 
 
 
 
 
 
Figure 115: Total Time Spent Exercising Per Year (Minutes) Vs. Sex 
 
 
 
 
 
 
 
 
 
Table 64: Time Spent Exercising Per Year (Hours) vs. Sex 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 116: Time Spent Running Per Year (Hours) vs. Sex 
 
 
 
 
 
 
Figure 117: Time Spent Strength Training Per Year (Hours) vs. Sex 
 
 
 
 
 
 
 
Figure 118: Time Spent Biking Per Year (Hours) vs. Sex 
 
 
 
 
 
Figure 119: Time Spent Walking Per Year (Hours) vs. Sex 
 
 
 
 
 
 
Figure 120: Time Spent Swimming Per Year (Hours) vs. Sex 
 
 
 
 
 
Figure 121: Time Spent Exercising Per Year (Hours) vs. Sex 
 
 
 
 
 
 
Table 65: Time Spent Sitting Per Year (Hours) vs. Sex 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 122: Time Spent Sitting at Work Per Year (Minutes) vs. Sex 
 
 
 
 
 
 
Figure 123: Time Spent Sitting for Leisure Per Year (Minutes) vs. Sex 
 
 
 
 
 
 
 
Figure 124: Time Spent Sitting Per Year (Minutes) vs. Sex 
 
 
 
 
 
 
 
Table 66: Time Spent Sitting Per Year (Hours) vs. Sex 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 125: Time Spent Sitting at Work Per Year (Hours) vs. Sex 
 
 
 
 
 
 
 
 
Figure 126: Time Spent Sitting for Leisure Per Year (Hours) vs. Sex 
 
 
 
 
 
 
 
Figure 127: Total Time Spent Sitting Per Year (Hours) vs. Sex 
 
 
 
 
 
 
Table 67: Study Leptin Levels vs. Normal Population Leptin Levels 
 
 
Figure 128: Study Leptin Levels vs. Normal Population Leptin Levels 
 
Table 68: Study Leptin Levels vs. Obese Population Leptin Levels 
 
 
 
Figure 129: Study Leptin Levels vs. Obese Population Leptin Levels 
 
Table 69: Study Osteocalcin vs. Normal Population Osteocalcin 
 
Figure 130: Study Osteocalcin vs. Normal Population Osteocalcin 
 
 
 
 
Table 70: Leptin and Osteocalcin vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 131: Leptin vs. Stress Levels  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 132: Osteocalcin vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 71: WHR and BMI vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 133: WHR vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 134: BMI vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 72: Bone Health Measures vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 135: Stiff Bone vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 136: T-Score vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 137: BUA vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 138: SOS vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 73: Time Spent Exercising Per Year (minutes) vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 139: Time Spent Running Per Year (minutes) vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 140: Time Spent Strength Training Per Year (minutes) vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 141: Time Spent Biking Per Year (minutes) vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 142: Time Spent Walking Per Year (minutes) vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 143: Time Spent Swimming Per Year (minutes) vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 144: Time Spent Exercising Per Year (minutes) vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 74: Time Spent Exercising Per Year (hours) vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 145: Time Spent Running Per Year (hours) vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 146: Time Spent Strength Training Per Year (hours) vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 147: Time Spent Biking Per Year (hours) vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 148: Time Spent Walking Per Year (hours) vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 149: Time Spent Swimming Per Year (hours) vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 150: Total Time Spent Exercising Per Year (hours) vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 75: Time Spent Sitting Per Year (minutes) vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 151: Time Spent Sitting for Work Per Year (minutes) vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 152: Time Spent Sitting for Leisure Per Year (minutes) vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 153: Total Time Spent Sitting Per Year (minutes) vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 76: Time Spent Sitting Per Year (hours) vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 154: Time Spent Sitting for Work Per Year (hours) vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 155: Time Spent Sitting for Leisure Per Year (hours) vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 156: Total Time Spent Sitting for Work Per Year (hours) vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 157: Average Number of Hours Slept Per Night vs. Stress Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 77: Leptin and Osteocalcin vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 158: Leptin vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 159: Osteocalcin vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
  
Table 78: WHR and BMI vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 160: WHR vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 161: BMI vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 79: Bone Health Measures vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 162: Stiff Bone vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 163: T-Score vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 164: BUA vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 165: SOS vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 80: Time Spent Exercising Per Year (minutes) vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
Figure 166: Time Spent Running Per Year (minutes) vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 167: Time Spent Strength Training Per Year (minutes) vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 168: Time Spent Biking Per Year (minutes) vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 169: Time Spent Walking Per Year (minutes) vs. Socioeconomic Status  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 170: Time Spent Swimming Per Year (minutes) vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 171: Total Time Spent Exercising Per Year (minutes) vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 81: Time Spent Exercising Per Year (hours) vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 172: Time Spent Running Per Year (hours) vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 173: Time Spent Strength Training Per Year (hours) vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 174: Time Spent Biking Per Year (hours) vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 175: Time Spent Walking Per Year (hours) vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 176: Time Spent Swimming Per Year (hours) vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 177: Total Time Spent Exercising Per Year (hours) vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 82: Sedentary Time (minutes) vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 178: Time Spent Sitting for Work Per Year (minutes) vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 179: Time Spent Sitting for Leisure Per Year (minutes) vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 180: Total Time Spent Sitting Per Year (minutes) vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 83: Sedentary Time (hours) vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 181: Average Amount Slept Per Night (hours) vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 182: Time Spent Sitting for Work Per Year (minutes) vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 183: Time Spent Sitting for Leisure Per Year (minutes) vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 184: Total Time Spent Sitting Per Year (minutes) vs. Socioeconomic Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 84: Leptin and Osteocalcin vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 181: Leptin vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 182: Osteocalcin vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 85: WHR and BMI vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 183: WHR vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 184: BMI vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 86: Bone Health Measures vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 185: Stiff Bone vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 186: T-Score vs. Sunscreen Use  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 187: BUA vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 188: SOS vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 87: Time Spent Exercising Per Year (minutes) Figure 186: vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 189: Time Spent Running Per Year (minutes) vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 190: Time Spent Strength Training Per Year (minutes) vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 191: Time Spent Biking Per Year (minutes) vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 192: Time Spent Walking Per Year (minutes) vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 193: Time Spent Swimming Per Year (minutes) vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 194: Total Time Spent Exercising Per Year (minutes) vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 88: Time Spent Exercising Per Year (hours) Figure 186: vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 195: Time Spent Running Per Year (hours) vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 196: Time Spent Strength Training Per Year (hours) vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 197: Time Spent Biking Per Year (hours) vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 198: Time Spent Walking Per Year (hours) vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 199: Time Spent Swimming Per Year (hours) vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 200: Total Time Spent Exercising Per Year (hours) vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 89: Sedentary Time (minutes) vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 201: Time Spent Sitting for Work Per Year (minutes) vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 202: Time Spent Sitting for Leisure Per Year (minutes) vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 203: Total Time Spent Sitting Per Year (minutes) vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 90: Sedentary Time (hours) vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 203: Average Amount of Sleep Per Night (hours) vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 203: Time Spent Sitting for Work Per Year (hours) vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 204: Time Spent Sitting for Leisure Per Year (hours) vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 205: Total Time Spent Sitting Per Year (hours) vs. Sunscreen Use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 91: Leptin and Osteocalcin vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 206: Leptin vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 207: Osteocalcin vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 92: WHR and BMI vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 208: WHR vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 209: BMI vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 93: Bone Health Measures vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 210: Stiff Bone vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 211: T-Score vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 212: BUA vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 213: SOS vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 94: Time Spent Exercising Per Year (minutes) Figure 186: vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 214: Time Spent Running Per Year (minutes) vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 215: Time Spent Strength Training Per Year (minutes) vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 216: Time Spent Biking Per Year (minutes) vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 217: Time Spent Walking Per Year (minutes) vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 218: Time Spent Swimming Per Year (minutes) vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 219: Total Time Spent Exercising Per Year (minutes) vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 95: Time Spent Exercising Per Year (hours) Figure 186: vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 220: Time Spent Running Per Year (hours) vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 221: Time Spent Strength Training Per Year (hours) vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 222: Time Spent Biking Per Year (hours) vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 223: Time Spent Walking Per Year (hours) vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 224: Time Spent Swimming Per Year (hours) vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 225: Total Time Spent Exercising Per Year (hours) vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 96: Sedentary Time (minutes) vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 226: Time Spent Sitting for Work Per Year (minutes) vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 227: Time Spent Sitting for Leisure Per Year (minutes) vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 228: Total Time Spent Sitting Per Year (minutes) vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 97: Sedentary Time (hours) vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 229: Average Amount of Sleep Per Night (hours) vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 230: Time Spent Sitting for Work Per Year (hours) vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 231: Time Spent Sitting for Leisure Per Year (hours) vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 232: Total Time Spent Sitting Per Year (hours) vs. Average Outside Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
Linear Regression 
Stiff Bone vs. BMI 
Figure 233-235: Scatterplots and histogram for Stiff Bone vs. BMI regression 
       Figure 233                             Figure 234 
             
   
          Figure 235 
 
 
 
 
 
 
 
 
Table 98: Stiff Bone vs. BMI Regression Model Summary 
Model R R Square Adjusted R 
Square 
Std. Error of the 
Estimate 
Durbin-Watson 
1 .370a .137 .121 21.87667 1.872 
a. Predictors: (Constant), BMI 
b. Dependent Variable: Stiff Bone 
 
 
 
Table 99: Stiff Bone vs. BMI Regression ANOVAa 
Model Sum of Squares df Mean Square F Sig. 
1 
Regression 4089.070 1 4089.070 8.544 .005b 
Residual 25843.787 54 478.589   
Total 29932.857 55    
a. Dependent Variable: Stiff Bone 
b. Predictors: (Constant), BMI 
 
 
 
Table 100: Stiff Bone vs. BMI Regression Coefficientsa 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 95.0% Confidence Interval 
for B 
B Std. Error Beta Lower Bound Upper Bound 
1 
(Constant) 38.457 26.300  1.462 .149 -14.272 91.186 
BMI 3.163 1.082 .370 2.923 .005 .993 5.332 
a. Dependent Variable: Stiff Bone 
 
 
 
Table 101: Stiff Bone vs. BMI Residuals Regression Statisticsa 
 Minimum Maximum Mean Std. Deviation N 
Predicted Value 98.8642 136.1837 114.8571 8.62245 56 
Residual -33.39431 48.81048 .00000 21.67688 56 
Std. Predicted Value -1.855 2.473 .000 1.000 56 
Std. Residual -1.526 2.231 .000 .991 56 
a. Dependent Variable: Stiff Bone 
 
 
 
Regression Formula: Stiff Bone = 38.457 + (3.163 x BMI) 
 
 
T-Score vs. BMI 
Figure 236-238: Scatterplots and histogram for T-Score vs. BMI regression 
   Figure 236       Figure 237 
                 
 
 
Figure 238 
 
 
 
 
 
 
 
 
 
 
 
 
Table 102: T-Score vs. BMI Regression Model Summaryb 
Model R R Square Adjusted R 
Square 
Std. Error of the 
Estimate 
Durbin-Watson 
1 .380a .144 .128 1.37017 1.909 
a. Predictors: (Constant), BMI 
b. Dependent Variable: T-Score 
 
 
 
Table 103: T-Score vs. BMI Regression ANOVAa 
Model Sum of Squares df Mean Square F Sig. 
1 
Regression 17.082 1 17.082 9.099 .004b 
Residual 101.378 54 1.877   
Total 118.461 55    
a. Dependent Variable: T-Score 
b. Predictors: (Constant), BMI 
 
 
 
Table 104: T-Score vs. BMI Regression Coefficientsa 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 95.0% Confidence Interval 
for B 
B Std. Error Beta Lower Bound Upper Bound 
1 
(Constant) -3.997 1.647  -2.427 .019 -7.300 -.695 
BMI .204 .068 .380 3.016 .004 .069 .340 
a. Dependent Variable: T-Score 
 
 
 
Table 105: T-Score vs. BMI Regression Residuals Statisticsa 
 Minimum Maximum Mean Std. Deviation N 
Predicted Value -.0930 2.3191 .9407 .55731 56 
Residual -2.11914 3.08415 .00000 1.35766 56 
Std. Predicted Value -1.855 2.473 .000 1.000 56 
Std. Residual -1.547 2.251 .000 .991 56 
a. Dependent Variable: T-Score 
 
 
 
Regression Formula: BUA = -3.997 + (.204 x BMI) 
 
 
BUA vs. BMI 
Figure 239-241: Scatterplots and histogram for BUA vs. BMI regression 
 
Figure 239          Figure 240 
                      
 
             Figure 241 
 
 
 
 
 
 
 
 
 
 
 
Table 106: BUA vs. BMI Regression Model Summaryb 
Model R R Square Adjusted R 
Square 
Std. Error of the 
Estimate 
Durbin-Watson 
1 .391a .153 .137 17.53639 1.819 
a. Predictors: (Constant), BMI 
b. Dependent Variable: BUA 
 
 
 
Table 107: BUA vs. BMI Regression ANOVAa 
Model Sum of Squares df Mean Square F Sig. 
1 
Regression 2933.901 1 2933.901 9.540 .003b 
Residual 16298.825 53 307.525   
Total 19232.726 54    
a. Dependent Variable: BUA 
b. Predictors: (Constant), BMI 
 
 
 
Table 108: BUA vs. BMI Regression Coefficientsa 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 95.0% Confidence Interval 
for B 
B Std. Error Beta Lower Bound Upper Bound 
1 
(Constant) 64.066 21.203  3.022 .004 21.539 106.594 
BMI 2.699 .874 .391 3.089 .003 .946 4.452 
a. Dependent Variable: BUA 
 
 
 
Table 109: BUA vs. BMI Regression Residuals Statisticsa 
 Minimum Maximum Mean Std. Deviation N 
Predicted Value 115.6190 147.4683 129.1478 7.37099 55 
Residual -29.72381 35.41555 .00000 17.37326 55 
Std. Predicted Value -1.835 2.485 .000 1.000 55 
Std. Residual -1.695 2.020 .000 .991 55 
a. Dependent Variable: BUA 
 
 
 
Regression Formula: BUA = 64.066 + (2.699 x BMI) 
 
 
 
SOS vs. BMI 
Figure 242-244: Scatterplots and histogram for SOS vs. BMI regression 
 
Figure 242          Figure 243 
                      
 
 
Figure 244 
 
 
 
 
 
 
 
 
 
 
 
 
Table 110: SOS vs. BMI Regression Model Summaryb 
Model R R Square Adjusted R 
Square 
Std. Error of the 
Estimate 
Durbin-Watson 
1 .309a .096 .079 50.29608 2.199 
a. Predictors: (Constant), BMI 
b. Dependent Variable: SOS 
 
 
 
Table 111: SOS vs. BMI Regression ANOVAa 
Model Sum of Squares df Mean Square F Sig. 
1 
Regression 14424.135 1 14424.135 5.702 .020b 
Residual 136603.539 54 2529.695   
Total 151027.674 55    
a. Dependent Variable: SOS 
b. Predictors: (Constant), BMI 
 
 
 
Table 112: SOS vs. BMI Regression Coefficientsa 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 95.0% Confidence Interval 
for B 
B Std. Error Beta Lower Bound Upper Bound 
1 
(Constant) 1462.720 60.467  24.191 .000 1341.492 1583.948 
BMI 5.940 2.488 .309 2.388 .020 .953 10.927 
a. Dependent Variable: SOS 
 
 
 
Table 113: SOS vs. BMI Regression Residuals Statisticsa 
 Minimum Maximum Mean Std. Deviation N 
Predicted Value 1576.1742 1646.2664 1606.2116 16.19435 56 
Residual -86.09639 113.29971 .00000 49.83674 56 
Std. Predicted Value -1.855 2.473 .000 1.000 56 
Std. Residual -1.712 2.253 .000 .991 56 
a. Dependent Variable: SOS 
 
 
 
Regression Formula: SOS = 1462.720 + (5.940 x BMI) 
 
 
SOS vs. OC 
Figure 245-247: Scatterplots and histogram for SOS vs. OC regression 
 
Figure 245          Figure 246 
                      
 
Figure 247 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 114: SOS vs. OC Regression Model Summaryb 
Model R R Square Adjusted R 
Square 
Std. Error of the 
Estimate 
Durbin-Watson 
1 .395a .156 .140 2841.75515 1.875 
a. Predictors: (Constant), SOS 
b. Dependent Variable: Osteocalcin blood level in pg/mL 
 
 
 
Table 115: SOS vs. OC Regression ANOVAa 
Model Sum of Squares df Mean Square F Sig. 
1 
Regression 79215750.376 1 79215750.376 9.809 .003b 
Residual 428005332.719 53 8075572.315   
Total 507221083.095 54    
a. Dependent Variable: Osteocalcin blood level in pg/mL 
b. Predictors: (Constant), SOS 
 
 
 
Table 116: SOS vs. OC Regression Coefficientsa 
Model Unstandardized Coefficients Standardized 
Coefficients 
t Sig. 95.0% Confidence Interval 
for B 
B Std. Error Beta Lower Bound Upper Bound 
1 
(Constant) -33049.886 11766.023  -2.809 .007 -56649.539 -9450.232 
SOS 22.936 7.323 .395 3.132 .003 8.248 37.624 
a. Dependent Variable: Osteocalcin blood level in pg/mL 
 
 
 
Table 117: SOS vs. OC Regression Residuals Statisticsa 
 Minimum Maximum Mean Std. Deviation N 
Predicted Value 2040.8785 6510.6538 3781.5280 1211.18056 55 
Residual -4498.02734 6198.77295 .00000 2815.31964 55 
Std. Predicted Value -1.437 2.253 .000 1.000 55 
Std. Residual -1.583 2.181 .000 .991 55 
a. Dependent Variable: Osteocalcin blood level in pg/mL 
 
Regression Formula: Osteocalcin = -33049.886 + (22.936 x SOS) 
 
 
 
 
 
Time Spent Strength Training Per Year (minutes) vs. Stiff Bone 
Figure 248-250: Scatterplots and histogram for Strength Training Per Year (minutes) vs. Stiff Bone regression 
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Table 118: Strength Training vs. Stiff Bone Regression Model Summaryb 
Model R R Square Adjusted R 
Square 
Std. Error of the 
Estimate 
Durbin-Watson 
1 .241a .058 .041 22.85005 1.877 
a. Predictors: (Constant), Minutes strength training per year 
b. Dependent Variable: Stiff Bone 
 
 
 
Table 119: Strength Training vs. Stiff Bone Regression ANOVAa 
Model Sum of Squares df Mean Square F Sig. 
1 
Regression 1738.109 1 1738.109 3.329 .074b 
Residual 28194.748 54 522.125   
Total 29932.857 55    
a. Dependent Variable: Stiff Bone 
b. Predictors: (Constant), Minutes strength training per year 
 
 
 
Table 120: Strength Training vs. Stiff Bone Regression Coefficientsa 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 95.0% Confidence Interval 
for B 
B Std. Error Beta Lower 
Bound 
Upper 
Bound 
1 
(Constant) 110.161 3.993  27.586 .000 102.155 118.168 
Minutes strength 
training per year 
.001 .000 .241 1.825 .074 .000 .001 
a. Dependent Variable: Stiff Bone 
 
 
 
Table 121: Strength Training vs. Stiff Bone Regression Residuals Statisticsa 
 Minimum Maximum Mean Std. Deviation N 
Predicted Value 110.1613 134.1820 114.8571 5.62156 56 
Residual -45.61431 47.23556 .00000 22.64137 56 
Std. Predicted Value -.835 3.438 .000 1.000 56 
Std. Residual -1.996 2.067 .000 .991 56 
a. Dependent Variable: Stiff Bone 
 
 
Regression: Stiff Bone = 110.161 + (.001 x Strength Training Per Year in min) 
 
 
 
Time Spent Strength Training Per Year (minutes) vs. T-Score 
Figure 251-253: Scatterplots and histogram for Strength Training Per Year (minutes) vs. T-Score regression 
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Model Summaryb 
Model R R Square Adjusted R 
Square 
Std. Error of the 
Estimate 
Durbin-Watson 
1 .244a .060 .042 1.43632 1.946 
a. Predictors: (Constant), Minutes strength training per year 
b. Dependent Variable: T-Score 
 
 
 
ANOVAa 
Model Sum of Squares df Mean Square F Sig. 
1 
Regression 7.057 1 7.057 3.421 .070b 
Residual 111.403 54 2.063   
Total 118.461 55    
a. Dependent Variable: T-Score 
b. Predictors: (Constant), Minutes strength training per year 
 
 
 
Coefficientsa 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 95.0% Confidence Interval 
for B 
B Std. Error Beta Lower 
Bound 
Upper 
Bound 
1 
(Constant) .641 .251  2.556 .013 .138 1.145 
Minutes strength 
training per year 
3.543E-005 .000 .244 1.850 .070 .000 .000 
a. Dependent Variable: T-Score 
 
 
 
Residuals Statisticsa 
 Minimum Maximum Mean Std. Deviation N 
Predicted Value .6415 2.1721 .9407 .35820 56 
Residual -2.86152 2.92891 .00000 1.42321 56 
Std. Predicted Value -.835 3.438 .000 1.000 56 
Std. Residual -1.992 2.039 .000 .991 56 
a. Dependent Variable: T-Score 
 
 
Regression: T-Score = 0.641 + (3.543x10-005 x Strength Training Per Year in min) 
Appendix D: Statistical Treatment of Raw Hormone Data 
 
Table 1: Standard Curve Data for Hormones after Removing Invalid Points 
 Insulin Osteocalcin Leptin 
Standard 1 58.0314 137.1391 47.5085 
Standard 2 265.0761 659.4012 202.9828 
Standard 3 891.5635 2321.7309 727.3099 
Standard 4 4658.1411 9958.0248 4178.6856 
Standard 5 19584.7021 26019.3088 17311.2662 
Standard 6 143600.5500 X 56317.5531 
Standard 7 X X 189729.0757 
*Numbers in bold and red signify lower and upper detection limits. 
 
Table 2: Insulin Standard Curve with Invalid Points 
 
 
Table 3: Insulin Standard Curve with Invalid Points Removed 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Osteocalcin Standard Curve with Invalid Points 
 
 
Table 4: Osteocalcin Standard Curve with Invalid Points Removed 
 
 
Table 5: Leptin Standard Curve with Invalid Points 
 
 
Table 5: Leptin Standard Curve with Invalid Points Removed 
 
Osteoporosis and use 
of heel ultrasound
Kenneth G. Faulkner, Ph.D. • Chief Scientist, GE Healthcare†
GE Healthcare
Introduction 
Osteoporosis is a disease defined by low bone density. It is a “silent”
disease in that it often exists undiagnosed until a fracture occurs.
The best way to identify patients with osteoporosis before fractures
occur is through a bone density exam. In recent years, spine and
femur bone density measurements have gained acceptance as the
clinical “gold standard” by which physicians diagnosis osteoporosis,
evaluate fracture risk, and monitor skeletal changes. The most
commonly used clinical technique is dual-energy x-ray
absorptiometry (DXA), which is capable of measuring bone density 
at virtually any skeletal site. Yet despite the relative availability of
DXA systems, the recent report from the US Surgeon General
suggests the majority of individuals at risk for osteoporosis have 
not had a bone density test.1 While there are 20 million women
aged 65 and older in the United States, Medicare reimbursed for
only 2.6 million bone mineral density tests in 2002. Meanwhile, the
hospitalization rate for osteoporosis-associated vertebral fractures
for this demographic group, as reported for 2002 by Health People
2010, remains virtually unchanged since 1998 at 17.4 (age adjusted
per 10,000 standard population aged 65 years and older). Clearly,
use of DXA alone has not been sufficient to reduce the fracture rate
in this most vulnerable segment of the population. There are several
potential reasons for this phenomenon of under diagnosis, including
the cost of the BMD test, convenience (i.e. proximity to a DXA
system), as well as public and health care provider awareness. 
Fortunately, there are alternatives to DXA to aid physicians in
diagnosis of osteoporosis. The International Society for Clinical
Densitometry (ISCD) has confirmed that peripheral bone density
measurements have value for assessing fracture risk and identifying
patients who should be considered for a DXA measurement and/or
treatment.2 Of the available techniques for peripheral densitometry,
quantitative ultrasound (QUS) measurement of the heel (calcaneus)
is one of the best methods for assessing fracture risk in men and
postmenopausal women. QUS works by passing a high frequency
sound wave through the bone; the speed and attenuation of the
transmitted sound is directly related to the properties of the bone.
The primary advantage of QUS is the absence of ionizing radiation,
so that QUS measurements can be performed virtually anywhere
and by anyone (with minimal operator training). The heel is the
measurement site of choice for QUS, as it is easy to access, has
very little overlying soft tissue, and has a relatively uniform size 
and structure. Equally important, the heel is a highly trabecular,
weight-bearing site. QUS devices exist for measuring other skeletal
sites (such as the hand and forearm), but the evidence supporting
these measurements is not as strong as that available for the heel.
Today, the large majority of QUS systems installed around the world
measure the heel, due to the superior fracture prediction abilities 
of the calcaneus measurement.3
The use of heel ultrasound to aid
diagnosis of osteoporosis
As detailed above, heel QUS measurements have many advantages
for programs designed to increase public awareness, identify those
at a high risk of fracture, and determine which individuals should 
be referred for a DXA exam. However, a useful test must be both
sensitive and specific for detecting the desired clinical variable. A
sensitive test is one that correctly identifies all subjects at risk and
avoids “false negative” readings (a normal result in an individual
who is actually at high risk). However, sensitivity alone is not 
enough – the measurement must also be specific to be clinically
useful. For example, a test may be sensitive simply by identifying
everyone measured as having a high risk. This would be a sensitive
test in that it would capture all individuals at high risk (there would
be no false negatives), but the test is not efficient because it refers
all individuals to DXA including those who are actually at low risk.
Such a test does nothing to reduce the number of people identified
for additional follow-up. A specific test is one that minimizes “false
positives” by reducing the number of people classified as high risk
whose result is subsequently not confirmed. In practice, a useful
procedure attempts to balance sensitivity and specificity, though a
† Currently at Perceptive Informatics. Dr. Faulkner can be contacted at ken.faulkner@perceptive.com
highly sensitive test is usually preferred. In other words, it is better
when assessing a population to have a false positive reading than 
a false negative reading. While a false positive result may create
temporary anxiety for the patient until the diagnostic test is
completed, a false negative reading will result in a high-risk patient
being dismissed without any indication of their high-risk status.
In their 2001 position development conference, the ISCD recom-
mended that peripheral densitometry devices be used for testing 
and risk assessment rather than for the definitive diagnosis of
osteoporosis2. The strategy is to use the QUS T-score to classify
individuals as low risk (not likely to have osteoporosis), high risk 
(i.e. high likelihood of having osteoporosis and thus in need of a
central DXA for diagnosis) and a middle category of moderate 
risk where additional measurements (specifically DXA) should be
considered depending on other risk factors. Ideally, these risk
categories would coincide with existing T-score definitions proposed
by the World Health Organization for use with central DXA.
Specifically, T-scores of –1.0 or above would represent low risk, 
-2.5 and lower would represent high risk, and T-scores between 
–1.0 and –2.5 would indicate the moderate risk individuals. However,
published research has shown that not all peripheral densitometers
provide T-scores that are consistent with spine and femur DXA or
with each other.4 Figure 1 shows the large differences in T-scores
obtained from different peripheral systems compared to spine and
hip values. It is clear that not all peripheral densitometry systems
provide the same results, and that many devices yield T-scores
significantly different from those obtained at the spine and femur. 
Figure 1. Differences in T-scores Reported by Peripheral
Densitometers
Achilles* Testing Protocol
Because of differences in T-scores obtained from different peripheral
devices, the ISCD has recommended that specific T-scores using 
the 90% sensitivity criterion be obtained for each peripheral
densitometry device.2 Of all the peripheral devices on the market,
the Lunar Achilles QUS systems were designed specifically to give 
T-scores (using the Stiffness Index) that are closely aligned with the
DXA T-scores at the spine and hip. Furthermore, the Achilles InSight
provides a real-time ultrasound images of the heel to ensure the
measurement is performed at the correct region of the calcaneus.**
Multiple studies performed with the Lunar Achilles QUS system
confirm that 90% sensitivity for detecting osteoporosis at the spine
and hip can be obtained using an Achilles T-score referral threshold
of –0.8 to –1.2, which is centered on the WHO definition of low bone
(T-score of –1.0).5 Furthermore, these studies have shown that using
an Achilles T-score of –2.5 or lower provides excellent specificity
(greater than 90%) for identifying only those high risk subjects in
need of additional testing and/or treatment. Based on these
studies, individuals with Achilles T-scores above –1.0 should be
considered at low risk for having osteoporosis and, depending on
the presence of additional risk factors, asked to return for a repeat
measurement at some future point. Those with an Achilles T-score
of –2.5 or lower should be considered at a higher fracture risk
based on the peripheral measurement alone, although other risk
factors should be considered as well. For those individuals with an
“intermediate” Achilles T-score between –1.0 and –2.5, a central
DXA test should be recommended to determine the spine and hip
bone density. The decision of whether or not to refer for a central
DXA should include other factors including the individual’s age and
additional risk factors such as those recommended by the National
Osteoporosis Foundation (Table 1).6 Even in individuals where a
treatment decision is made based on the peripheral measurement
and risk factors, a central DXA measurement may be recommended
to monitor therapeutic response. This QUS protocol is outlined in
Figure 2.
Figure 2. QUS Testing Protocol
Differences in peripheral densitometers
**image not for diagnosis.
The National Osteoporosis Foundation recommends BMD testing for
all Caucasian women aged 65 and older regardless of risk factors.6
In addition, the NOF recommends that younger postmenopausal
Caucasian women with more than one risk factors (as shown in
Table 1) have a bone density test. In their 2001 position development
conference, the ISCD expanded on the NOF recommendation to
include all women 65 and older regardless of race.7 More recently,
the US Preventive Services Task Force also recommended that
women aged 65 and older be tested routinely for osteoporosis and
that women at high risk for fractures begin testing at age 60.8
Finally, experts agree that postmenopausal women of all races who
present with fractures are at high risk for subsequent fractures and
should have a bone density test.7,8
For men, no professional organization has published consensus
guidelines for osteoporosis testing, although several experts in the
field have made recommendations.7,9,10 As with women, men
presenting with a history of low trauma fracture are at risk for
subsequent fracture and should be considered for additional 
testing and/or treatment. Men with any of the risk factors shown 
in Table 2 are also at a high risk for fracture and should be tested
for osteoporosis. Finally, it has also been suggested that physicians
consider routinely testing men aged 70 and older, as this is the age
when fracture rates increase most rapidly.7,9,10
Table 2: Major Risk Factors for Osteoporosis in Men
History of low-traumatic fracture (hip, vertebrae, or wrist)
Osteopenia seen on plain radiograph
Glucocorticoid use of 5 mg or more per day for longer 
than six months
Hypogonadism (glucocorticoid-induced or following orchiectomy)
Hyperparathyroidism
In summary, osteoporosis testing should be considered 
for the following individuals:
1) All women aged 65 years and older.
2) Postmenopausal Caucasian women under 65 with 
1 or more risk factors (Table 1).
3) All men aged 70 years and older.
4) Men under 70 with one or more risk factors (Table 2).
5) Men and women with personal history of low trauma fracture.
Conclusions 
Experts agree that spine and hip DXA is the gold standard for the
diagnosis of osteoporosis. According to recommendations from
several professional societies, women 65 and older and men 70 
and older, as well as younger men and women with additional risk
factors for osteoporosis, should have their bone density measured.
However, despite the availability of DXA systems in most cities, a
large number of high-risk individuals are still not getting bone
density tests. The US Surgeon General’s Report on Osteoporosis
highlights the need for additional measures to stem the tide of a
growing osteoporosis epidemic. Accessibility to DXA devices, as 
well as poor public awareness, are major contributors this dilemma.
Experts have agreed that peripheral densitometry measurements
can be used for identifying high-risk individuals when appropriate
criteria are used. Of all the available techniques for peripheral
testing, heel ultrasound has significant advantages over other
peripheral devices, as it is easy to use, is an excellent predictor of
hip and spine fracture, and avoids the use of ionizing radiation. The
Lunar Achilles offers the additional advantages of rapid assessment
(10 seconds or less), T-scores that are aligned with WHO guidelines
for spine and femur measurements, and (in the case of the Achilles
InSight) a real-time image of the heel for confident positioning. To
aid in the diagnosis of osteoporosis, use of Achilles T-scores
corresponding to the WHO classifications identifies moderate and
high-risk individuals in need of additional testing with DXA. 
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Table 1: Major Risk Factors for Osteoporosis 
in Caucasian Women 
Personal history of low-trauma fracture as an adult
History of fragility fracture in a first-degree relative
Low body weight (< about 127 lbs)
Current smoking
Use of oral corticosteroid therapy for more than 3 months
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FOR RESEARCH USE ONLY.  NOT FOR USE IN DIAGNOSTIC PROCEDURES. 
 
By purchasing this product, which contains fluorescently labeled microsphere beads authorized by 
Luminex Corporation (“Luminex”), you, the customer, acquire the right under Luminex’s patent rights, 
if any, to use this product or any portion of this product, including without limitation the microsphere 
beads contained herein, only with Luminex’s laser based fluorescent analytical test instrumentation 
marketed under the name of Luminex 100® IS, 200TM, HTS, FLEXMAP 3DTM,MAGPIX®. 
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Human Bone Magnetic Bead Panel 
 
INTRODUCTION 
 
Bone metabolism is the dynamic process of ongoing bone deposition and resorption, 
controlled by osteoblasts, osteocytes, and osteoclasts.  While osteoblasts and osteocytes 
(osteoblasts surrounded by matrix) are responsible for bone deposition, osteoclasts are 
responsible for bone resorption.  Both are required to maintain bone structure, as well as an 
adequate supply of calcium.  To maintain this metabolic balance these cells rely on complex 
signaling pathways involving hormones and cytokines to achieve the appropriate rates of 
growth and differentiation.  The disruption of bone metabolism results in such disease as 
osteoporosis, osteoarthritis, rheumatoid arthritis, chronic kidney disease and bone 
metastases. 
 
EMD Millipore recognizes the need to understand better the role that bone metabolism 
biomarkers play both in preserving normal bone structure and in the development of disease.  
Magnetic Beads can make the process of automation and high throughput screening easier with 
features such as walk-away washing.  Advantages even outside automation include:  
 More flexible plate and plate washer options 
 Improved performance with turbid serum/plasma samples  
 Assay results equivalent to non-magnetic beads 
 Automated washing eliminates technical obstacles (i.e., clogging of wells that contain viscous 
samples) which may result during vacuum manifold/manual washing 
Therefore, the MILLIPLEX® MAP Human Bone Magnetic Bead panel enables you to focus on the 
therapeutic potential of bone metabolism.  Coupled with the Luminex xMAP® platform in a magnetic 
bead format, you receive the advantage of ideal speed and sensitivity, allowing quantitative multiplex 
detection of dozens of analytes simultaneously, which can dramatically improve productivity. 
 
EMD Millipore’s MILLIPLEX HUMAN BONE Magnetic Bead panel is the most versatile system available 
for bone metabolism research. 
 MILLIPLEX MAP offers you the ability to: 
o Select a 13 plex or 
o Choose any combination of analytes from our panel of 13 analytes to design a custom 
kit that better meets your needs. 
 A convenient “all-in-one” box format gives you the assurance that you will have all the 
necessary reagents you need to run your assay. 
 
EMD Millipore’s MILLIPLEX MAP Human Bone Magnetic Bead kit is to be used for the 
simultaneous quantification from the following ACTH, DKK1, IL-6, Insulin, Leptin, TNFOPG, OC, 
OPN, SOST, IL-1PTH and FGF23.  
 
For Research Use Only. Not for Use in Diagnostic Procedures.  
Please read entire protocol before use. 
It is important to use same assay incubation conditions throughout your study. 
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PRINCIPLE 
MILLIPLEX MAP is based on the Luminex® xMAP® technology — one of the fastest growing 
and most respected multiplex technologies offering applications throughout the life-sciences 
and capable of performing a variety of bioassays including immunoassays on the surface of 
fluorescent-coded magnetic beads known as MagPlexTM-C microspheres.  
 
 Luminex® uses proprietary techniques to internally color-code microspheres with two 
fluorescent dyes.  Through precise concentrations of these dyes, 100 distinctly colored 
bead sets can be created, each of which is coated with a specific capture antibody. 
 After an analyte from a test sample is captured by the bead, a biotinylated detection 
antibody is introduced. 
 The reaction mixture is then incubated with Streptavidin-PE conjugate, the reporter 
molecule, to complete the reaction on the surface of each microsphere. 
 The microspheres are allowed to pass rapidly through a laser which excites the 
internal dyes marking the microsphere set.  A second laser excites PE, the fluorescent 
dye on the reporter molecule. 
 Finally, high-speed digital-signal processors identify each individual microsphere and 
quantify the result of its bioassay based on fluorescent reporter signals. 
 
The capability of adding multiple conjugated beads to each sample results in the ability to 
obtain multiple results from each sample.  Open-architecture xMAP® technology enables 
multiplexing of many types of bioassays reducing time, labor and costs over traditional 
methods. 
 
 
STORAGE CONDITIONS UPON RECEIPT 
 Recommended storage for kit components is 2 - 8°C. 
 For long-term storage, freeze reconstituted standards and controls at  -20°C.  Avoid 
multiple (>2) freeze/thaw cycles. 
 DO NOT FREEZE Antibody-Immobilized Beads, Detection Antibody, and 
Streptavidin-Phycoerythrin. 
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REAGENTS SUPPLIED 
 
Note:  Store all reagents at 2 – 8 °C 
Reagents Supplied Catalog Number Volume Quantity 
Human Bone Standard HBN-8051 Lyophilized 1 vial 
Human Bone Quality Controls 1 and 2 HBN-6051 Lyophilized 2 vials 
Serum Matrix 
Note: Contains 0.08% Sodium Azide 
LHED-SD Lyophilized 1 vial 
Bead Diluent LBNBD 3.5 mL 1 bottle 
Set of one 96-Well Plate with 2 sealers ----------- ----------- 1 plate 2 sealers 
Assay Buffer L-AB1 30 mL 2 bottles 
10X Wash Buffer 
Note: Contains 0.05% Proclin 
L-WB 30 mL 2 bottles 
Human Bone Detection Antibodies HBN-1051 5.5 mL 1 bottle 
Streptavidin-Phycoerythrin L-SAPE 5.5 mL 1 bottle 
Mixing Bottle  
(not provided with premixed panel) ----------- ----------- 1 bottle 
 
 
Included Human Bone Antibody-Immobilized Beads are dependent on customizable 
selection of analytes within the panel (see next page). 
Human Bone Antibody-Immobilized Magnetic Beads: 
 
Bead/Analyte Name 
Luminex 
Bead 
Region 
Customizable 13 Analytes 
(20X concentration, 200 µL) 
 Available               Cat. # 
Anti-ACTH Beads 12 ✔ HACTH-MAG 
Anti-DKK1 Beads 29 ✔ HDKK1-MAG 
Anti-IL6 Beads 34 ✔ HIL6-MAG 
Anti-Insulin Beads 36 ✔ HINS-MAG 
Anti-Leptin Beads 39 ✔ HLPTN-MAG 
Anti-TNFα Beads 55 ✔ HTNFA-MAG 
Anti-OPG Beads 61 ✔ H0PG-MAG 
Anti-OC Beads 63 ✔ H0C-MAG 
Anti-OPN Beads 64 ✔ H0PN-MAG 
Anti-SOST Beads 67 ✔ HS0ST-MAG 
Anti- IL-1β  Beads 72 ✔ HIL1B-MAG 
Anti- PTH Beads 74 ✔ HPTH-MAG 
Anti- FGF-23  Beads 77 ✔ HFGF23-MAG 
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MATERIALS REQUIRED BUT NOT PROVIDED 
 
Reagents 
1. Luminex Sheath Fluid (Luminex Catalog #40-50000) or Luminex Drive Fluid (Luminex 
Catalog # MPXDF-4PK) 
 
Instrumentation / Materials  
1. Adjustable Pipettes with Tips capable of delivering 25 μL to 1000 μL 
2. Multichannel Pipettes capable of delivering 5 μL to 50 μL or 25 μL to 200 μL 
3. Reagent Reservoirs 
4. Polypropylene Microfuge Tubes 
5. Rubber Bands 
6. Aluminum Foil 
7. Absorbent Pads 
8. Laboratory Vortex Mixer 
9. Sonicator (Branson Ultrasonic Cleaner Model #B200 or equivalent) 
10. Titer Plate Shaker (Lab-Line Instruments Model #4625 or equivalent) 
11. Luminex 200™, HTS, FLEXMAP 3D™, or MAGPIX® with xPONENT software by 
Luminex Corporation  
12. Automatic Plate washer for magnetic beads (Bio-Tek ELx405, EMD Millipore Catalog 
#40-015 or equivalent) or Hand-held Magnetic Separation Block (EMD Millipore 
Catalog #40-285 or equivalent) 
   
Note: If a plate washer or hand held magnetic separation block for magnetic beads is not 
available, one can use a microtiter filter plate (EMD Millipore Catalog #MX-PLATE) to run 
the assay using a Vacuum Filtration Unit (EMD Millipore Vacuum Manifold Catalog 
#MSVMHTS00 or equivalent with EMD Millipore Vacuum Pump Catalog #WP6111560 or 
equivalent). 
 
 
SAFETY PRECAUTIONS 
 All blood components and biological materials should be handled as potentially 
hazardous.  Follow universal precautions as established by the Centers for Disease 
Control and Prevention and by the Occupational Safety and Health Administration 
when handling and disposing of infectious agents. 
 Sodium Azide or Proclin has been added to some reagents as a preservative.  
Although the concentrations are low, Sodium Azide and Proclin may react with lead 
and copper plumbing to form highly explosive metal azides.  Dispose of unused 
contents and waste in accordance with international, federal, state, and local 
regulations. 
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TECHNICAL GUIDELINES 
To obtain reliable and reproducible results, the operator should carefully read this entire 
manual and fully understand all aspects of each assay step before running the assay.  The 
following notes should be reviewed and understood before the assay is set up. 
 FOR RESEARCH USE ONLY.  NOT FOR USE IN DIAGNOSTIC PROCEDURES. 
 Do not use beyond the expiration date on the label. 
 Do not mix or substitute reagents with those from other lots or sources. 
 The Antibody-Immobilized Beads are light sensitive and must be protected from light 
at all times.  Cover the assay plate containing beads with opaque plate lid or aluminum 
foil during all incubation steps. 
 It is important to allow all reagents to warm to room temperature (20-25°C) before use 
in the assay. 
 Incomplete washing can adversely affect the assay outcome.  All washing must be 
performed with the Wash Buffer provided.   
 The standards prepared by serial dilution must be used within 1 hour of preparation.  
Discard any unused standards except the standard stock which may be stored at       
-20°C for 1 month and at  -80°C for greater than one month. 
 If samples fall outside the dynamic range of the assay, further dilute the samples with 
the appropriate diluent and repeat the assay. 
 Any unused mixed Antibody-Immobilized Beads may be stored in the Mixing Bottle at 
2-8°C for up to one month. 
 During the preparation of the standard curve, make certain to mix the higher 
concentration well before making the next dilution.  Use a new tip with each dilution. 
 The plate should be read immediately after the assay is finished.  If, however, the plate 
cannot be read immediately, seal the plate, cover with aluminum foil or an opaque lid, 
and store the plate at 2-8°C for up to 24 hours.  Prior to reading, agitate the plate on 
the plate shaker at room temperature for 10 minutes.  Delay in reading a plate may 
result in decreased sensitivity for some analytes. 
 The titer plate shaker should be set at a speed to provide maximum orbital mixing 
without splashing of liquid outside the wells.  For the recommended plate shaker, this 
would be a setting of 5-7 which is approximately 500-800 rpm. 
 Ensure that the needle probe is clean.  This may be achieved by sonication and/or 
alcohol flushes.   
 When reading the assay on Luminex 200™, adjust probe height according to the 
protocols recommended by Luminex to the kit solid plate using 4 alignment discs.  
When reading the assay on FLEXMAP 3D™, adjust probe height according to the 
protocols recommended by Luminex to the kit solid plate using 1 alignment disc.  
When reading the assay on MAGPIX, adjust probe height according to the protocols 
recommended by Luminex to the kit solid plate using 2 alignment discs. 
 For cell culture supernatants or tissue extraction, use the culture or extraction medium 
as the matrix solution in background, standard curve and control wells.  If samples are 
diluted in assay buffer, use the assay buffer as matrix. 
 For serum/plasma samples that require further dilution beyond 1:2, use the assay 
buffer provided in the kit. 
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 For cell/tissue homogenate, the final cell or tissue homogenate should be prepared in 
a buffer that has a neutral pH, contains minimal detergents or strong denaturing 
detergents, and has an ionic strength close to physiological concentration.  Avoid 
debris, lipids, and cell/tissue aggregates.  Centrifuge samples before use. 
 Vortex all reagents well before adding to plate. 
 
 
SAMPLE COLLECTION AND STORAGE 
A. Preparation of Serum Samples: 
 Allow the blood to clot for at least 30 minutes before centrifugation for 10 
minutes at 1000xg.  Remove serum and assay immediately or aliquot and store 
samples at  -20°C.   
 Osteocalcin is sensitive to freeze/thaw cycles.  Avoid multiple (>2) freeze/thaw 
cycles.  
 When using frozen samples, it is recommended to thaw the samples completely, 
mix well by vortexing and centrifuge prior to use in the assay to remove 
particulates.   
 Serum samples should be diluted 1:2 in the assay buffer provided in the kit. For 
example, in a tube, 35 µL of serum may be combined with 35 µL of Assay 
Buffer.   When further dilution beyond 1:2 is required, use assay buffer as the 
diluent.   
 
B. Preparation of Plasma Samples: 
 Plasma collection using EDTA as an anti-coagulant is recommended.  
Centrifuge for 10 minutes at 1000xg within 30 minutes of blood collection.  
Remove plasma and assay immediately or aliquot and store samples at  -20°C.   
 Osteocalcin is sensitive to freeze/thaw cycles.  Avoid multiple (>2) freeze/thaw 
cycles.   
 When using frozen samples, it is recommended to thaw the samples completely, 
mix well by vortexing and centrifuge prior to use in the assay to remove 
particulates.   
 Plasma samples should be diluted 1:2 in the assay buffer provided in the kit. For 
example, in a tube, 35 µL of serum may be combined with 35 µL of Assay 
Buffer.   When further dilution beyond 1:2 is required, use assay buffer as the 
diluent.   
 
C. Preparation of Tissue Culture Supernatant: 
 Centrifuge the sample to remove debris and assay immediately or aliquot and 
store samples at  -20°C.  
 Avoid multiple (>2) freeze/thaw cycles.   
 Tissue culture supernatant may require a dilution with an appropriate control 
medium prior to assay.  Tissue/cell extracts should be done in neutral buffers 
containing reagents and conditions that do not interfere with assay performance.  
Excess concentrations of detergent, salt, denaturants, high or low pH, etc. will 
negatively affect the assay.  Organic solvents should be avoided.  The tissue/cell 
extract samples should be free of particles such as cells or tissue debris. 
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SAMPLE COLLECTION AND STORAGE (continued) 
NOTE: 
 A maximum of 25 μL per well of 1:2 freshly diluted serum or plasma can be used.  
Tissue culture or other media may also be used. 
 All samples must be stored in polypropylene tubes.  DO NOT STORE SAMPLES IN 
GLASS. 
 Avoid debris, lipids and cells when using samples with gross hemolysis or lipemia. 
 Care must be taken when using heparin as an anticoagulant since an excess of 
heparin will provide falsely high values.  Use no more than 10 IU heparin per mL of 
blood collected. 
 
PREPARATION OF REAGENTS FOR IMMUNOASSAY 
A. Preparation of Antibody-Immobilized Beads 
For individual vials of beads, sonicate each antibody-bead vial for 30 seconds; vortex 
for 1 minute.  Add 150 µL from each antibody-bead vial to the Mixing Bottle and bring 
final volume to 3.0 mL with Bead Diluent.  Vortex the mixed beads well.  Unused 
portion may be stored at 2-8°C for up to one month. (Note: Due to the composition of 
magnetic beads, you may notice a slight color in the bead solution. This does not 
affect the performance of the beads or the kit.) 
Example 1: When using 3 antibody-immobilized beads, add 150 µL from each of the 
3 bead sets to the Mixing Bottle.  Then add 2.55 mL Bead Diluent. 
Example 2: When using 4 antibody-immobilized beads, add 150 µL from each of the 
4 bead sets to the Mixing Bottle.  Then add 2.40 mL Bead Diluent. 
 
B. Preparation of Quality Controls 
Before use, reconstitute Quality Control 1 and Quality Control 2 with 250 µL deionized 
water.  Invert the vial several times to mix and vortex.  Allow the vial to sit for 5-10 
minutes.  Unused portion may be stored at  -20°C for up to one month. 
C. Preparation of Wash Buffer 
Bring the 10X Wash Buffer to room temperature and mix to bring all salts into solution.  
Dilute 60 mL of 10X Wash Buffer (two bottles) with 540 mL deionized water.  Store 
unused portion at 2-8C for up to one month. 
D.  Preparation of Serum Matrix 
This step is required for serum or plasma samples only. 
Add 1.0 mL of Deionized Water and 1.0 mL of Assay Buffer to the bottle containing 
lyophilized Serum Matrix.  Mix well.  Allow at least 10 minutes for complete 
reconstitution.  Leftover reconstituted Serum Matrix should be stored at  -20C for up 
to one month. 
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E.  Preparation of Human Bone Standard   
1.) Prior to use, reconstitute the Human Bone Standard with 250 µL deionized water 
to give a concentration described in the table below. Invert the vial several times 
to mix.  Vortex the vial for 10 seconds.  Allow the vial to sit for 5-10 minutes.  This 
will be used as the Standard 7; the unused portion may be stored at  -20C for 
up to one month. 
2). Preparation of Working Standards 
Label six polypropylene microfuge tubes as Standard 6, Standard 5, Standard 4, 
Standard 3, Standard 2 and Standard 1.  Add 150 µL of Assay Buffer to each of the 
six tubes.  Prepare 1:4 serial dilutions by adding 50 µL of the reconstituted Standard 
7 to the Standard 6 tube, mix well and transfer 50 µL of the Standard 6 to the 
Standard 5 tube, mix well and transfer 50 µL of the Standard 5 to the Standard 4 
tube, mix well and transfer 50 µL of the Standard 4 to the Standard 3 tube, mix well 
and transfer 50 µL of the Standard 3 to the Standard 2 tube, mix well and transfer 
50 µL of the Standard 2 to the Standard 1 tube.  The 0 Standard (Background) will 
be the Assay Buffer. 
 
Standard 
 
Volume of Deionized 
Water to Add 
Volume of Standard 
to Add 
Standard 7 250 µL 0 
 
Standard Tube 
Number 
Volume of Assay 
Buffer to Add 
Volume of Standard 
to Add 
Standard 6 150 µL 50 µL of Standard 7 
Standard 5 150 µL 50 µL of Standard 6 
Standard 4 150 µL 50 µL of Standard 5 
Standard 3 150 µL 50 µL of Standard 4 
Standard 2 150 µL 50 µL of Standard 3 
Standard 1 150 µL 50 µL of Standard 2 
 
Preparation of Standards 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
50 µL 
150 µL 
50 µL50 µL50 µL50 µL 50 µL 
   Stock 150 µL 150 µL 150 µL 150 µL 150 µL 
Reconstituted 
  Standard  7 
Standard 6 Standard 5 Standard 4 Standard 3 Standard 2 Standard 1 
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After dilution, each tube has the following concentrations for each analyte: 
 
 
 
 
 
 
 
 
 
 
Standard 
 
ACTH & 
IL6 
(pg/mL) 
DKK1 & 
PTH 
(pg/mL)
Insulin 
(pg/mL)
Leptin 
(pg/mL) 
TNF
(pg/mL)
OPG 
(pg/mL)
Standard 1 1 5 61 49 0.24 7 
Standard 2 6 20 244 195 0.98 29 
Standard 3 23 78 977 781 4 117 
Standard 4 94 313 3,906 3,125 16 469 
Standard 5 375 1,250 15,625 12,500 63 1,875 
Standard 6 1,500 5,000 62,500 50,000 250 7,500 
Standard 7 6,000 20,000 250,000 200,000 1,000 30,000 
 
 
 
Standard 
 
OC 
(pg/mL) 
OPN 
(pg/mL)
SOST 
(pg/mL)
IL-1
(pg/mL) 
FGF23
(pg/mL) 
Standard 1 146 98 24 1 37 
Standard 2 586 391 98 3 146 
Standard 3 2,344 1,563 391 12 585 
Standard 4 9,375 6,250 1,563 47 2,343 
Standard 5 37,500 25,000 6,250 188 9,375 
Standard 6 150,000 100,000 25,000 750 37,500 
Standard 7 600,000 400,000 100,000 3,000 150,000 
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IMMUNOASSAY PROCEDURE 
 Prior to beginning this assay, it is imperative to read this protocol completely and to 
thoroughly understand the Technical Guidelines. 
 Allow all reagents to warm to room temperature (20-25C) before use in the assay. 
 Diagram the placement of Standards [Std 0 (Background), Standard 1, Standard 2,  
Standard 3, Standard 4, Standard 5, Standard 6, Standard 7] Controls 1 and 2, and 
Samples on Well Map Worksheet in a vertical configuration.  (Note: Most instruments 
will only read the 96-well plate vertically by default.)  It is recommended to run the assay 
in duplicate. 
 If using a filter plate, set the filter plate on a plate holder at all times during reagent 
dispensing and incubation steps so that the bottom of the plate does not touch any 
surface. 
 
1. Add 200 µL of Assay Buffer into each well of 
the plate.  Seal and mix on a plate shaker for 10 
minutes at room temperature (20-25C).   
2. Decant Assay Buffer and remove the residual 
amount from all wells by inverting the plate and 
tapping it smartly onto absorbent towels several 
times.  
3. Add 25 µL of each Standard or Control into the 
appropriate wells.  Assay Buffer should be used 
for 0 standard (Background). 
4. Add 25 µL of Assay Buffer to the sample wells. 
5. Add 25 µL of appropriate matrix solution to the 
background, standards, and control wells.  
When assaying serum or plasma, use the 
Serum Matrix provided in the kit as the matrix 
solution.  When assaying tissue culture or other 
supernatant, use proper control culture medium 
as the matrix solution. 
6. Add 25 µL of Sample (1:2 diluted) into the 
appropriate wells. 
7. Vortex Mixing Bottle and add 25 μL of the Mixed 
or Premixed Beads to each well.  (Note: During 
addition of Beads, shake bead bottle 
intermittently to avoid settling.) 
8. Seal the plate with a plate sealer.  Wrap the 
plate with foil and incubate with agitation on a 
plate shaker overnight (16–18 hours) at 4C or 
incubate with agitation on a plate shaker 2 
hours at RT (20-25C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Add 200 µL Assay Buffer 
per well 
 Add 25 µL Standard or 
Control to appropriate wells 
 Add 25 µL of Assay Buffer 
to background and sample 
wells 
 Add 25 µL appropriate 
matrix solution to 
background, standards, and 
control wells 
 Add 25 µL (1:2 diluted) 
Samples to sample wells 
 Add 25 µL Beads to each 
well 
Shake 10 min, RT 
 
Decant 
Incubate overnight 
(16-18 hours) at 4C 
or incubate 2 hours 
at RT 
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9. Gently remove well contents and wash plate 3 
times following instructions listed in the PLATE 
WASHING section.  
10. Add 50 µL of Detection Antibodies into each 
well.  (Note: Allow the Detection Antibodies to 
warm to room temperature prior to addition.) 
11. Seal, cover with foil and incubate with agitation 
on a plate shaker for 30 minutes at room 
temperature (20-25C).  DO NOT ASPIRATE 
AFTER INCUBATION. 
12. Add 50 µL Streptavidin-Phycoerythrin to each 
well containing the 50 µL of Detection 
Antibodies.  
13. Seal, cover with foil and incubate with agitation 
on a plate shaker for 30 minutes at room 
temperature (20-25C). 
14. Gently remove well contents and wash plate 3 
times following instructions listed in the PLATE 
WASHING section. 
15. Add 100 µL of Sheath Fluid (or Drive Fluid if 
using MAGPIX®) to all wells.  Resuspend the 
beads on a plate shaker for 5 minutes. 
16. Run plate on Luminex 200TM, HTS, FLEXMAP 
3DTM  or MAGPIX® with xPONENT software.   
17. Save and analyze the Median Fluorescent 
Intensity (MFI) data using a 5-parameter logistic 
or spline curve-fitting method for calculating 
analyte concentrations in samples.  Note: For 
diluted samples, multiply the calculated 
concentration by the dilution factor.) 
 
 
 
 
 
Remove well contents and 
wash 3X with 200 µL Wash 
Buffer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Add 50 µL Detection 
Antibodies per well 
Incubate for 30 
minutes at RT 
 
Do Not Aspirate 
Add 50 µL Streptavidin-
Phycoerythrin per well 
Incubate for 30 
minutes at RT 
Add 100 µL Sheath Fluid or 
Drive Fluid per well 
Read on Luminex 50 µL, 50 
beads per bead set) 
Remove well 
contents and wash 
3X with 200 µL 
Wash Buffer 
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PLATE WASHING 
1.) Solid Plate 
If using a solid plate, use either a hand-held magnet or magnetic plate washer. 
A.) For hand-held magnet, rest plate on magnet for 60 seconds to allow complete 
settling of magnetic beads.  Remove well contents by gently decanting the plate 
in an appropriate waste receptacle and gently tapping on absorbent pads to 
remove residual liquid.  Wash plate with 200 uL of Wash Buffer by removing 
plate from magnet, adding Wash Buffer, shaking for 30 seconds, reattaching to 
magnet, letting beads settle for 60 seconds and removing well contents as 
previously described after each wash.  Repeat wash steps as recommended in 
Assay Procedure. 
B.) For magnetic plate washer, let plate “soak” on magnet for 60 seconds to allow 
complete settling of the magnetic beads.  Remove well contents by aspiration.  
Wash plate with 200 µL/well of Wash Buffer, letting beads “soak” for 60 
seconds and removing Wash Buffer by aspiration after each wash. Repeat 
wash steps as recommended in Assay Procedure.  Note: If using the 
recommended plate washer for magnetic beads (Bio-Tek ELx405) follow the 
appropriate equipment settings outlined in EQUIPMENT SETTINGS. 
 
2.) Filter Plate (EMD Millipore Cat #MX-PLATE) 
If using a filter plate, use a vacuum filtration manifold to remove well contents.  
Wash plate with 200 µL/well of Wash Buffer, removing Wash Buffer by vacuum 
filtration after each wash.  Repeat wash steps as recommended in the Assay 
Procedure. 
 
 
EQUIPMENT SETTINGS 
Bio-Tek ELx405: 
The general recommended wash protocol (Link Protocol) is as follows: 
 
Soak Program:     Wash Program:      
Soak  →            Aspirate→Dispense→Soak→Aspirate→Dispense→Soak→Aspirate 
 
1.) Soak program: 
1. Soak duration: 60 sec  
2. Shake before soak?: NO 
 
2.) Wash program: 
Method: 
1. Number of cycles: 3 
2. Soak/shake: YES 
3. Soak duration: 60 sec 
4. Shake before soak: NO 
5. Prime after soak: NO 
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EQUIPMENT SETTINGS (continued) 
Dispense: 
1. Dispense volume: 200 µL/well 
2. Dispense flow rate: 5 
3. Dispense height: 130 (16.51 mm) 
4. Horizontal disp pos: 00 (0 mm) 
5. Disable Aspirate:  YES 
6. Bottom Wash first?: NO 
7. Prime before start?: NO 
Aspiration: 
1. Aspirate height: 35  (4.445 mm) 
2. Horizontal Asp Pos: 30 (1.372 mm) 
3. Aspiration rate: 06 (15.0 mm/sec) 
4. Aspiration delay: 0 
5. Crosswise Aspir: NO 
6. Final Aspir: YES 
7. Final Aspir delay: 0 (0 msec) 
 
3.) Link program: (Note: this is the program to use during actual plate washing). 
Link together the Soak and Wash programs outlined above.  
 
Note:  After the final aspiration, there will be approximately 25 μL of residual 
Wash Buffer in each well.  This is expected when using the BioTek Plate washer 
and this volume does not need to be aspirated from the plate. 
 
If using an automatic plate washer other than BioTek ELx405, please refer to the 
manufacturer’s recommendations for programming instructions. 
 
 
Luminex 200™, HTS, FLEXMAP 3D™ and MAGPIX® with xPONENT software: 
 
These specifications are for the Luminex 200™, Luminex HTS, Luminex FLEXMAP 
3D™ and Luminex MAGPIX®with xPonent software.  Luminex instruments with other 
software (e.g. MasterPlex, StarStation, LiquiChip, Bio-Plex, LABScan100) would need 
to follow instrument instructions for gate settings and additional specifications from the 
vendors for reading Luminex Magnetic Beads. 
 
For magnetic bead assays, the Luminex 200™ and HTS instruments must be 
calibrated with the xPonent 3.1 compatible Calibration Kit (EMD Millipore Cat #40-275) 
and performance verified with the Performance Verification Kit (EMD Millipore Cat 
#40-276).  The Luminex FLEXMAP 3D™ instrument must be calibrated with the 
FLEXMAP 3D™ Calibrator Kit (EMD Millipore Cat #40-028) and performance verified 
with the FLEXMAP 3D™ Performance Verification Kit (EMD Millipore Cat #40-029).  
The Luminex MAGPIX® instrument must be calibrated with the MAGPIX® Calibration 
Kit (EMD Millipore Cat #40-049) and performance verified with the MAGPIX® 
Performance Verification Kit (EMD Millipore Cat #40-050). 
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NOTE: These assays cannot be run on any instruments using Luminex IS 2.3 or 
Luminex 1.7 software. 
 
The Luminex probe height must be adjusted to the plate provided in the kit.   Please 
use Cat #MAG-PLATE, if additional plates are required for this purpose. 
 
Events: 50, per bead 
Sample Size: 50 µL 
Gate Settings: 8,000 to 15,000 
Reporter Gain: Default (low PMT) 
Time Out: 60 seconds 
Bead Set: Customizable 13-Plex Beads
  
  
ACTH 12
DKK1 29
IL6 34
Insulin 36
Leptin 39
TNFα 55
OPG 61
OC 63
OPN 64
SOST 67
IL-1 β 72
PTH 74
FGF23 77
 
QUALITY CONTROLS 
The ranges for each analyte in Quality Control 1 and 2 are provided on the card insert 
or can be located at the EMD Millipore Corporation website 
www.millipore.com/techlibrary/index.do using the catalog number as the keyword. 
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ASSAY CHARACTERISTICS 
Cross-Reactivity 
There was no or negligible cross-reactivity between the antibodies for an analyte and 
any of the other analytes in this panel.  
 
Assay Sensitivities (minimum detectable concentrations, pg/mL) 
Minimum Detectable Concentration (MinDC) is calculated using the Milliplex Analyst.  It 
measures the true limits of detection for an assay by mathematically determining what 
the empirical MinDC would be if an infinite number of standard concentrations were run 
for the assay under the same conditions. 
 
Analyte 
Overnight Protocol (n = 8)  2 Hour Protocol (n = 4) 
MinDC 
(pg/ml) 
MinDC+2SD 
(pg/ml) 
MinDC 
(pg/ml) 
MinDC+2SD 
(pg/ml) 
ACTH 0.7 2.2 2.2 7.3 
DKK1 1.4 3.1 1.2 2.3 
IL6 1.4 2.9 2.1 3.4 
Insulin 25.9 51.9 18.7 36.7 
Leptin 7.3 16.4 3.5 5.5 
TNF 0.4 0.7 0.4 0.8 
OPG 1.9 4.1 1.8 2.7 
OC 68.5 114.7 37.5 77.3 
OPN 37.7 89.5 15.6 34.1 
SOST 31.1 67 33 82.4 
IL-1 0.6 1.9 0.7 1.6 
PTH 1.8 3.4 1.6 4.5 
FGF23 9.2 22.7 7.7 17.6 
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Precision 
Intra-assay precision is generated from the mean of the %CV’s from 8 reportable results 
across two different concentrations of analytes in a single assay.  Inter-assay precision 
is generated from the mean of the %CV’s across two different concentrations of 
analytes across 6 different assays. 
 
 
Analyte 
Overnight Protocol 2 Hour Protocol 
Intra-assay %CV Inter-assay %CV Intra-assay %CV 
ACTH 8 12 7 
DKK1 7 8 6 
IL6 7 13 5 
Insulin 6 8 4 
Leptin 5 11 4 
TNF 8 7 4 
OPG 5 11 3 
OC 5 12 3 
OPN 2 12 3 
SOST 6 13 4 
IL-1 7 9 6 
PTH 4 9 5 
FGF23 8 12 4 
 
Accuracy 
Spike Recovery: The data represent mean percent recovery of spiked standards 
ranging from low, medium, and high concentration in serum matrices (n=5).   
 
Analyte 
Overnight 
Protocol 
2 Hour 
Protocol 
% Recovery 
in Serum 
Matrix 
% Recovery 
in Serum 
Matrix 
ACTH 95 82 
DKK1 88 90 
IL6 82 88 
Insulin 93 95 
Leptin 92 94 
TNF 86 76 
OPG 95 97 
OC 89 104 
OPN 97 102 
SOST 82 95 
IL-1 90 101 
PTH 92 96 
FGF23 94 88 
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TROUBLESHOOTING GUIDE 
 
Problem Probable Cause Solution 
Insufficient Bead 
Count 
Plate Washer aspirate 
height set too low 
Adjust aspiration height according to 
manufacturers’ instructions. 
 
 Bead mix prepared 
inappropriately 
Sonicate bead vials and vortex just prior to 
adding to bead mix bottle according to 
protocol. Agitate bead mix intermittently in 
reservoir while pipetting this into the plate. 
 
 Samples cause 
interference due to 
particulate matter or 
viscosity 
See above. Also sample probe may need to 
be cleaned with Alcohol flush, Back flush and 
washes; or if needed probe should be 
removed and sonicated. 
 
 Probe height not adjusted 
correctly When reading the assay on Luminex 200™, adjust probe height according to the 
protocols recommended by Luminex to the 
kit solid plate using 4 alignment discs.  When 
reading the assay on FLEXMAP 3D™, adjust 
probe height according to the protocols 
recommended by Luminex to the kit solid 
plate using 1 alignment disc.  When reading 
the assay on MAGPIX, adjust probe height 
according to the protocols recommended by 
Luminex to the kit solid plate using 2 
alignment discs. 
Background is too 
high 
Background wells were 
contaminated 
Avoid cross-well contamination by using 
sealer appropriately, and pipeting with 
Multichannel pipets without touching reagent 
in plate. 
 
 Matrix used has 
endogenous analyte or 
interference 
Check matrix ingredients for cross reacting 
components (e.g. interleukin modified tissue 
culture medium). 
 
 Insufficient washes Increase number of washes. 
Beads not in region 
or gate 
Luminex not calibrated 
correctly or recently 
Calibrate Luminex based on Instrument 
Manufacturer’s instructions, at least once a 
week or if temperature has changed by >3oC. 
 
 Gate Settings not adjusted  
correctly 
Some Luminex instruments (e.g. Bioplex) 
require different gate settings than those 
described in the Kit protocol. Use Instrument 
default settings. 
 
 Wrong bead regions in 
protocol template 
Check kit protocol for correct bead regions or 
analyte selection. 
 
 Incorrect sample type 
used 
Samples containing organic solvents or if 
highly viscous should be diluted or dialyzed 
as required. 
 
 Instrument not washed or 
primed 
Prime the Luminex 4 times to rid of air 
bubbles, wash 4 times with sheath fluid or 
water if there is any remnant alcohol or 
sanitizing liquid. 
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 Beads were exposed to 
light 
Keep plate and bead mix covered with dark 
lid or aluminum foil during all incubation 
steps. 
Signal for whole 
plate is same as 
background 
Incorrect or no Detection 
Antibody was added 
Add appropriate Detection Antibody and 
continue. 
 Streptavidin-Phycoerythrin 
was not added 
Add Streptavidin-Phycoerythrin according to 
protocol. If Detection Antibody has already 
been removed, sensitivity may be low. 
Low signal for 
standard curve 
Detection Antibody may 
have been removed prior 
to adding Streptavidin 
Phycoerythrin 
 
May need to repeat assay if desired 
sensitivity not achieved. 
 Incubations done at 
inappropriate 
temperatures, timings or 
agitation 
Assay conditions need to be checked. 
Signals too high, 
standard curves are 
saturated 
Calibration target value set 
too high 
With some Luminex Instrument (e.g. Bio-
plex) Default target setting for RP1 calibrator 
is set at High PMT. Use low target value for 
calibration and reanalyze plate. 
 
 Plate incubation was too 
long with standard curve 
and samples 
Use shorter incubation time. 
Sample readings 
are out of range 
Samples contain no or 
below detectable levels of 
analyte 
If below detectable levels, it may be possible 
to use higher sample volume. Check with 
tech support for appropriate protocol 
modifications. 
 
 Samples contain analyte 
concentrations higher than 
highest standard point. 
Samples may require dilution and reanalysis 
for just that particular analyte. 
 Standard curve was 
saturated at higher end of 
curve. 
See above. 
High Variation in 
samples and/or 
standards 
Multichannel pipet may not 
be calibrated 
Calibrate pipets. 
 Plate washing was not 
uniform 
Confirm all reagents are removed completely 
in all wash steps. 
 Samples may have high 
particulate matter or other 
interfering substances 
See above. 
 Plate agitation was 
insufficient 
Plate should be agitated during all incubation 
steps using a vertical plate shaker at a speed 
where beads are in constant motion without 
causing splashing. 
 Cross well contamination Check when reusing plate sealer that no 
reagent has touched sealer. 
  Care should be taken when using same pipet 
tips that are used for reagent additions and 
that pipet tip does not touch reagent in plate. 
FOR FILTER PLATES ONLY 
Filter plate will not 
vacuum 
Vacuum pressure is 
insufficient 
Increase vacuum pressure such that 0.2 mL 
buffer can be suctioned in 3-5 seconds. 
 
 Samples have insoluble 
particles 
Centrifuge samples just prior to assay setup  
and use supernatant. 
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 High lipid concentration After centrifugation, remove lipid layer and 
use supernatant. 
 
Plate leaked Vacuum Pressure too high Adjust vacuum pressure such that 0.2 mL 
buffer can be suctioned in 3-5 seconds. May 
need to transfer contents to a new (blocked) 
plate and continue. 
 
 Plate set directly on table 
or absorbent towels during 
incubations or reagent 
additions 
 
Set plate on plate holder or raised edge so 
bottom of filter is not touching any surface. 
 Insufficient blotting of filter 
plate bottom causing 
wicking 
Blot the bottom of the filter plate well with 
absorbent towels after each wash step. 
 
 Pipette touching plate filter 
during additions 
 
Pipette to the side of plate. 
 Probe height not adjusted 
correctly 
Adjust probe to 3 alignment discs in well H6. 
 Sample too viscous May need to dilute sample. 
 
 
  
REPLACEMENT REAGENTS  Catalog # 
Human Bone Standard HBN-8051 
Human Bone Quality Controls 1 and 2 HBN-6051 
Serum Matrix  LHED-SD 
Human Bone Detection Antibodies HBN-1051 
Streptavidin-Phycoerythrin  L-SAPE 
Assay Buffer L-AB1 
Set of two 96-Well plates with sealers MAG-PLATE 
10X Wash Buffer L-WB 
Bead Diluent LBNBD 
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Antibody-Immobilized Magnetic Beads  
 
Analyte Bead # Cat. # 
Human ACTH Beads 12 HACTH-MAG 
Human DKK1 Beads 29 HDKK1-MAG 
Human IL6 Beads 34 HIL6-MAG 
Human Insulin Beads 36 HINS-MAG 
Human Leptin Beads 39 HLPTN-MAG 
Human TNFα Beads 55 HTNFA-MAG 
Human OPG Beads 61 H0PG-MAG 
Human OC Beads 63 H0C-MAG 
Human OPN Beads 64 H0PN-MAG 
Human SOST Beads 67 HS0ST-MAG 
Human IL-1 β Beads 72 HIL1B-MAG 
Human PTH Beads 74 HPTH-MAG 
Human FGF23 Beads 77 HFGF23-MAG 
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ORDERING INFORMATION 
To place an order: 
To assure the clarity of your custom kit order, please FAX the following 
information to our customer service department: 
 
Include: 
 Your name, telephone and/or fax number 
 Customer account number 
 Shipping and billing address 
 Purchase order number 
 Catalog number and description of product 
 Quantity of kits 
 Selection of MILLIPLEX® Analytes 
 
FAX: (636) 441-8050 
 
Toll-Free US: (800) MILLIPORE 
 (636) 441-8400 
 
Mail Orders:  EMD Millipore Corp. 
 6 Research Park Drive 
 St. Charles, Missouri 63304 U.S.A. 
 
For International Customers: 
To best serve our international customers in placing an order or obtaining 
additional information about MILLIPLEX  MAP products, please contact your 
multiplex specialist or sales representative or email our European Customer 
Service at customerserviceEU@Millipore.com. 
 
Conditions of Sale 
For Research Use Only. Not for Use in Diagnostic Procedures.  
 
Material Safety Data Sheets (MSDS) 
Material Safety Data Sheets for EMD Millipore products may be ordered by fax 
or phone or through our website at www.millipore.com/techlibrary/index.do 
 
Technical Services 
For product technical assistance call or write. 
 
Toll-Free US: (781)533-8159 
 
E-mail: techserv.dd@merckgroup.com 
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WELL MAP 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
 
A 
Standard 0 
pg/mL 
(Background) 
Standard 4 QC-1 Control   
       
 
B 
Standard 0 
pg/mL 
(Background) 
Standard 4 QC-1 Control   
       
 
C Standard 1 Standard 5 QC-2 Control   
       
 
D Standard 1 Standard 5 QC-2 Control   
       
 
E Standard 2 Standard 6 Sample  1   
       
 
F Standard 2 Standard 6 Sample  1   
       
 
G Standard 3 Standard 7  
Sample  
2   
       
 
H Standard 3 Standard 7  
Sample  
2   
       
 
 
